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ABSTRACT

USING AN ETHICS OF CARE TO RE-INTERPRET CONSENT IN THE
MANAGEMENT OF CARE FOR ADDICTION DISORDERS

By
DiAnn C. Ecret
May 2018

Dissertation supervised by Dr. Gerard Magill
Patients who suffer from the biological, genetic, epigenetic neurocognitive
dysfunction and social sequela of substance use disorders and addiction require the
empowering support from healthcare professionals; necessitating the need to utilize an
ethics of care to re-interpret consent for the management of care for those who suffer
from substance use disorders and addiction. The care of the ‘other’ should embrace a care
paradigm that is relational and collaborative in order to eliminate constructs of stigma,
moral weakness and individual blame, which isolates those who manifest the trajectory of
harms associated with addiction pathology. Relational consent and an ethics of care seeks
to enhance the relational decision making processes for those who experience the
complications from this stress surfeit and executive cognitive functioning disorder. The
re-interpretation of consent seeks to improve patient outcomes, improve quality of
healthcare delivery and enhance human dignity for vulnerable populations.
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Chapter. 1 Introduction
This dissertation’s thesis asserts that the ethics-of-care should be used to re-interpret
consent in the management of care for addiction disorders. The re-interpretation of consent for
the management of addiction disorders is necessary, because the biological and scientific
evidence supports pathophysiological alterations in neurological and cognitive functioning that
illuminates impaired decisional capacity. This dissertation does not assert that the reinterpretation of consent is required more generally; but rather, that consent processes should be
re-evaluated differently in regard to the neurological, biological and epigenetic cause of direct
cognitive dysfunction as it relates to the nuances of addiction. By utilizing an ethics of care
framework for those who suffer the trajectory of chronic and physiological addiction pathology it
becomes necessary to utilize interventions that assist in the repair and restoration of
physiological and neurobiological impairment.
The complexity of clarifying the terms of dependency, addiction, and substance abuse
disorders is an ongoing inquiry in academic and scientific fields of study. Therefore, the
utilization of the terms dependency and addiction, will be utilized throughout this dissertation
text in harmony with the American Psychological Associations (APA)’s Diagnostic and
Statistical Manual 5th Edition (DSM-V). According to the newest edition of the DSM-V,
addiction is defined as a spectrum disorder that waxes and wanes as a chronically relapsing
disorder that occurs in three stages, which include binge/ intoxication, withdrawal/ negative
affect, and preoccupation/ anticipation; additionally, the DSM-V specifies that the chronically
relapsing disorder meets the following criteria: compulsion to seek and take the drug, emergence
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of negative states, which include dysphoria, anxiety, and irritability that invokes physiological or
psychological withdrawal syndromes.1 According to the APA, dependency is the first stage of
addiction and it occurs when the person’s drug seeking motivation is their dominant feature, as
evidenced by: uncontrollable craving, an inability to stop using substance, onset of physiological
anxiety, and persistence of symptoms over time.2
Implementing an ethics of care for those with addiction disorders, potentiate the repair
and restoration of biological, neurological, physiological brain functioning that seeks to enhance
the dignity for those who are predisposed to the vulnerability and the exceedingly harmful
consequences associated with addiction. By implementing an ethics of care paradigm with the
goal of improving neurological and biological, functioning through improved community,
professional, family, and individual responsiveness needs, an alteration of genetic and biological
predisposition is potentiated. It is through relationship, connection, and professional
collaboration that a deconstruction of stigma can be actualized. Consequently, the trajectory of
addiction science assuredly supports interventions that seek to improve and repair decisional
capacity ability for those diagnosed with addiction, in order to decrease further neurological
impairment and the sequela of increasing harms.
The significant correlation between the social, psychological, physiological, and the
neurobiological dysfunction that is associated with the harmful alterations in long-term decisionmaking abilities with the prevalence of addiction disorders has grown exponentially; yet, the
integration and application of the astounding discoveries that potentiate the improvement of care
delivery for this stigmatized population is sluggishly and inconsistently being implemented in the
holistic management of care for individuals. As a result, associated harms and disparities
increasingly widen the marginalization of individuals, families, and entire generations across all
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sociocultural and socio economic segments of society.3 The relevance of the current dissertation
research is paramount, because adequate management of care paradigms for addiction and
dependency has yet to produce the essential quality improvement outcomes that are so necessary
for individuals, families, communities and societies at risk and for those who suffer from the
harms associated with dysfunction.
An ethics of care framework seeks to potentiate a trajectory of care for the ‘other’
through constructs of connectedness and relational human interactions of care that seek to
substantially decrease the staggeringly poor outcomes associated with the neurobiological,
epigenetic, and social sequela of complications that plague the current addiction and dependency
dysfunction conundrum.4 Rarely, if ever has the ‘ethics of care’ in its paradigmatic entirety been
applied to potentiate the significant improvements necessary to narrow the divide, that increases
the vulnerability and which contributes to the increasingly harmful trajectory associated with
addiction disorders; the implications for reframing individual and autonomous decision making
through collaborative, supportive and relational decision making process, becomes a vital
component necessary to rectify the perceived moral blame associated with those diagnosed or
labeled with ‘addiction or dependency.’5 Offering supportive humane connections through
relationship, community, and shared decision making becomes paramount in the management of
care for the ‘other’.
To examine how an ethics-of-care framework can re-interpret consent for those
diagnosed with addiction disorders, the analysis considers the following components: the
scientific nature of the neurobiological, genetic, and epigenetic influences of addiction; the
historical components of societal responses to addiction. (Ch. 2); the relevance of utilizing an
ethics of care framework (Ch. 3); the nuances of informed consent in addiction disorders (Ch.4);
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the development of a relational paradigm of care for the amelioration of the management of care
(Ch. 5); and implementing relational consent to improve quality outcomes of care for addiction
disorders (Ch. 6).
The literature review for this dissertation begins with a thorough examination of the
scientific evidence that acknowledges the heritability of biological and epigenetic influences that
increase the risk for addiction and dependency. Additionally, this dissertation supports the call
for a paradigmatic revision of consent through a care framework that examines the utilization of
consent through shared decision-making when the sequela of neurological alterations caused by
addiction further potentiate accelerations of physiological harms.6
Historical constructs that view addiction as a series of conscious actions and therefore
supportive of individual moral failings are non-sustainable after systematic review of the
neurological, biological, genetic and epigenetic evidence. Through the eradication of shame,
blame, and stigma, a paradigm shift, which focuses on the facilitation of individual wellness,
disease prevention, decrease in disease progression and empowerment of individuals, families
and communities for improved understanding of management of care is potentiated for at risk
populations; the vision for decreasing harms is actualized.7 The re-interpretation of consent has
the potential to reverse this exponential trajectory of harms associated with the current crisis of
addiction and dependency.
The evidence that supports the neurobiological, genetic and epigenetic influences that
perpetuate addiction and dependency disorders through heritability and transgenerational
biological factors through alteration in specific genetic expression can offer hope for healthy
transformation through implantation of purposeful environmental interventions, which support
prevention, wellness, healing.8 Recognition that our historical and social responses to the
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management of addiction perpetuate a correlation/ or connection to isolation, suppression,
marginalization and stigmatization has grave progression of consequences for those individuals
and families with greatest biological and epigenetic risk of addiction and dependency
dysfunction; reconstructing the construct of choice is necessary.9
By looking at the neurobiological and genetic nature of addiction the scientific evidence
should be utilized to systematically uncover the genetic influences, specific phenotypes of
addiction, evaluate the historical and social constructs of addiction, examine the legal and public
health policy as it relates to addiction, examine the neurobiology of belief and how internal
constructs of belief effects addiction management of care and influences the expression of
impaired biological functionality.10 Care theories and neurological science uncovers the
detrimental and destructive influences that previous historical and social constructs of care have
elicited unjustly for those vulnerable; implementing an ethics of care to re-interpret consent is
necessary in order to reconstruct paradigms of improved models of care for future generations.11
Chapter three further evaluates the ethics of care framework by extrapolating the nuances
of autonomy through the visualizing of autonomy through relationships; thus, recognizing the
communal and relational nature of autonomy.12 The additional recognition that autonomy is
dependent on ‘the other;’ is paramount in placing the need for professional and relational
responsiveness for individuals during vulnerability and impaired cognitive decision-making
states is essential. An ethics of care applies the principles of human dignity by understanding that
all persons, despite frailty and vulnerability require professional action and care when affected
by physiological and neurobiological disease states.13 Professional responsibility,
responsiveness, and wise action are necessary in implementing a management of care paradigm.
Therefore, an ethics of care reveals how the incorporation of human values such as
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connectedness, attentiveness, responsiveness, responsibility, competency, wisdom, empathy of
the other and relational autonomy is at the core of relationships, communal living and social
interactions within communities. The construct of care within relationships is a necessary
consideration in order to actualized an increase human flourishing and decrease human
vulnerability and frailty; an ethics of care brilliantly focuses on the empowerment of individuals
through relationships versus escalated decline of disease states through constructs of neglect and
blame.14
Marginalizing and isolating those with addiction disorders has not eliminated the
progression of dysfunction; rather, research has suggested that the current political structure of
criminalizing, marginalizing, and isolating those with dysfunction has exponentially perpetuated
the epigenetic consequences of dependency for future generations. An ethics of care considers
the particularity of the other, not in a hierarchical placement of worth, rules, and rights, but rather
in a participatory and relational context where responsibility and connectedness are valued.15 An
ethics of care recognizes that each person has intrinsic worth in society, an ethics of care places
the value of disparate and vulnerable populations within the context of the same rights within
culture and democracy as those who write the laws; it recognizes that in the pursuit of personal
autonomy, human strength is achieved through relationships, remaining an essential element that
builds strong supportive and productive societies.16
The re-interpretation of consent for patients who suffer with impaired decisional capacity
due to the neurological dysfunction associated with dependency disorders is examined in chapter
four. Therefore, chapter four examines the particularities of obtaining informed consent for
patients diagnosed with addiction disorders and how the determination of individual autonomous
decisional-capacity is problematic. Attempting to apply traditional processes of obtaining
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informed consent and assessing decisional capacity, requires a close examination of the elements
of informed consent and how addiction disorders restrict adequate adherence to those elements;
the elements include, determining competency, maintaining voluntariness, ensuring adequate
disclosure, assessing capacity of understanding complex disease processes and treatment
interventions, determining one’s capacity to assess risks and benefits of complex health
information.17
Determining competency for consent for medical treatment for patients diagnosed with
dependency disorders, addiction, and abnormal neurological functioning dysfunction from
biological diseases such aa Parkinson’s Disease and Alzheimer’s disease helps guide exciting
new application of consent processes. As a result the nuances of substance abuse, dependency
and addiction is analyzed by evaluating and considering how of the complexities of
neurocognitive and neurological dysfunction impedes decisional capacity and places the person
with neurocognitive impairment from addiction at an increased risk of continuous and escalating
harms; it a professional requirement to recognize the manifestations of neurodegenerative
deterioration during addiction and dependency dysfunction and to adequately recognize impaired
decisional capacity with regards to implementing a holistic and ethical plan of care.18
Despite clear bioethical standards related to the standard requirements and elements of
obtaining informed consent, current traditional processes perpetuate complications for those
known to have neurobiological dysfunction; utilizing an ethics of care paradigm view to
incorporate relational decision-making processes, through an expanded paradigm of selfdetermination and empowerment for the ‘other’ relational and partnership decision-making is
evaluated in order to potentiates actualization or wholeness for individuals through constructs of
care relationships, and through wellness initiatives that are supported by community and
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healthcare treatment plans.19 Improved decision-making and management of care paradigms are
essential in establishing the dignity of those with addiction and dependency dysfunction.
The nuances of informed consent for those with addiction disorders, is further examined
by isolating the elements of altered consciousness that occurs in addiction; hence, deconstructing
the historical model of addiction as rational choice through elements of application of ethics in
neurological dysfunction effecting mental health.20 The criteria for obtaining informed consent is
careful examined through the added protections of partnerships and relational interpretation of
competency for consent; this relational interpretation of consent must carefully avoid
paternalistic coercion and it must seek ways to improve competency, through careful application
of shared decision-making models that implement partnerships and proxy decision-making
supported guidelines that seek to improve the care outcome trajectory of the ‘other’ versus the
radical neglect and oppression of the ‘other’ that currently isolates and disconnects those
diagnosed with addiction. Revised management of care initiatives that embrace relational and
shared decision-making could support optimal patient and societal benefit for generations.
Chapter five, justifies the support for the need of a relational paradigm of care by
acknowledging the psychiatric and neuroimmune comorbidities of addiction and dependency,
that predispose patients to unnecessary and unforeseen vulnerabilities; these vulnerabilities are
frequently not freely chosen by those who suffer from the neurological and neurobiological
abnormalities of addiction due to the neurological sequela of dysfunction. The necessity to
restore and repair consciousness in order to re-obtain full decisional capacity becomes the
treatment priority in order to alter the trajectory of disease, to decrease human suffering, and to
empower personhood.
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Additionally, chapter five formulates a paradigm of care that alters the management for
those with dependency and addiction disorders by uncovering the statistical evidence that
highlights the current stagnation of effective treatment plans by illuminating the barriers of
current public policy, by identifying the complexities of disease trajectory, and uncovering the
research that supports the epigenetic consequences of isolation, criminalization, labeling; the
resulting loss of individual life can no longer be justified through the construct of choice;
comorbidities, disease tragectory, complications from neurological dysfunction that can no
longer be dismissed as solely an individual character disparagement.21
An ethics of care seeks to carefully consider and treat all comprehensive elements of
dependency dysfunction in order to respond to the escalating comorbidities of addiction, which
include a careful evaluation of the physiological aspects of dysfunction. Additional and careful
evaluation of protein regulation that alters cellular expression, hormonal influences that modulate
neuroimmune complications, neurotransmitters that potentiate psychiatric complications,
exacerbations of concomitant disease states such as liver, pancreatic, and nutritional
dysfunctions. The recognition and identification that the current treatment regime, has grave
consequences within the current trajectory of care demands responsive action to eliminate the
escalating and concomitant pathology of disease for individuals and communities.22
Management of care within an ethics of care framework requires implementation of
strategies that decrease suffering, decrease harms and decrease vulnerabilities associated with the
neurobiological dysfunction, neuroimmune dysfunction, and cellular processes that exacerbate
organ dysfunction and ultimately result in altered neuro cognitive states; the management of care
shift must include innovative treatment modalities that include implementation of therapeutic
plans that facilitate alterations in genetic expression, utilize pharmacogenomics that alter cellular
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expression, implement appropriate immunotherapies, and neurological enhancement modalities
through relational consent processes and paradigmatic treatment protocols that aim to restore
individual outcomes of disease and alter stress response states that decrease heritability for future
generations.23
Cultivating compassionate and relational connections for individuals who suffer from the
sequela of the chronicity of addiction requires improved understanding and application of
etiology, physiological dysfunction progression and treatment modalities that enhance the
extensive potential for neurological repair, restoration and reorganization by seeking treatment
options that enhance neuroplasticity in order to decrease risk of comorbidities and poor
outcomes; improving social determinants of health for this patient population necessitates
implementation of relational consent process of care and shared decision making for the
management of those vulnerable to addiction.24 The literature review examines the relational
paradigm of care framework by incorporating literature which compares and contrasts key
elements of addiction and dependency management of care concerns such as consent and
coercion, increasing vulnerabilities associated with increasing comorbidities of disease, and
elements of care that seek to relieve suffering, marginalization, and disparate access of care that
include breaking edge treatment modalities such as neuroenhancement, immunotherapies,
manipulation.25
Chapter six extensively examines and evaluates how implementing a relational consent
processes in the management of care for those diagnosed with addiction disorders can
relationally improve quality of care through responsive professional initiatives that decrease
vulnerabilities for individuals, who are negatively affected by the present management of care
paradigm; through shared decision making, deconstruction of stigma, implementation of
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educational and preventative strategies, which implement revised social policies, examines the
benefits of community and the structure of belonging.26 An ethics of care can aim to transform
the current consequences of exponential suffering toward healing for individuals and society
through shifting the conversation and construct of care to connectedness and caring for the
‘overall’ whole of what it means to be an individual within community and social constructs.
This conversation requires implementations of operational guidelines that construct restorative
relationships through conversations of possibilities; rather than, focusing on limitations and
faults, which ignore human potential and giftedness.27
The new paradigm shift requires improving communication, implementing patient and
family centered care paradigms, and developing strategies that improve innovative quality of
care frameworks that are relational and community centered; this includes re-interpretation of a
relational consent processes for the treatment of dependency disorders; applying revised and
enhanced consent processes and identifying the need to skillfully implement reliable capacity
assessment evaluation tools to determine decisional capacity for those who require treatment in
order to prevent harms associated with the chronicity and exacerbations of neurologically
impaired decision making in the treatment of dependency and addiction should become the new
standard of care.28
Implementing a shared decision-making capacity of care model attempts to integrate
holistic life management skills, such as employment retention, establishment of stability in
housing, strategies to support social connections, ensuring access to health care services as
identified in the national outcomes measurements (NOM) project and improving understanding
of services; assessing the quality of treatment for dependency and addiction dysfunction requires
careful data collection of interventions in programs that aim to reintegrate patients continuously

11

with social and interactive community participation roles, while also seeking to decrease
mortality and morbidity associated with the increase in consequences of dependency and
substance misuse.29 The complexity of such treatment goals require assistance from families and
communities, and policies that acknowledge that individuals are strengthened through supportive
social relationships; hence, enhancing the integrity of individuals through relational support and
empowerment in order to decrease the deleterious consequences of the rise of addiction disorders
becomes a community imperative, which is actualized by a embracing a vision and promise of
the possibility of human potential for all people.
The process of implementing a relational consent framework that potentiates an
exponentially improved quality of care outcomes for patients, families, and communities by
deconstructing the stigma conversation by implementing restorative processes that focus on
human giftedness, transforming policy that invites possibility of health promotion, disease
prevention, and incorporation of shared decision-making methodologies to enhance treatment
outcomes, improve impaired consciousness and restore dignity to individuals and generations
through dissemination of knowledge and implementation of relational care paradigms.30
In summary, the re-interpretation of consent in the management of care for addiction and
dependency dysfunction requires careful exploration. The benefits of implementing relational
consent processes for the management of care for those who suffer from addiction and
dependency requires the implementation of transformational treatment methods; albeit, the
dignity of those who suffer from addiction cannot remain an individual’s challenge but, rather a
community, professional, and societal need. Utilizing an ethics of care to re-conceptualize
autonomy through empowerment of relational autonomy and relational decision-making
processes require a careful analysis and paradigm of care shift. The sequela of chronic
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neurological and cognitive impairments associated with addiction disorders and how support
through vulnerability can promote neurological and epigenetic repair and that supports
physiological wellness and support. Vigilant implementation of a relational re-interpretation of
consent processes must be attentively formulated for this vulnerable and marginalized
population; incorporating public health collaborative frameworks of care are essential, in order to
comprehensibly implement the call to action, which the institute of Medicines and the National
Behavioral Health Quality Framework (NBHQF) care coordination improvement initiatives
promote. Implementing an ethics of care must synergistically occur between providers of care to
successfully improve outcomes of care between acute care systems, public health, while also
assisting in successful transitions of care environments; this occurs by rigorous education
programs in communities, cultures and societies in order to improve care for the vulnerable.
This complex endeavor requires a robust and sustainable implementation plan that truly
seeks the improvement of systems of care, through coordination and facilitation of clear and
concise public health initiatives that aim to place the health of individuals and the safety of
communities first; policy development must adhere to standards of least restrictive means,
including grass roots education initiatives, while also embracing strong multilevel prevention
education strategies that simultaneously seek to decrease stigma and social isolation in order to
embrace the possibility of enhancing the responsibility of many to promote the dignity of the
vulnerable. Empowerment of the other is necessary not through isolation; but rather through
relationship, connectedness, responsiveness, communication, education, discussion, solidarity,
community and professional support that seeks to deconstruct the deleterious isolation of those
susceptible to the perpetuation of individual, generational, and societal harms that dysfunction
inflicts upon communities and populations.
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Chapter 2 Scientific Evidence and Social Response of Addiction Disorders
The conceptualization of addiction cannot be simplistically attributed to the reductionism
of the biological sciences. The complexities associated with addiction disorders, must also
consider the historical, cultural, and social aspects that contribute to the epigenetic influences of
substance use disorders, addiction and dependency. This chapter will evaluate the objective
neurobiological components of addiction disorders, while correlating the historical
misconception perpetuated through the construct that addiction is simply an individual character
flaw, isolated and independent of societal circumstances and culpability. The current and
historical problems associated with substance misuse, dependency and addiction are monumental
not only for individuals, but for families, communities, and society as a whole; the medical or
disease model of addiction contributes substantially to the advancing knowledge of the
deleterious physiological effects and neurocognitive dysfunction that is associated with the
complexities and the trajectory of dysfunction.1
The epigenetic influences of substance use disorders and addiction uncovers the
connection of the cultural and social contributions of escalating risks and vulnerabilities by
uncovering a broader understanding of substance use and misuse; a closer evaluation of the
contributing factors that influence the ever increasing perpetuation of human devastation,
physiological, psychological, and social dysfunction must evaluate all of the associated risks that
result in individual harm, decreased health outcomes, increased health care costs, poor health
management and ultimately the often times unspoken heritability devastation that affect
individuals, families and future generations.2
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Obtaining a universal definition for substance use disorder terminology, such as addiction
continues to develop over time as evident by the historical changes in the American Psychiatric
Association’s updated use of definitions in the Diagnostic and Statistical Manual of Mental
Health Disorders (DSM) related to substance abuse disorders terminology.3 The terminology of
addiction has been used interchangeable and deleteriously with dependency terminology,
resulting in poor management of care outcomes; therefore, the 2013, DSM-V manual
terminology distinctions include softening the language of addiction, by describing chronic
neurological changes associated with substance use in those who are vulnerable to the
neurobiological and neurocircuitry adaptation mechanisms as a chronic relapsing disorder that
results from disordered neuro-adaptive mechanisms versus the historical, simplistic, dismissive,
and marginalizing implications of individual blame through negative constructs addiction that
further marginalizes and isolates individuals.4
However, the usage of addiction terminology persists, despite the DSM-V changes. The
terminology of substance use disorders and addiction continues to invoke negativity for
individuals as blameworthy, even though current scientific conceptualization clearly identifies it
as a ‘maladaptive pattern of substance use’ because of complex physiological and psychological
responses to the biologically striving toward homeostasis functioning of the brain; as a result,
manifestations and behavior for individuals include strong desires to use a substance, which
begins as the impulse control disorder, that can progress through stages of increased tolerance of
the drug effect or substance effect over time, with eventual cycle progression toward negative
withdrawal symptoms once a substance is not available, leading to compulsive use, despite
negative consequences.
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Dependency, can occur independently in persons and is distinctly different than substance
use disorders and addiction; dependency speaks toward the psychological withdrawal and/or
physical withdrawal effects that occurs after a substance is no longer present. Addiction or
substance use disorder, on the other hand, can cause distinct changes in the brain’s neurocircuitry
and functioning, even after detoxification and recovery states are established.5 Substance use
disorders and addiction are considered as a chronic spectrum disorder that meet the following
criteria: 1. Individual verbalizes consistent desire to decrease or discontinue use, without success.
2. The individual spends an extraordinary amount of time seeking, using and recovering from
substance use. 3. Individuals daily routines revolve completely around the substance. 4.
Individual craving is persistent and associated with allostatic changes in the individuals
neurocircuitry alterations in the brains reward structures.6 Addiction’s progression to compulsive
use despite substantial physical, psychological or social ‘reasons’ to discontinue its use, becomes
one of the problematic progression states.7 Therefore, addiction and dependency disorders should
be viewed on a continuum that is associated with escalating effects of risk for chronic relapsing
progression and harms.8
The global burden of addiction has been widely recognized by the World Health
Organization (WHO). The WHO statistics in 2000 calculated more than a three percent mortality
rate globally associated with alcohol consumption and a contributing four percent global
disability rate related to the consequence of alcohol use alone.9 Additionally, the same report
estimated the global percentage of deaths as a result of illicit and prescription drugs use, alcohol
use and nicotine use collectively reported at 12.4 percent of of annual deaths in the year 2000,
totaling more than 3.4 million loss of life throughout the world.10 According to the National
Institute of Drug Abuse, the exponential increase in heroin and synthetic opioid overdose deaths
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in the United States alone in 2016 was greater than 64,000 deaths, this number exceeds the total
number of loss of human life during the entire Vietnam conflict; this exponential increase in
overdose deaths has doubled in a ten year period from 2006 to 2016.11 Additionally, the
economic disadvantages of addictive behaviors have resulted in increased healthcare costs for
individuals, organizations, and societies.12
Physiological and psychological manifestations commonly associated with substance use
disorders and addiction are widely documented in the health literature and include prolonged risk
for health care disabilities associated with excessive consumption. They include, but are not
limited to increased incidence of trauma related injuries, psychiatric disorders, liver dysfunction,
acute pancreatitis, cancer, cardiac disease, hypertension, multiple organ failure, which can
include encephalopathy and substance induced brain damage.13 Current research recognizes that
the physiological and psychological effects of alcohol addiction and illicit and prescription drug
addiction contribute to, not only individual suffering, but toward familial and societal suffering
globally; concurrently, the public health crisis associated with illicit and prescription drug use,
misuse and addiction is rising in epidemic proportions in the United States and throughout the
world.14
Decreasing harms by attempting to understand and disseminate the biomedical and
neurobiological physiology that interplay with social constructs of vulnerability requires a close
examination. For individuals and families who experience an increased risk for dependency and
addiction, incorporating constructs of care that explain the associated neurobiological risks may
help reverse the trajectory of sustaining generationally inherited traits, which will encourage the
abandonment of practices that have statistically paralyzed the implementation of best practice
interventions, increased risk for vulnerability and harms. Increasing the implementation of
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interventions that decrease the predisposition to the deleterious consequence of dysfunction,
disability, and coexisting comorbidities should be an essential element of societal care.
Additionally, reversing the trajectory of the harms associated with the marginalization,
social stigmatization and discrimination for individuals who are diagnosed with addiction as an
intrinsic sign of human weakness requires a sensitive investigation to uncover how social
constructs have potentiated monumental harms. By implementing an epidemiologic approach to
community assessment or by implementing a developmental model or retrospective and
historical community health assessment, uncovering the essential improvement elements
necessary to decrease vulnerability and alter the perpetuation of disparate health outcome
becomes evident. By closely examining the critical public health concerns of addiction and
examining the evolutional development of negative social constructs, such as drunkenness,
intemperance, and moral blame have monumental societal significance to potential alter poor
management of care and resultant poor health outcomes.15
Unfortunately, the stigma and marginalization associated with addiction can be identified
in early Christian writings of Saint Paul, Saint Augustine, and Saint Aquinas, where moral
culpability or individual blame was placed on individual persons and entire families through the
descriptive discourse that identified the ‘unknown’ through the language of sin, vice and
intemperance; constructs of sin often times sought to ‘warn’ people from human vulnerability
and harm; however, by identifying illnesses as moral failures, before science was able to uncover
the physiological circumstances that predispose person’s to disease states perpetuated
contemporary constructs that are associated with increasing vulnerability of individuals, families,
and entire communities. 16 The scientific evidence increasingly supports the neurobiological,
genetic and epigenetic influences that perpetuate dependency and addictive disorders through
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heritability and transgenerational biological factors that alter gene functioning, alter gene
expression that are related to a vast range of internal and external psychological, physiological,
and environmental influences.17
The historical and social responses toward substance use disorders and addiction closely
responded to the horrific consequences of individuals through the lens of fear, which resulted in
separating individuals from communities, through marginalization and stigmatization practices,
which further perpetuates the biological complications and the epigenetic consequences of
transgenerational harms for individuals and entire families who are predisposed to the intrinsic
prevalence of biological heritability.18 The consequences of societal and environmental isolation
for those with substance use disorders and addiction has fueled the current addiction epidemic by
perpetuating the dysfunction as if individual responses were simply a matter of free will and
choice, independent of societal intervention.19
2.1 Scientific Evidence
The physiological functioning of the human person is dependent on the environment in
which it lives. Just as the cellular functioning of all biological creatures depend upon network
chains of cellular collaboration through interrelated networks that regulate the synergistic
functioning of the whole; the complexities of cellular functioning require a network of cellular
communication, and inter-reliability on that cellular communications that facilitate precise
functioning of cells that enable the complex and holistic functioning of the entire organism.
Albeit, the surmounting evidence continues to uncover the importance of the interconnectedness
between cells, which are necessary to ensure optimal functioning of neuro-circuitry, hormone
secretion, and cytokine regulation, that facilitate homeostasis and precise organ functioning;
cohesiveness of all individual elements become central constructs that rely on the
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interdependency of vital organ functioning, wellness of persons, and collaborative wellness
within constructs of communities. The formation of individual strivings, wellness, thoughts and
actions, rely on behavioral and social constructs of relationships and ultimately individual
responses to health are social responses that directly influence cellular, hormonal, and
neurological functioning.20 This interconnectedness between cellular functioning of
deoxyribonucleic acid (DNA), ribonucleic acid RNA, and proteins greatly influences biological
functioning, expression, and communication, which, directly influences the evolutionary survival
of all organisms collectively; thus, greatly influencing the intrinsic biological and extrinsic
environmental factors, during all stages of human development. Therefore, examining the
crossroads between the neurobiology and the social constructs of substance use disorders and
addiction disorders must incorporate a holistic framework of care that incorporates all elements
of neurobiological repair, while promoting prevention strategies that decrease the risk of
heritability by drastically altering the continuation of negative societal responses.
The complexity of clarifying the terms of substance use disorders and addiction is an
ongoing task in the academic and scientific fields of study. Therefore, the utilization of the terms
substance use disorder and addiction, will be utilized throughout this dissertation text in harmony
with the American Psychological Associations (APA)’s Diagnostic and Statistical Manual 5th
Edition (DSM-V). According to the newest edition of the DSM-V, addiction is defined as a
spectrum disorder that waxes and wanes as a chronically relapsing disorder that occurs in three
stages, which include binge/ intoxication, withdrawal/ negative affect, and preoccupation/
anticipation; additionally, the DSM-V specifies that the chronically relapsing disorder meets the
following criteria: compulsion to seek and take the drug, emergence of negative states, which
include dysphoria, anxiety, and irritability that invokes physiological or psychological
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withdrawal syndromes.21 According to the APA, dependency is the first stage of addiction and it
occurs when the person’s drug seeking motivation is their dominant feature, as evidenced by:
uncontrollable craving, an inability to stop using substance, onset of physiological anxiety, and
persistence of symptoms over time.22 Dependency does not always progress to substance use
disorder or addiction; this distinction is clear in the DSM-V’s clarification of terms, clarification
was necessary because providers of care were inaccurately labeling those who had developed
dependence and therefore often times cruelly abruptly discontinuing interventions for medical
management of care when manifestations of ‘dependency’ were identified.
Every organ within a living organism has specified cells that constitute the functional unit
of that organ. The functional unit of the lungs are the alveoli, which systematically exchange
oxygen and carbon dioxide through the alveolar capillary membrane in order to facilitate gas
exchange and provide oxygenation to all other organs.23 The functional unit of the kidneys are
the nephrons, which systematically filter and reabsorb proteins, fluid, and electrolytes in order to
eliminate waste products, maintain homeostasis and provide fluid volume regulation.24 The
functional unit of the brain is the neuron. Each neuron is made of a cell body, an axon, and
dendrites; the cell body and the cell’s nucleus help coordinate the activity of the neurons, the
axon helps transmit messages to other neurons, much like a telephone wire communicator, and
the dendrites are the ‘receivers’ of the transmitted messages sent through the axon.25 Neurons
must utilize chemical messengers called neurotransmitters in order to communicate with oneanother effectively.26
Neurons are clustered in the brain according to their specific functional needs and are
grouped according to their functional roles, such as: learning, emotion, memory, muscle
stimulation, sensory functioning, etc.27 Additionally, neurotransmitters functioning occurs within
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the neurons through binding sites that either inhibit or stimulate the brain’s action potential; the
brain and neurotransmitter activity are instrumental in regulating activity throughout the entire
organism, by influencing functions such as breathing, digesting, concentrating, and contracting.
All living organisms seek balance or homeostasis for optimal functioning; therefore, inhibitory
and excitatory neurotransmitters normally seek to function for optimal organism functioning.
Some inhibitory neurotransmitters include, gamma-aminobutyric acid (GABA) and serotonin;
excitatory neurotransmitters include dopamine, epinephrine, norepinephrine and glutamate. The
addiction cycle impairs normal functioning of neurotransmitter network functioning within
numerous regions of the brain.28
Before evaluating the abnormal brain functioning, which occurs in addiction, examining
normal brain functioning in some commonly associated areas of the brain is necessary. The basal
ganglia is located deep inside the brain and it helps to keep the body’s movements coordinated,
while also becoming influential in learning routine behaviors and forming habits; sub-regions of
the basal ganglia are the nucleus accumbens and the dorsal striatum.29 The nucleus accumbens
influences a person’s motivation and utilizes experiences of reward through activation of
intrinsic reward mechanisms and the dorsal striatum influences the formation of habits, routine
behaviors after activation of reward circuitry; activating the reward circuitry of the brain serves
the purpose to ‘link’ pleasure with elements that increase species survival.30 The extended
amygdala is located beneath the basal ganglia and it regulates the brain’s reaction to stress
through functioning of the sympathetic nervous systems fight or flight response to negatively
respond to environmental cues through invoking stress states expressed through uneasy
emotions, such as anxiety and irritability; the extended amygdala interacts closely to the
hypothalamus to activate the warning mechanism as a protection against potentially life
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threatening environmental influences.31 The hypothalamus is the master endocrine gland, which
controls hormone regulation through the hypothalamus-pituitary-axis (HPA); through this
sophisticated biological functioning mechanism, the HPA communicates all intrinsic organ
responses through the sympathetic and parasympathetic system functioning to seek organism
homeostasis. And lastly, the prefrontal cortex is located in the front of the brain, directly over the
eyes. The prefrontal cortex is responsible for the complex ability of humans to process elaborate
and heterogeneous cognitive input that influences decision-making capabilities known as
executive functioning.32 When increase stress states occur, due to hyper stimulation of the HPA
and SNS, the ability of the pre-frontal cortex is greatly diminished and negative executive
functioning persists.
Addiction pathology directly correlates with the three stages identified in the APA’s
DSM-V definitions, which include binge/ intoxication, withdrawal/ negative affect, and
preoccupation/ anticipation.33 In order to understand the neurobiology of addiction, a closer look
at the three stages of the addiction cycle as they relate to the nuances of substance use, such as
alcohol, opioids, and psychostimulants will be evaluated as they relate to the neurobiology of
addiction, neurocognitive impairment, genetics and epigenetic influences. Scientific inquiry that
evaluates and studies the anatomy, the physiology and pathology of the nervous system in
addiction disorders establishes the interlinking multifaceted variables that identify the
neurobiological factors associated with addiction; this discernment of science historically
uncovers and dissects the neurobiological factors of addiction. Yet, the constituent elements are
interrelated with the genetic, epigenetic, and social constructs that also influence dependency
dysfunction and addiction.34
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a. Neurobiology of Addiction
As previously mentioned all biological life seeks to maintain homeostasis internally and
externally in relationship to environmental and societal stimuli; during the exposure to addictive
substance, homeostasis becomes unattainable, both intrinsically and extrinsically. As a result,
allostasis and neuroadaptations occur intrinsically in an attempt for the brain to strive toward
stability.35 The precise components of the neurobiology of addiction include, but are not limited
to, the neurological and neuro-circuitry pathway changes noted in the brain that potentiate
progression of addiction dysfunction through reward-deficit disorders, stress surfeit disorders,
negative emotional state dysfunctions and neuroadaptations that contribute to chemical
neurotransmitter alterations in dopamine, glutamate, GABA corticotropin-releasing factor, and
serotonin via both inhibitory or excitatory dysfunction.36
Additionally, emotional states and behavioral regulation is dependent upon proper
functioning of regions of the brain such as the basal ganglia, amygdala, the prefrontal cortex
(PFC), the prefrontal-limbic-striatal circuit, the mesolimbic circuitry, and role of intracellular
interactions with neurotransmitters and proteins; the effects of intracellular changes potentiate
alterations in brain control as a result of genetic expression with single acute exposure of
substances such as alcohol for some people with increased risk.37 Each stage of the addiction
process cycles in intensity and ultimately culminate in the pathology of addiction.38
The basal ganglia is positioned deep in the brain and is generally thought to influence the
smooth coordination of body movements; however, the basal ganglia is also responsible for
learning of repetitive behaviors, which include the formation of habits.39 The neurobiology of the
binge/ intoxication stage of addiction includes the learning associated with substance use
administration that then changes the reward circuitry functioning of the basal ganglia; the brain’
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is no longer regulated by normal homeostasis functioning, but rather through processes that
cause dysregulation through alterations in reward neurocircuitry pathways; the development of
the allostatic state seeks stability through excess reward and stimulates the down regulation that
results in the neuro-adaptive state that results from the external reward stimulation.40
The alterations in neurocircuitry, occur initially in response to the drug induced increases
that stimulate pleasure states in excessiveness, which are associated with the exogenous drug
induced elevations in dopamine levels; consequently, anticipated rewards are established and
learned as essential components of one’s intrinsic need for survival. When the allostatic
mechanisms caused by the drastic increases in exogenous dopamine levels occur in the basal
ganglia, the reinforcing effects established through memory and learning quickly increase the
anticipation reward pathways for substance seeking behavior; anticipation subsequently
increases dopamine level responses in the basal ganglia’s nucleus accumbens just by the memory
of the sought after cues, which are associated with the positive reward itself.41 The basal
ganglia’s ventral striatum plays a major role in intrinsic impulse motivation that seeks to act
upon this hedonistic striving for memorable pleasure.42
However, normal hedonistic responses are stimulated as mechanisms of reward for food,
water, and sex through reinforcing activation of the mesocorticolimbic dopamine and the
nigrostriatal dopamine systems as a mechanism to potentiate learning for the essential response
for species survival.43 However, activation of the dopamine reward systems through
administration of substances of abuse are unable to provide homeostasis for the organism, in fact,
the pleasurable affects that originally exponentially increases dopamine release begins to
dissipate; the perpetuation of the positive reward cycle associated with the binge/ intoxication
stage of addiction, quickly shifts into a negative emotional state through activation of stress-
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surfeit mechanisms that contribute to the withdrawal/ negative affect cycle stage of addiction
through the complex allostatic dysregulation of the amygdala.44
The neurobiology of the withdrawal/ negative affect stage of addiction marks the shift
from positive reward reinforcement associated with the hedonistic pleasures associated with
substance use toward the negative reinforcement of substance withdrawal and increased
tolerance that account for the complexity of adverse emotional states, which include anxiety,
discontentment, increased stress response, and hypersensitivity to emotional duress; this
progression is directly associated with the allostatic down regulation of reward mechanisms,
which are associated with the perpetuation of the dark side of addiction.45 Additionally, the
switch to negative reinforcement stage alters the primary impulse control disorder to a
compulsive disorder state, as first described by Dr. Richard Solomon through the affective
phenomena associated with the hedonistic contrast, or counteradaptation or opponent process.46
The amygdala is located beneath the basal ganglia and is associated with the brains
reaction to the withdrawal of substance and increased tolerance in the negative emotional state
that is precipitated through the release of stress hormone and neurotransmitter release, interfers
with normal neurocircuitry functioning.47 The sympathetic nervous system (SNS)’s fight or flight
response is initiated through the hypothalamus-pituitary-adrenal (HPA) axis-release of
corticotropin-releasing hormone (CRH), which in turn activates the neuroadaptations interactions
with nor-adrenaline (NA), which further activates the perpetuating cycle of CRF release and the
pathological responses that occur during the withdrawal of substance use.48 The activation of the
physiological stress response processes in the absence of substance marks the beginning of
compulsivity; compulsivity is associated in psychiatry as a person’s innate impulse to perform an
act, even when the act is irrational or against one’s free will to perform the act. Compulsion

30

occurs in response to the neuroadaptations associated with the allostatic changes noted with
substance use disorders and addiction by influencing the person’s repetitive and continued
behaviors, despite the adverse physiological and societal consequences.49
The activation of the stress response directly correlates to the negative reward stage,
while also consequently setting up future binge/ intoxication stages of substance use, continuing
the cycle of use, abuse, withdrawal, and negative effects despite recognition that consequences of
substance use results in negative rewards or harmful effects.50 Additionally, the withdrawal/
negative affect stage of addiction is associated with elevated tolerance of substance, requiring a
person to consume increasing amounts of substance to ‘achieve’ correlating hedonistic or
pleasurable effect of drug; this cycle perpetuates exponentially an escalating desire or
physiological craving despite increased consumption of substance and regardless of long periods
of abstinence.
Withdrawal of substance and especially the acute withdrawal of substance increases the
release of nor-adrenaline (NA) or nor-epinephrine (NE), increase dynorphine release, and
increase corticotropin releasing factor, while also decreasing neuropeptide Y (NPY) or the
brain’s anti-stress system; the release of catecholamines, excessive cellular and increased
organism excitation responses are associated with intracellular programing of stress responses
activated by the intrinsic cellular reward memory deficit; cellular memory contributes to the
cellular expression known as methylation of cellular programming that potentiates
transgenerational stress states and affinity for substance use disorders for up to four generations
according to heritability studies.51 Once the binge/intoxication, withdrawal/ negative affect
stages takes hold, the neuroadaptations cycle through intense physiologic preoccupation/
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anticipation/ craving stages that further sustain the neuroadaptation stronghold, exponentially
increases risks that perpetuate addiction cellular cycles trans-generationally .
The neurobiology of the preoccupation/ anticipation stage links the construct of ‘craving’
with the executive functioning of the prefrontal cortex. The prefrontal cortex, is directly involved
with memory, language, intelligence, emotional regulation, planning, inhibitory control of
interferences, and factors associated with learning that constitute executive functioning.52 The
functions of the prefrontal cortex additionally, include learning from experience and the ability to
feel and express emotions such as empathy.53 Dr. George F. Koob describes the executive
functioning qualities of the prefrontal cortex within the framework of stimulating and inhibitory
responses, that initiate the decisional ability through ‘go-responses,’ and ‘stop-responses’
through functions of memory retrieval, that include rules, values, and action response
inhibitions.54
The stimulating responses help people make decisions, plan, and set goals and the stop
substance use or drug use stimulates increased activity in the prefrontal cortex by activating the
release of glutamate to the nucleus accumbens.55 Glutamate is the major excitatory neurotransmitter in the brain and it is associated with increases in drug seeking behavior when there is
increased release from the prefrontal cortex; whereas, when studies that have blocked glutamate
receptors in the prefrontal cortex prevention of drug seeking behavior was noted.56 The stop
function of the prefrontal cortex, inhibits the stimulation or ‘go’ processes that regulate stress
responses, emotional responses and incentive salience.57
Incentive Salience enables the activation of the brains reward system by associating
certain stimuli with the use of substance; hence, recognizing the learned association with
pleasurable feelings or ‘memories’ associated with substance use.58 As a result, internal states
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such as mood or emotions and external states such as people, place or things can trigger cues or
desires for substances to persist, even after the direct effects of substance have diminished even
into years of recovery or abstinence.59 The most revolutionary scientific findings regarding the
neurobiology of chronic diseases, such as addiction include the increased understanding of the
relationship between genetic and epigenetic heritability of dysfunction; once, stigma is
eliminated, and once adequate educational initiatives are implemented and disseminated to those
at most risk, unprecedented human harms will discontinue from causing early death and
subsequent biological harms.
b. Genetic Influences
Addiction disorders, along with most other chronic disease states, such as diabetes
mellitus (DM), hypertension (HTN), and Alzheimer’s disease are polygenetic in nature;
meaning, that heritability does not depend upon one exact gene or one specific genetic code for
the transmission of dysfunction, generation after generation.60 However, increased heritability of
substance use disorders and addiction were first investigated and recognized through patterned
occurrences that were noted in longitudinal research methods that analyzed comparisons between
monozygotic and dizygotic twins of alcoholic parents; monozygotic twins had an increased
heritability of alcohol addiction, despite being raised in different environments.61 Present day
research continues to find the genetic influences that predispose patients to addiction; they
include genes that impact metabolism of various substances, genes that influence reward and
reinforcement of substances, and they include looking at the transgenerational neurogenetic
adaptation variants of single nucleotide polymorphisms (SNP)s.62
SNP’s are single base pair positions in deoxyribonucleic acid (DNA), where sequencing
alternatives of (A, C, T, G) pairs are placed in ‘different’ sequencing positions; genetic studies
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have indicated an association between SNP of the growth hormone secretagogue receptor
(GHSR) and substantial alcohol use, several cannabinoid 1 (CNR1) gene in humans are indicated
to susceptibility of alcohol dependence, gamma aminobutyric acid type A (GABAA) and gammaaminobutyric acid type A receptor alpha2 subunits (GABRG2) are associated with increased
vulnerability to both alcohol and drug addiction associated dysfunction.63 The polygenetic nature
of disease states is difficult to specifically identify, because of the nature of how genes also
respond to interactions with their social and environmental surroundings; encoding of genes is
passed along from generation to generation, but the greatest promise of determining expression
of this genetic encoding suggests development of resiliency over time versus rigidity of
heritability.64
The social awareness of the adverse effects of the disordered use of alcohol and its
generational effects on families has been widely studied. Some sources report a staggering
estimation of a forty to seventy percent increase in heritability of gene traits that predispose
individual risk for acquiring a substance use disorder or addiction to alcohol.65 Research that
examined the genetic risk for substance use disorders and began to also examine additional
genetic influences of increased heritability of alcoholism in adoption studies.66 Information
obtained from research revealed that sons of alcoholic fathers who were raised in non-alcoholic
environments had a significantly increased risk for ‘becoming’ an alcoholic as the child grew to
adulthood. 67 Additionally, monozygotic (MZ) twin adoption studies, or twins that have the same
human leukocyte antigen (HLA), indicate a stronger correlation of alcoholism compared to
dizygotic (DZ) twins, by more than thirty to forty percent.68
Unfortunately, isolating the exact genetic component of substance use disorders, such as
alcohol addiction has not successfully been accomplished. Recent genetic research findings
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indicate that substance use disorders and addiction are more accurately described as ‘polygenetic
disorders,’ meaning that multiple genes and influences ‘on’ genes effect predicted risk.69 The
investigation of genetic influences associated with alcohol use disorders and alcohol addiction
isolated two broad groups of gene alleles. The two groups of alleles include ones that ‘impact
alcohol metabolism’ and alleles that influence ‘reward, reinforcement, and cognitive effects of
alcohol consumption.’70 Additionally, neurogenic studies on alcohol abuse have revealed that
neurogenetic adaptations are commonly associated with the complexities of behavior; scientists
have replicated single nucleotide polymorphisms (SNP)s of inbred ‘alcohol preferred’ genetic
strains in mice that parallel with the human genome.71 These neurogenetic adaptation models
reveal significant findings that point toward the significance of the hypothesized
transgenerational effects of genetic variants that are inherited. Transgenerational influences that
potentiate ‘created genetic variants’ would increase alcohol abuse disorder and alcohol addiction
risks in familial lineage; this understanding could greatly impact the management of care
provided to populations with increased vulnerability risk related to heritability.72
Genes that influence alcohol metabolism are claimed to be the most reliable indicator of
alcohol use disorders.73 Metabolic break down of alcohol occurs by the enzymes called alcohol
dehydrogenase (ADH) and acetaldehyde dehydrogenase (ALDH2).74 Three types of alleles,
ADH1B*2, ADH1*3, and ADH1C*1 have been identified to protect against alcohol abuse and
addiction, fetal alcohol syndrome, and birth defects related to alcohol consumption.75 ADH1B*2
and ALDH2 *2 alleles are commonly found in East Asian populations and are not found, or
uncommonly found in Caucasians of European descent. The protective properties associated with
the ADH1B*2 alleles include increases in acetaldehyde accumulation in the blood that produce
the deleterious manifestations of mild facial flushing, headaches, and more serious symptoms
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such as cardiovascular collapse, and convulsions.76 The inability to metabolize alcohol restricts
consumption for some populations by initiating severe side effects associated with alcohol
consumption and therefore decreasing long-term use, disability and addiction from increased
consumption.77
The interesting correlation is that Caucasian populations of European descent who are
predisposed to alcohol abuse disorder and alcohol addiction do not carry the ADLH1B*2 or
ALDH2*2 alleles. Populations who inherit the protective gene allele combinations also
experience ‘faster’ alcohol or substance elimination, thus further decreasing the adverse
metabolic effects that are experienced by populations of European descent.78 Additional genes
such as ADH4 and ADH4-7 are also associated with increased risk of alcohol use disorder and
addiction, both of these genes are commonly found in Europeans and Americans of European
descent.79
Gene Alleles that influence ‘reward, reinforcement, and cognitive effects’ of alcohol are
even more complex than the genes that influence metabolism. The latest research that examined
the human genome project identified almost 1,500 genes that are associated with the
phenomenon of substance abuse and addiction.80 There is also an interesting correlation between
the neurobiological stress response states, as they are associated with the ‘withdrawal/ negative
affect cycle of substance use disorders and addiction; these gene studies are traced to elements of
stress and craving with the SNP corticotrophin-releasing hormone binding protein (CRH-BP)
gene in stress induced recurrence of substance abuse.81
Through advances in technology, scientists are identifying genes that influence
neurotransmission or inhibit neurotransmission by analyzing complex polygenetic influences of
heritable allele combinations.82 The implications for practice includes advancing comprehension
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of risk that can potentiate avoidance of behaviors or lead to improved understanding of
predisposing substance use and addiction traits.83 Additionally, the need to further evaluate the
possibility that individual subjective responses to drugs of abuse may have a genetic
predisposition related to psychiatric or neurobiological hyper-excitatory disorders or inhibitory
disorders such as depression or anxiety, must also be considered.84 Genetic predisposition to
alterations in drug effects are known to predict future substance abuse or disinterest. Advances in
recognizing the genetic influences on substance use disorders and addiction could help identify
which polygenetic allele combinations could potentiate risk for individuals and families;
identification of allele combinations could provide high-risk populations with the vital
information that could significantly improve health outcomes for families and future generations
in order to decrease risks for harms.
c. Epigenetic Influences
Epigenetics is the exciting science that evaluates how the environment and social
relationships interact with biological DNA coding and responses to human lives; in the study of
epigenetics we begin to unravel the mystery of how generational responses to stress, illness, and
wellness influence heritability and familial lineage of suffering or flourishing. Epigenetics seeks
to understand the functioning of those interactions of genes within the environmental and social
constructs of relationships without changing individual DNA structures. Through epigenetic
expression of heritability traces of suffering, struggle and hardships are effected from generation
to generation; this is perhaps the single most essential element of understanding the complexity
of dependency, substance use, and addiction as it relates to heritability of those traits.85 It was
originally thought that the heritability of genetic DNA structure was the single most component
necessary in understanding the heritability of disease; however, further advances in science
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reveal discovery that the epigenetic, changes in gene expression are also inherited from one
generation to the next. This epigenetic inheritance progression helps to uncover how individual
experiences potentiate heritability through the development of epigenetic tags; epigenetic tags
can activate or silence genetic expression through processes such as methylation for as many as
three to four futuristic generations.86
The genetic expression that can be altered by environmental stimuli, such as carcinogenic
exposure, physiological disease states, nutritional deficits, stress, and environmental toxins can
be identified via targeted technological interpretation advances recognized in candidate gene
association studies via genetic markers; gene association studies and genetic marker findings
show alterations in chromatin remodeling, DNA methylation, phosphorylation and
dephosphorylation of proteins are recognized as cellular processes that can contribute to the
environmental and social/ or epigenetic influences of substance use and addiction disorders.87
Understanding the physiological processes that increase the risk of heritability for addiction has
the ability to alter the crippling effects of potentiation of decreased human flourishing often
associated with dependency, substance use and addiction disorders; historically social constructs
of thought about addiction disorders, places an unsupported stigma or blame on individuals that
are classified as weakness and sin. However, the scientific, neurobiological, genetic, and
epigenetic evidence indicates, that cellular vulnerability of individuals and societies are
perpetuating disease related harms, just by simply isolating and ostracizing those with substance
abuse disorders and addiction through constructs of marginalization and criminalization.
The physiological and neurobiological constructs of disease, the supportive genetic and
epigenetic connections that link the causative impact of environmental and sociological stressors
to direct pathophysiological changes within persons has great potential to change the way
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substance use and addiction disorders are socially constructed and managed. The biological and
cellular sequela of the hormonal response to stress states is controlled by the functioning of the
hypothalamus-pituitary-adrenal axis (HPA) axis, which is part of the neuroendocrine response to
a perceived threat to safety; the interesting component of the physiological stress responses is
how the intrinsic cellular response is directly correlated to DNA and mechanisms of cellular
expression.88 This means that cellular regulation during stress is not equal from person to person,
or from generation to generation; the HPA axis potential influences hypersensitivity to cellular
dysregulation states that predispose pathological responses that potentially become leading
factors for substance use and abuse, but it additionally plays a significant role in increased
anxiety like behavior states during withdrawal of substance use.89
The emerging field of epigenetics began its public descriptive début in 2010, when Time
Magazine announced the marvels of how environments and human choices through behaviors
influenced the epigenome and genetic coding of the human species.90 The epigenome became
known as ‘the level above the gene’ that controls cell fate; this gene expression is determined by
environment, nutrition, stress, and other altering factors.91 The inquiry that seeks to investigate
the relationship between genetic and environmental factors has been philosophically investigated
for centuries; actualization of concept application can now descriptively and objectively emerge.
Present science is beginning to understand the relational causes of genetic influences and its
intense interconnection with social and environmental influences; it is becoming evident within
the study of epigenetics that the daunting task to fully ‘map’ the intricate relationships between
genetic and epigenetic controls influencing the expression and silencing of complex cellular
interactions such as human behavior will require continued investigative research.
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However, the scientific research is becoming increasingly clear that biochemical
determinants are associated with organism development and that alterations in central nervous
system (CNS) functioning are highly affected by experience, genetics, and environmental
factors.92 The complex interactions between experience, environment, and genetic factors are
clearly interrelational in nature, confirming that the chemical reactions that activate and
deactivate cellular responses are part of our heritability patterns. The scientific discoveries that
are occurring in epigenetics are initiating the development of new therapeutic health
interventions that seek to manipulate cellular responses in order to promote health and wellness
in chronic disease management states, including substance use disorders, addiction, cancer,
mental health disorders, and neurodegenerative disease.93
The biochemical regulating functions in substance abuse disorders and addiction that
modify the gene without altering deoxyribonucleic Acid (DNA) sequencing include the
epigenetic mechanisms known as ‘DNA Methylation, histone modification, noncoding
Ribonucleic Acid (RNA), and other chemical alterations of DNA molecules.’94 The
environmental influences from alcohol consumption show chromatin remodeling, histone
deacetylations, and DNA methylation in sustained and chronic use.95 Cytosine 5-methylation is
the gold standard of epigenetics because it specifically regulates gene transcription.96 Regulating
gene function is called transcription and over periods of persistent change such as with
administration of alcohol or persistent CNS stimulation such as stress, significant and lasting
change can occur to gene expression.97 In disorders that are associated with increased stress
response and sustained sympathetic nervous system (SNS) stimulation, such as depression, posttraumatic stress disorder, and addiction disorders additional cellular changes are noted to occur
through protein histone modifications, DNA methylation, and nucleotide sequencing alterations;
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these alterations have been found to indicate significant changes of cellular expression that result
in significant damage to human nervous system functioning.98
Rodent studies have revealed unquestionable linkage to heritable epigenetic influences
when endogenously administered alcohol is given to individual mice; similar modifications are
recorded in consecutive generations. The epigenetic modifications correlate to the hypothalamuspituitary-axis stress response mechanisms that potentiate sustained SNS responses, increased
‘ethanol drinking preferences in rodents activate the stress response and cellular changes.’99
Additionally, the epigenetic changes to chromatin are noted with the administration of chronic
dosing of benzyl alcohol in mice, which causes an induced ‘tolerance’ of the substance and
‘remodeling of cellular memory by’ transcription.100 This discovery actualizes the experiential
components of the previously thought to be ‘subjective criteria’ of substance abuse disorders and
diagnostic guidelines. The epigenetic changes that influences behavior in patients diagnosed with
substance use disorders and addiction objectively document personal thoughts, moods, and
experiences.
The scientific discoveries of epigenetics potentiate improved management of care for
those diagnosed with substance use and addiction disorders. The inability to isolate specific
genes becomes less significant with the realization that epigenetic gene expression can provide
perhaps a clearer potential in the development of new pharmacological, pharmacodynamics
potentially influencing genetic modifications; understanding the pathophysiology of disease
potentiates benefits of treatment intervention modifications that positively influence epigenetic
changes that enhance cellular functioning and may alter the damaging effects of acetylation,
remodeling, or methylation processes through purposeful and therapeutic manipulation of
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epigenetic processes that seek to decrease the deleterious effects of prescription narcotic use,
illicit substance use, alcohol consumption over time and for future generations.101
Unfortunately, transgenerational stigma often impacts not only individuals, but entire
families and communities who are socially labeled or isolated, because of social constructs of
deviance; generational blame is perpetuated through social perception that addiction is a defect
of moral character and that decline in moral value is passed from generation to generation.
Transgenerational epigenetic inheritance is proven to occur in plants, fungi, and mammals.102
Current transgenerational epigenetic inheritance research has also proven that epimutations in the
human DNA occurs by multifactorial causes of impaired gene expression in cancer, metabolic
disorders, neurological disorders, and mental health dysfunction.103 Yet, the transgenerational
epigenetic inheritance as it relates to substance use disorders and addiction is not a strongly
understood correlation within recognizing, that risk for genetic heritability of substance use
disorders and addiction meet the same rigorous scientific certitute as other transgenerational
epigenetic disorders; because of negative perception. However, the polygenetic influences
associated with substance use disorders, such as alcohol dependence have been well documented.
However, correlating and scientifically ‘proving’ the association of the ‘inherited’ influences of
gene expression and genetic imprinting due to environmental manipulations on the central
nervous system’s functions as it relates to DNA expression is ‘becoming’ an expanded frontier of
scientific discovery as it relates to improved understanding of mental illness and addiction
disorders.104
Not all genes are ‘functioning’ at all times. One of the processes that silence gene
expression is DNA methylation. DNA methylation has a distinct role in substance abuse and
addiction, because it ‘shows’ a chemical ‘mark,’ which takes place near ‘promoter regions of
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genes;’ the correlation related to methylation near promoter regions of genes determines the
degree of chemical modifications that ‘promote’ or ‘silence’ gene expression. The DNA
methylation function in normal gene expression is an essential element of maintaining cellular
homeostasis. However, abnormal DNA methylation can cause disordered cell ‘fate’
determination, such as in hypermethylation and tumor suppression.105 DNA methylation can be
influenced by environmental influences such as diet, chemicals, alcohol and illicit drug abuse.106
DNA methylation has been found to be an important element of genetic imprinting for Xchromosome inactivation, and silencing of gene expression in cancer studies through
hypermethylation, and similarly, the activation of abnormal silencing also occurs in regional
promoter sites called CpG islands in substance abuse.107 The sad truth is that hypermethylation
commonly found in tumor gene suppression in cancer cells does not ‘carry’ the same social
stigma implications that are associated with hypermethylation or silencing of gene expression in
cells associated with substance abuse and addiction disorders.
It was previously hypothesized that genetic expression could not be heritably transmitted
from generation to generation; however, transgenerational elements of learned behavioral and
environmental associations are indeed evolutionarily passed from one generation to another. This
transference has been difficult to trace, but complex elements of classic genetic heredity along
with the predisposition to sustained stress can drastically affect family response or expression of
the hyperactivity of catecholamine and neurotransmitter response to potentially harmful
environmental stimuli. Increased understanding of genetic mapping, neuroepigenetic changes to
adult central nervous system response, and inbred genetic strains of increased nicotine, alcohol,
and illicit drug use such as opioid heritability began with the study of mice; the prolonged opioid
and ethanol exposure was studied extensively in 1959.108 As a result, implications from the
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research studies have continued to develop. Consequently, in 2002 research initiatives sought to
parallel mice and human genome mapping in an attempt to compare DNA methylation, gene
expression, and ‘lasting’ heritable consequences in developing risk for substance abuse
disorders.109 Because of the noted consequences related to changes in behavioral and societal
isolation in the mice, application of human discrimination, as it related to the inbred breeding of
rodents helped collect data that supports that both genetic and epigenetic transgenerational data
collection is relevant in identifying significance of increased generational risk for substance
abuse that includes heritability of responses.110 Transgenerational familial risk for substance
abuse and addiction is also associated with pre-existing or increased development of conditions
such as depression, anxiety, panic disorders, that can lead to suicide, chronic liver failure,
hypertension, hyperlipidemia, and cancers.111 It is evident that the genetic and epigenetic
phenomenon of substance use disorders and addiction can be heritability transmitted from one
generation to another; however, the replication of specific heritability of epigenetic factors
continues to require further analysis to assist in the cumulative power to target prevention
strategies, implementation of treatment modalities to decrease the deleterious consequences of
abhorrent methylation and genetic expression that increases individual and generational risk.
2.2 Social Stigma of Addiction
Stigma is a construct of belief that identifies individuals or groups of individuals with
socially contemptuous qualities; stigma is sociologically associated with exploitable components
of isolation and discrimination; the social stigma of addiction considers substance abuse and
addiction as a rational choice, as individual weakness to the vulnerability of pleasure seeking
vice, and therefore demanding moral and social culpability. Stigma has its evolutionary routes in
culture by labeling individuals as being different; therefore, justifying their removal from the
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community.’112 Excluding and isolating those who exhibit undesirable behaviors and
characteristics within social structures has a rich historicity; the development of such practices
are responses to physical and emotional differences, fear of social disruptions, and fear of harms
to others within the community because of the potential for disease transmission.113
Stigmatization also occurs within societal structures when people are perceived as
different or potentially harmful to the group. Stigmatization is projected toward another person
when they are considered morally weak and vulnerable to sin and wrong doing, which greatly
increases individual stress, perpetuates a negative self-worth and ruins one’s personal identity
and reputation.114 Additionally, social constructs of stigma are associated through the lens of the
linguistics that describe individual character flaw and sin. Historically, conditions such as
leprosy, infectious wounds that did not heal, organ and systemic infection states were perceived
disdainfully for the persons who were afflicted, in fear that the physical condition would also
harm others. This philosophical approach to illness states subjected increased vulnerability for
individuals because of fear and ‘unknowing’; applying constructs of sin and blame for unknown
circumstances, invoked escalating images of fear, isolation, and stigmatization for those afflicted
with disease states. Therefore, practices of isolation, and separation from social groups began
invoking dehumanizing qualities of personhood to those who were afflicted, ill, or suffering.115
Stigma abhorrently, devalues the intrinsic dignity of a human person. The devaluing, or
the deconstruction of human worth, places negative labeling or scaring upon those with
substance use disorders and addiction as a disorder inflicted by choice due to character flaws,
which are fully controlled by or within a person; however, isolation, labeling, and dehumanizing
individuals potentiates the acceleration of vulnerability within social groups. Separation and
alienation of persons outside of community greatly contributes to power imbalances, exploits the
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labeled, and perpetuates the neurobiological stress for those at risk for the transgenerational
harms with a single exposure to substance despite genetic risk of heritability in combination to
the negative effects of societal culpability to entire family lineages, which increases potential
suffering for many generations.116
Social stigma is closely associated with discrimination, social salience, perceived
negative characteristics, labeling, and status loss; historical treatment for those who have
substance use disorders and addiction has cultural and historical significance because it portrays
the associated stigma that has inflicted millions of persons throughout the world.117 The ‘War on
Drugs’ further exacerbated the justification for stigma by declaring moral culpability that
projected disdainful reproach toward those diagnosed with substance abuse disorders and
addiction, further spoiling personal identity and marginalizing populations who were routinely
associated with illegal drugs, illicit drug use and addiction.118 Perhaps, one of the most poignant
contribution of stigmatization toward one another is the creation of fear directed toward oneanother; fear is a natural part of human living and it occurs whenever one’s safety is threatened
or perceived to ‘be’ threatened.119
The ‘War on Drugs’ inflicted fear in the American people, it inflicted fear of individuals
who did not use drugs and it inflicted fear in those who already had substance abuse problems.
Fear was inflicted in people who ‘use’ drugs, because, now they were unable to publically ask
for help for fear of incarceration; the current criminalization of persons as a result of illicit
substance use continues to isolate communities, perpetuating barriers that impede social
responses to care, and often times accelerates the perception that there is ‘nowhere’ to turn for
help. Public health initiatives, acute care education initiatives, public policy and community
outreach should seek to promote policy formation that eliminates fear and stigmatization.
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The human tendency to protect oneself and other members of one’s community has
evolutionary characteristic roots, which seek species preservation. The ‘War on Drugs’ was
initiated as a moral imperative with the overarching goal to stop the continued use of addictive
substances that causes physiological harm to individuals and populations; hence, its intention
was to avoid the enormous consequences associated with the harm of drug use. Unfortunately, by
inflicting fear and strong emotions of negativity to individuals, the War on Drugs’ invoked upon
the heartstrings of American citizens resulted with development of deep, personal, and moral
convictions that substance use disorders and addiction was an of absolute moral wrong doing and
completely preventable through responsible action of individuals versus public policy
implementation.120
Escalation of fear as a result of the effects of drug use within communities also have
historical impact on perception of increased crime in communities, escalation of compulsive
behavior to escalate violence and death. The ‘War on Drugs’ criminology approach to substance
use disorders and addiction incorrectly constructs the moral view of blame, versus the
understanding and knowledge that substance use alters normal and intrinsic neurobiological,
genetic, and epigenetic reward pathways through neurocircuitry mechanisms not previously
understood; applying the relevance of deontological ethics, virtue/ vice ethics, and
consequentialism, unknowingly and harmfully influenced the loss of millions of lives.121
The narrow view that blames and stigmatization individuals through this moral viewpoint
increases elements of fear and further isolates members of the community from adequately
developing policies and treatment interventions that could help eradicate the exponential crisis of
substance use disorder and the transgenerational progression of severe and devastating harms.122
Consequently, inflicting fear, marginalization, and stigmatization does not decrease the
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perpetuation of substance use disorders; nor did fear and marginalization ever decrease the
transmission of communicable diseases, decrease the development of mental illnesses, cancers,
skin disorders or any other associated human vulnerability states.
During a European study that sought to objectify the elements of stigmatization of
persons who were diagnosed with alcohol substance use disorders, lay population opinion
surveys were assessed to evaluate the perception regarding the ‘believability’ of substance use
disorders or addiction as an authentic disease state; participants ranked strong emotions such as
irritation and anger as a common response to the repulsiveness of substance use disorders and
addiction.123 Across all populations, study participants were unable to disassociate the
pervasiveness of individual blame projected onto the addict and they reported, that they had a
strong desire to ‘create’ a significant social distance from those who suffered with substance
abuse disorder and addiction.124 Victim blaming is also a common response of healthcare
providers to individual patients during acute substance withdrawal complications, chronic health
related to substance use or mental health consequences; the study significantly identified that it is
difficult for the general populations to understand that genetic factors, environmental factors, and
societal factors all interplay as causative agents or causal responsibility of the complex nature of
substance use disorders.125
Advanced education is necessary in distributing knowledge to healthcare providers and to
the public that ‘victim blaming’ is not an effective way to decrease the deleterious effects of
health and social consequences associated with substance use disorders and addiction.
Additionally, recognizing that environmental influences, laws, and fear can also further
discriminate, stigmatized and isolate vulnerable populations from acquiring the help that they
need is essential.126 Education should be disseminated to the public, so that societal influences
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that further impair recovery, or prevent identification of health determinants of diseases,
including comorbidities of disease will not be ignored.127 To individually blame people versus
impact of community systems and societal constructs of relationship deters the implementation
of public health interventions that can seek to improve lives and remove vulnerability of
harms.128 An ethics of care requires implementation of a substance use disorder and addiction
management of care framework that publically helps the stigmatized and acts in assistance by
provide hope for the disenfranchised, and the marginalized.129 It envisions empowering children,
families, and generations through education initiatives related to genetic predisposition risks and
the epigenetic influences that decrease substance use disorders, by decreasing vulnerability,
isolation and stigmatization and recognizing that addiction management of care supports realistic
options for relational and community participation toward a comprehensive societal health
wellness plan for everyone, despite risk through the deconstruction of the myth that substance
abuse and addiction is influenced solely as a disorder of rational choice .130
a. Addiction as a Rational Choice
In an attempt to prevent the deleterious physical and social effects of illicit drug use and
substance use disorders, governmental law attempted to remove the autonomous rights of
individual citizens to legally consume drugs such as heroin and cocaine; although legal
permission is granted for the usage of nicotine and alcohol, it is questionable whether those who
have a substance use disorder or are have physiological addiction to substances truly have the
capacity to freely choose usage.131 The very definitions that classify substance use disorders,
clearly indicates that some persons do not implicitly have person control to ‘stop’ the
pathophysiological processes of addiction. Within the past few decades, recent laws have lifted
strict prohibition of marijuana in states such as Nebraska, Alaska, and Colorado; many other
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states also permit medical marijuana use. The process that decriminalized use of marijuana is an
initiative sought to decrease the escalating costs of incarcerations and to permit autonomous
rights of individuals for recreationally consumption of select drugs.132
Additionally, Douglas Husak as a proponent of individual ability to autonomously decide
whether or not personally one would ‘like’ to consume certain drugs for recreational pleasure
agrees with developing social utility contracts that seeks to restrict the unlimited use of certain
drug consumption, but openly providing an option, while setting restrictions on consumption in
order to prevent harm to society.133 According to the Report of the Global Commission of Drug
Policy on the War on Drugs, decriminalization of marijuana or cannabis does not increase
cannabis consumption, crime, or societal harm.134 Additionally according to the report, most
people who consume drugs are not amoral citizens; therefore, it was seen as unrealistic for
societies to treat all substance users and producers of drugs as criminal masterminds.135
Therefore, a comprehensive analysis of public health principles would be necessary in evaluating
if the rights, which include individual autonomy within a universal framework of regulation
should necessarily restrict global permissibility of free and autonomous consumption of drugs,
despite ‘knowing’ the risk of the cyclic chronicity of harms that alters neurological
functioning.136
Substance use and addiction is often associated with the ‘perception that the ‘ability of
individuals who desire or ‘will’ the cessation of substance use, once substance use is initiated is
problematic for those with substance use disorders and addiction. The person often times
verbalizes the desire to ‘stop’ but autonomously has difficulty, understanding the cravings and
negative emotions that propel continued use; this dichotomy of self was described in ancient
Greek and Biblical writings with the inordinate consumption of alcohol for some people.137 This
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dichotomy or tension between the will and the self, identifies neurobiological mechanisms that
describe the alterations within neurological pathways, which fuels the dichotomy between will
and action; the neurobiological traits hijack neurological reward pathways, coercing the will to
use despite explicit expression of distress.138
The American Psychiatric Association (APA) and the American Society of Addiction
Medicine (ASAM) identify dependency as the first stage of addiction that adheres to the
following criteria: A.) Uncontrollable craving and inability to stop using substance; B.) Onset of
physiological anxiety for substance; C.) Symptoms persist over time and reoccur over time for
substance; D.) Substance abuse, addiction and dependency require long-term management of
care, and like other chronic disease states, substance use disorder, addiction, and dependency is
never cured.139 Dependency, substance use disorders and addiction are classified as chronic
spectrum disorders or conditions, which are considered a primary disease of the brain that
impairs memory, executive cognitive functioning, and reward neurocircuitry.140 If substance use
disorders and addiction are freely chosen and societal constructs of addiction is to perpetuate,
how is it that social policy and social constructs of blame, can completely reject the diagnostic
criteria that explicitly expresses the disorder as a primary disease state that impairs memory,
impairs neurological functioning through disruption of executive pre-frontal cortex cognitive
functioning and therefore impairs neurocircuitry.
Unfortunately, since the recognition of the scientific community’s specific criteria for
dependency, substance use disorders and addiction as processes of known neurological
impairment states of impaired-rationality processes, the cultural and societal constructs of
addiction continue to perpetuate the global perception that substance use disorders and addiction
remain individually blameworthy as if authentic decision-making processes were intact; the very
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idea that purposeful and normal executive decisional functioning occurs through the
autonomous ability to independently and consciously act freely, even though the devastating
biological reward circuitry malfunctioning is evident through allostatic brain pathology,
incorrectly labels and marginalizes millions of people, contributing to the exponential rise in
poor management of care for those with dysfunction.141 The socially abhorrent opioid epidemic
clearly illustrates the gross neglect of our social response to the epidemic.
Recognizing that the essential components of conscious decision-making include the
proper functioning of neurological pathways of cognition that do not impede decisional-capacity
is increasingly evident. In an attempt to further accelerate management of care initiatives, this
dissertation asserts to illuminate the parallel that substance use disorders and addiction criteria
meet as a neurocognitive dysfunction. Alterations in cognitive neurological dysfunction is
identified by the American Psychiatric Association (APA) as neurocognitive dysfunction that
occurs in specific or reginal domains of the brain that alter the brain’s functioning; substance use
disorders and addiction pathology identifies dominant changes in the brain’s basal ganglia,
extended amygdala, and the prefrontal cortex, through alterations in neurocircuitry.142 Conscious
decision-making requires capacity to make autonomous choices, while being able to decipher the
pros and cons of the trajectory of particular decisions; yet, those who succumb to the
physiological trajectory of substance use disorders and addiction often verbalize consistent desire
to cease usage of substance, without the capacity to do so.143
Determining decisional competency in healthcare requires providers of care to assess the
cognitive functioning of individual patients; this task becomes particularly challenging when
patients are diagnosed with substance use disorders and addiction and exhibit correlating
manifestations of neurodegenerative and neuropsychological disease processes; because of
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elements of stigmatization and oversite the overshadowing of believing that the person willfully
brings harm to self through consumption of substances are grossly overlooked. The scientific
evidence recognizes that individual competency fluctuations and inconsistent cognitive abilities
maintain unpredictable variability in decision-making for those with substance use disorders and
addiction; yet, application of sliding scale decisional capacity assessments for those with
substance use disorders and addiction is rarely, if ever identified, examined, or applied.144
The ability to make rational choices requires the ability to execute proper executive
functioning pathways dependent upon homeostasis of neurobiological functioning through
coordinated neurocircuitry pathways from the regions of the brain including the prefrontal
cortex, amygdala and basal ganglia.145 The progression from homeostasis to the neuro-adaptive
allostasis states within substance abuse and addiction dysfunction is extensively discussed in
the neuroscience of addiction and substance abuse through the complex processes of
neurochemical dysregulation noted within the brain; the brain’s ability to normally regulate
stress and reward circuitry mechanisms is greatly impaired for those with substance use disorders
and addiction. Therefore, insisting that antiquated and inaccurate social constructs of ‘free will’
and rational choice in substance use and addiction states is unwarranted; to continue viewing
decisional states as rational and freely chosen, as implemented in the criminal models of
culpability, further comprises the reality that addiction meets the criteria of neurocognitive
impairment and therefore, cannot justify that actions are a direct result of a person’s free will or
free choice.146
Substance use disorders and addiction, predispose individuals to the divergent ability to
respond and choose against preferential actions through cue triggered environmental stimuli that
result in systemic errors of brain responsiveness, and oppositional behavior as a result of
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opponent cue induced motivational processes.147 Additionally, compulsivity perpetuates
unintentionality; research indicates that similar patterns occur with systemic errors of habituation
influencing semi-automatic responses, for people that increase the risk for poorly forecasted
short-term outcomes even in normal habitual actions..148 A ‘hedonistic forecasting mechanism’
theory founded within the study of economics, articulates how mechanisms of behavior occur for
individuals in relationship to past experiences and similarly experienced situations; additional
neurotransmitter dysregulation alters motivational behavior.149
An example of non-substance abuse induced ‘poor forecasting responses’ due to one’s
habitual behavior responses include the brain’s patterns or actions that disregard the ‘knowledge’
of which side of the road a person is driving on when driving a car in the United States, versus
the United Kingdom; drivers, while on opposite ‘sides’ of the road, will seemingly choose an
action in an attempt to avoid harms, while reacting as though they are on the opposite, more
habitually familiar side of the road, despite ‘knowing’ and ‘understanding’ that they are driving
on the opposite side of the road. The theory, articulates that people will consistently and
inaccurately assess risks from oncoming traffic, in response to habituated and reactionary
functioning of past driving experiences, despite knowing that the opponent action results in risk
when facing oncoming traffic; reacting from past experiences of driving ‘hijack’ one’s
response.150 Opponent motivational processes of addiction and habitual reactionary mechanisms
associated with the dysregulation of substance use disorder and addiction increases vulnerability
of harms to those affected by the neurobiological attempts to restore homeostasis; reduction of
these harms requires the reconceptualization of addiction as moral weakness and moral
culpability. It is truly an illusionary and unfounded presupposition regarding those affected by
substance use disorder and addiction
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b. Addiction as Weakness and Vulnerability
Although monumental scientific discoveries indicate that substance use disorders and
addiction disorders are physiologically associated with neurological brain pathology and altered
functioning as evidenced by chemical dysfunction, neurotransmission dysfunction, and
neurocircuitry dysfunction, the commonly held perception that addiction is a construct that
strongly presupposes an individual is solely blamed for wrongdoing because of intrinsic
character flaws as evidenced by their personal failures and circumstances, places this population
at an exponential risk for harm and vulnerability.151 The concept of social stigma related to
excessive substance use and misuse has been significantly associated with the moral model
theory that labels individuals culpable for the dysfunction. This theory compares virtue and vice
associated with individual will and action that correlates discourse semantics through associated
alcohol consumption terms, such as wretchedness, vice, or pagan trademarks, which only serves
to further increase individual harms through societal disconnection and discrimination.152
Semantic descriptions that closely correlate all human actions in terms related to virtue
and vice are referenced in the Gospels of Mathew, Mark, Luke, John, and the Pauline Letters
within the New Testament.153 Original Christian writings can be translated from Greek words or
phrases through English interpretations that include; drunkenness, debauchery, drunkard,
drunken, given to strong drink, drunken dissipation, or drunken nausea.’154 The historical
translations become significant, as concepts develop to include acceptable or unacceptable norms
of socially ethical behavior. The social ethics of behavior include concepts regarding ‘extreme
good,’ love of neighbor, and rightly ordered actions versus extreme ‘bad’ causing societal harms
associated with wretchedness of individuals have strong moral consequences.155 Associated
societal norms correlated societal goods by eliminating perceived causes of conflict through
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discrimination of or removal of potential harms, this included discrimination of persons inflicted
with disease, infectious disease states, and mental health disorders.
Public perception of substance use disorders still hold a dominant ‘individual blame’
‘construct’ or conceptualization; hence, causing a societal tension in relation to the genetic and
disease model perspectives. Common public opinion blames individuals for addiction without
accepting social or genetic recognition of the progression of the disease state, which also
contributes to increasing vulnerability.156 Social stigma associated with substance use disorders
and addiction remains a prominent perspective in contemporary American Culture. Vulnerability
by continuing practices that promote stigma, include disqualifying people as ‘whole’ or
devaluing members as unacceptable members of the community; people who are stigmatized for
substance use disorders and addiction continue to be socially excluded, labeled or marked as
abhorrently different and dangerous, and therefore experience social power imbalances and
health disparities that exponentially increase vulnerability.’157
Current research clearly indicates that substance use disorders and addiction are not
perceived as a ‘mental health conditions’ or ‘physiological dysfunction’ by individuals within
society, which is specified by the World Health Organization (WHO) and DSM-V’s
categorization of substance use disorders is a chronic health condition; public opinion regarding
individuals who are diagnosed with substance use disorders and addiction are still assigned
moral blame, considered weak willed and held directly responsibility for their condition.
Substance use disorders are socially stigmatized against, being labeled as an abhorrent condition,
socially disruptive, and requiring punishment. Individuals diagnosed with substance use
disorders are stereotyped as being unpredictable and dangerous, therefore they are socially
distanced and rejected; individuals and families remain hidden in fear of rejection and
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criminalization. Public policy continues to allow for dominant organizational and structural
discrimination against those diagnosed with dysfunction.158
Dysfunctional use of substance was associated with drinking to insensibility; the
temperance movement sought prohibition and complete ‘abstinence of drink as opposed to
marginalization of family members.’159 The paradoxical Christian association of ‘sin’ soon began
to be associated with even moderate uses of alcohol. The ‘concept’ of ‘wrong doing’ and
weakness continues in contemporary moral and ethical constructs of alcohol and illicit substance
misuse. The early Christian traditions have shaped legal systems and policy development,
assigning blame on those who are in legally contempt of the social mandate, through social
culpable standards; however, legal culpability has been translated into absolute discrimination. It
is time to apply a renewed cultural understanding of substance use disorders such as alcohol,
prescription pill epidemic, and illicit drug misuse; it is time to decrease vulnerabilities by seeking
the implementation of interventions that seek to restore the intrinsic dignity of those stigmatized
by restrictive and demeaning philosophical views.
The moral model examines the nature of addiction by incorporating a philosophy that
presupposes that individuals voluntarily choose addiction through individual fault, moral
weakness and culpability.160 This concept was formulated because the decision to drink or not to
drink begins was thought to be a conscious decision to consume excessively, despite harm to self
and others. However, current neuroscience clearly documents that certain individuals due to
genetic influences are vulnerable to severe physiological consequences. In early Christian
thought, drunkenness is perceived as a desire that overpowers individuals or overpowers the will;
its historical relevance is noteworthy because of the social influences of thought that continue to
mold the conceptual theory of dependency remains strongly recognized as weakness in present
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times.161 The increasing evidence that supports the medical model of substance abuse disorder
and alcohol use disorders as relevant disease states, summons the need for the development of a
new moral model for addiction management; the old model, which assigns blame and
culpability, no longer has objective findings to support the relevance for further scientific
validation.
Therefore, a new moral model must carefully be implemented to counter the negative
consequences and vulnerability of disease, the increased social discrimination, marginalization,
and the suffering that resulted in social disparities, decreased access to healthcare coverage, legal
criminalization and social exclusion only served to increase transgenerational vulnerability and
harms.162 Hence, the new moral model must influence a new paradigm of care for those
restricted by neurobiological disease states. The moral model should encourage implementation
of reflective and forgiving paradigms of care that empower wellness for those who suffer from
substance use disorders and addiction; in this capacity, the new moral model may enhance the
disease model of addiction by embracing the imperfections of the biological plights of the human
condition that define all human vulnerability.163
Consequently, the moral tradition contributes to the vulnerability of human nature by
explaining the tensions of dependency through thought, will, and action.164 Genetic, epigenetic,
and transgenerational scientific discoveries may further help explain and uncover the evidence
that supports the elements of substance use disorders that simultaneously occur because of
genetic predispositions, which actualize the division of self and will.165 Unveiling the
contributory causes of substance use disorders and addiction through genetics, epigenetics, and
transgenerational contributions of disease may help provide improved paradigms of policy
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development and improved access to effective medical interventions that obliterate moral blame,
empower recovery, and enhance societal support.
Societal responsibility should recognize that participatory social and environmental
influences that have increased vulnerability for those with increased risk, by culturally promoting
substance use, such as alcohol and prescription drug use within community structures, while
governments, and public policy continue to ‘blame’ individuals almost exclusively without
carefully examining the elements of interrelationality and social responsibilities of collective
participation of vulnerability. An acceptable and responsible societal framework of substance use
disorders and addiction management of care should seek to discontinue personal blame and
stigma that persists for those who suffer the physical and societal consequences of substance use
disorders. It is no longer acceptable to isolate persons who are negatively affected by abnormal
consumption responses.166 The vulnerability associated with current substance use disorders and
addiction requires a closer examination within the bioethical discourse.
Vulnerability of persons with substance use disorders and addiction meet the elements of
vulnerability, meaning that they have been exposed to both internal and external stressors that
presuppose threats to internal biological functioning and perpetuate external threats of exclusion
and isolation, despite decreasing ability to care for self; additionally, persons with substance use
disorders and addiction experience a decreased ability to cope with both internal and external
stressors, as demonstrated with decreasing resiliency and chronic progression of dysfunction,
when left to individual devices.167 Therefore, recognizing that substance use disorder and
addiction increase vulnerability for individuals through the acknowledgement that the
dysfunction violates almost every component that strengthens human connection and individual
actualization through relationships with supportive and relational community constructs of care.
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Peter Block, brilliantly writes about the opposite of vulnerability, which increases
strengths of individuals within community, when he writes about the elements of the abundant
community and the structure of belonging; by describing the strength of restorative communities,
which focus on the gifts of individuals, embraces the power of possibilities in relationship,
believes in the power of language as valuable discourse with one another, and seeks the
transformative power for individuals within community that provides the hope of individuals and
individuals collectively through relationships.168 Human vulnerability need not be regarded as a
negative experience, when vulnerability promotes and motivates human responsiveness, and
actions that include reciprocal care of the other, collaboration and connectedness.169
c. Moral and Social Culpability
The political, social, and religious viewpoints have historically shaped the language of
culpability of substance use disorders and addiction in present day perspectives.170 Application
of semantics that assign sin and moral culpability, assert the need of punitive societal
consequences, which declares a war on drugs; this philosophical approach places a clear blame
and culpability on the individuals as if the person with substance use disorder and addiction were
a fully functioning moral agents. However, the person with substance use disorder and addiction
dysfunction distinctly do not meet the qualifications, which are necessary to meet a
comprehensive and rational moral agent.171
Moral agency requires a person’s ability to reason, an ability to use past experiences as a
guide in decision-making, and the moral agent must have the ability to freely choose actions,
while being able to know the long term consequences of their actions; the continuum from
dependency, to substance use disorders and addiction greatly impairs neurological executive
functioning ability and sustains volitional disability.172 Volitional disability, means that the
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person is unable to freely choose or resolve a problem; substance use disorders and addiction
disempowers the agent from freely resolving circumstances alone, the agent needs relational
support. Placing unfounded culpability and perpetual blaming of individuals upholds the
seemingly never ending cycle of social isolation and disconnectedness that predisposes
continuous human vulnerability within the cycle of addiction; substance use disorders and
addiction remain perhaps one of the final disease state associated with polygenetic,
pathophysiological, and psychological destruction, which is still considered to be a sin. As a
consequence, life expectancy in the United States decreased significantly as a result of
unnecessary opioid overdose deaths as noted in the 2016 statistic report results. More human life
was lost in one calendar year, then during the entire US Vietnam conflict; yet management of
care for this vulnerable population continues to stigmatize and label the individual as sinful and
thus worthy of physiological harm, dysfunction and death, versus implementation of
compassionate action that aims to end human suffering through components of care and
connection.173
The philosophical perspective of drunkenness and gluttony as it is identified in the New
and Old Testament writings and references, describes such actions as sinful, because the actions
separates one’s relationship from self, others, and God; interestingly enough, the moral snap shot
of culpability, requires an in-depth analysis of one’s intentions and circumstances, as they
precipitate one’s actions.174 It is never the intention of an individual to become paralyzed by the
sequential dysfunction of addiction; no one ever claims, “I want to be thrown into the cyclic
dysfunction of addiction and harms in my life.’ Populations that are at most risk for dependency
disorders, are almost always those who have experienced, discrimination, abuse, displacement,
trauma, genetic and epigenetic susceptibility; most notably those, whom have lost their cultural
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connectivity and disruption of family support are amongst the highest at risk for substance use
disorders.175
At risk populations include immigrants, children born into poverty, children who have
been abused, African Americans, Native Americans, families of holocaust survivors, and the
aboriginal people of Vancouver Canada all have increased risk for anxiety disorders, addiction
disorders, diabetes, and stress related neuro-immune inflammatory diseases; additionally the
modern socio-political commodification of institutional systems, the breakdown of the extended
family, the disconnection of communities and cultural ties, and extensive emphasis on
autonomous living versus community life, places enormous risks to everyone.176 Assigning or
placing individual blame and culpability, without considering the scientific evidence that sadly
perpetuates the unhealthy societal state of circumstances, refuses to consider the inherent dignity
and care of the other and places the culpability on the lack of social action, despite ‘knowing’
and having access to evidence and freely choosing to ‘stay’ disconnected and detached; thus,
refusing to assist those who are most vulnerable.
In order to reduce national and global consumption of addictive substance use, one must
first investigate an in-depth analysis regarding the societal causes that shape the perception of
addiction. Evaluating the historicity and perception of social policy and law formation can help
implement-rectifying solutions to previously applied social standards that marginalized and
stigmatized entire populations who suffered from addictive disorders and substance abuse.177 As
previously discussed addictive disorders are most popularly considered through the lens of the
moral model of addiction; this model perceives addiction as a problem of an individual’s poor
choice and culpability.178 However, the scientific literature and research progressively
understands addiction disorders though medical and genetic influences of disease that clearly
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results in severe brain dysfunction. Management of brain dysfunction requires medical
standardized intervention strategies aimed at harm reduction. Health systems must influence
improved management of care for those who suffer from substance use disorders and addiction
by offering real world interventions and solutions. Health solutions must potentiate decreased
drug consumption nationally through education initiatives, prevention strategies, and radical
change processes, which allow transformative potential to manage pathology; hence, changing
legal system processes that inhibit reformation and inhibit the development of improved models
of care.
Implementing a public health discourse that accurately assesses addiction requires a
‘reframing or re-description of the problem’ by evaluating the rights of individuals while
simultaneously evaluating the consequences that criminalization has for individuals and entire
communities.179 By utilizing a combination of an ethics of care, public health principle approach,
combined with health management outcome processes, which seek to implement and evaluate
measures that ensure transformative solutions for substance use disorder cares, a holistic
reestablishment of real world solutions becomes the imperative.180 By applying Upshur’s public
health principles approach through the classic lens of virtue and care, a framework of addiction
management that actualizes Mill’s Harm Principle, through sliding scale capacity assessments, a
transparent, minimally restrictive and coercive means, with the goal of reciprocity can be
actualized.181
Hence, the new health care framework must comprehensively evaluate and mandate
collaboration amongst disciplines while correlating the components of the substance use disorder
and addiction triad, which recognizes the applicability of scientific evidence as the motivator that
seeks restoration of dignity, seeks the respect of individuals and communities, while also seeking
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the hope for healthy social environments, that advocate for decreased access to unmonitored
substance use. This framework accepts the construct of social culpability. Therefore, it cannot
occur solely as a medicalization framework attempt to reduce the risk for patients, separate from
a universal framework of social responsibility; it must seek the understanding of an ethics of care
framework that extends into every aspect of contemporary life through grassroots initiatives that
educate individuals, families, communities. Initiatives of care seek understanding and
collaboration amongst all members of society, including individual persons, organizational
systems, schools, university campuses, universal places of employment, with the intention that
private and government health care insurance providers cooperate in health improvement
outcomes as well.
Therefore, making the important distinction between two types of public health initiatives
is necessary in order to apply the appropriate and ethical planning in the management of
substance use disorders and addiction risk reduction strategies. The first action recognizes that
the moral model of addiction theory must reframe from assigning responsibility of exclusiveness
on the ‘agent’ as the primary cause for the nation’s substance use disorder problem; assigning
individual blame increases human vulnerability because of a refusal to recognize the essential
components of societal and relational culpability. Second, a new moral theory based on an ethics
of care must initiate transformative social and scientific responsibility to protect vulnerable
populations from preventable disease through strategies that seek to protect the most vulnerable
from increased risk. Teaching resiliency and health coping strategies through relational networks
of support becomes a community endeavor that requires relationship. This dissertation asserts
that an implementing an ethics of care framework is the relevant solution to fundamentally repair
harms associated with decreasing the social constructs of harm, such as industrialization,
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immigration and dislocation that contributes to the current national and global substance use
disorder and addiction epidemic.
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Chapter 3 Ethics of Care
Early constructs of care and caring were articulated by the philosopher and professor,
Milton Mayeroff, in his work, entitled: ‘On Caring’ in 1971. Mayeroff stated that caring is
‘helping the other grow and progress in some way.’1 Caring is a process, which is active,
courageous, patient, trusting and hopeful; an ethics of care places normative ethical action within
structural and reciprocal relationships that move toward wholeness of the one who is cared for
and the one who is the caregiver; caring manifests itself through reciprocal and relational
behavior.2 Moral agents of care recognize that the values and actions of care seek avoidance of
harms, while also seeking benefits to others through responsive action; the aim is to influence
individual behavior that optimizes human potential and flourishing, versus unbalanced
dependency or dependent behavior.3 Consequently, seeking reciprocal relationships actualizes
the importance of activating the optimal potential of all persons.4
The universal and ontological ‘knowing’ of care exists in the heart of understanding that
human potential is reached in relationship and not in isolation or separation from relationship;
the narrow focus of absolute individualism only enhances vulnerability for those with physical
and cognitive dysfunction potentiates dependency for survival upon others; concurrently,
relational autonomy, inter-dependency and care empowers individual protection and flourishing.5
Normative constructs of care recognizes that moral agents are not always autonomous,
independent and self-sufficient; therefore, a careful analysis of human vulnerability and
dependency is necessary in order to comprehensively evaluate how caring actions potentiate a
decrease in harms, a decrease in discrimination and decrease in the exploitation of the most
vulnerability.
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An ethics of care recognizes that each person has intrinsic worth and purpose within
society and an ethics of care places the value and giftedness of each individual as meaningful,
despite physical disability, weakness, and dependency.6 Vulnerable populations should possess
the same rights within culture and democracy, as those who write the laws; care understands that
through the intrinsic act of knowing, that marginalization and discrimination can occur as a
reflection of fear within societal constructs that misrepresent the marginalized or the
underserved.7 It also recognizes that the pursuit of personal actualization is always achieved
within relationships; therefore, personal bondage or social constructs of dependency can be
created as a result of relational and societal dysfunction.8 Patients who suffer from addiction and
substance use disorders, are afflicted with neurocognitive and physiological dysfunction that
results in multidimensional dependency states; they are afflicted with a physical dependency,
social, and economic dependency, which manifests itself through increasing sociocultural
disparity.9 Research strongly supports that the progression of deteriorating social constructs of
support for those with substance use disorders and addiction substantially increases
vulnerabilities and harms for those who suffer.10
In health care settings and within the public health arena, those who are labeled as the
most vulnerable or as underserved populations, are associated with a culturally negative
construct of dependency upon others; this dependency as it relates to determinants of optimal
health or holistic wellbeing, presupposes that the vulnerable and dependent person, requires
essential information and services through the skilled care of a ‘professional’ other.11
Vulnerability, for those with substance use disorders, is magnified through the intrinsic and
complex social effects that result from criminalizing and isolating those with addiction;
consequently, the isolation and labeling induces shame, guilt, and stigma, which further threatens
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physiological health, individual identity, autonomy, and self-actualization.12 Those labeled are
particularly vulnerable to the perpetuation of the physiological, societal and environmental
consequences that perpetuate epigenetic influences of heritability and suffering, for self and for
future generations.13
An ethics of care seeks to decrease harms, exploitation, and vulnerability through the
incorporation of human values, such as connectedness, attentiveness, responsiveness,
responsibility, competency, wisdom, empathy of the other; therefore, seeking to decrease the
generational harms associated with substance use and addiction.14 Seeking a new paradigm of
care, which embrace the values of care is essential to reverse the trajectory of societal harms.
Recognizing that human flourishing occurs through relationship and human potential is achieved
through reciprocal interactions with one-another; therefore, aiming to increase human flourishing
and decrease human harms associated with the vulnerability and frailty of societal consequences
and individual neurocognitive dysfunction related to addiction is essential.15
An ethics of care focuses on the empowerment of all individuals, especially, the most
vulnerable through communities of care and relationships.16 An ethics of care considers the
particularity of the other, not the hierarchical placement of worth of individuals through stringent
and rigid rules and rights, but rather in a participatory and relational context where responsibility
and connectedness are valued indiscriminately for all members.17 Hence, making an ethics of
care an essential ethic in the management of those who struggle with substance use disorders
potentiating the essential elements of reconnection and healing. The bioethical discussion that
incorporates an ethics of care framework seeks to integrate the normative and universal standards
of care that envisions ‘care’ through a ‘mature’ lens; care through this ‘mature care lens’ stresses
that it is not a one-way or unilateral directional action.18 Rather, it is behavioral action, which
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occurs reciprocally, which seeks movement and actions that are similar to a dance that requires
coordinated movements and partnerships.19
Mature care, may initially appear unbalanced between the vulnerable and the
professional; however, an ethics of care, truly seeks transference of knowledge and the
development of positive coping strategies that actualizes the potential of the one who is being
cared for. Mature care recognizes the giftedness and value of each member of the community.
Additionally, mature care does not demand selfless sacrifice of the care provider that is selfnegating to the care provider.20 Rather, an ethics of care, recognizes that the intrinsic dignity of
each member of the relationship requires essential action that decreases vulnerability, decreases
dependability and decreases weakness through the redevelopment of the ‘other’ through
interdependency that values authentic relationships; this can be accomplished by decreasing the
likelihood of known vulnerability development associated with addiction.21 Authentic human
autonomy is not achieved through absolute independency and in isolation; but rather through the
strength of healthy and caring relationships. Responsible qualities of mature care are achieved
through qualities of responsive reaction, development of responsibility and wisdom, and while
remaining attentive to the intrinsic dignity of persons through qualities of responsiveness and
attentiveness that projects the hope and competency of all human potential.

3.1 Autonomy and Relationships.
The physiological nature of all human survival recognizes the need for support of family
and community; despite this fundamental understanding of the importance of relationship,
western civilization, liberal democracy and patriarchal societies, free market industrialized
nations have wrongly placed the priority emphasis on individualism and the rights of autonomy
separate from community and relationships.22 An ethics of care recognizes that the nature of
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human thriving occurs not only within power structures of escalating dominance that separate
individuals; but rather, through relational social structures that unite individuals into
communities of supportive and relational interactions.23 Relational social structures place the
care of the ‘other’ as a central concept that aims to strengthen the intrinsic value of each
individual person within a community, versus isolation and neglect; ultimately, an ethics of care
ideally enhances the behavioral responses of all members within the community.24
Through an ethics of care, the intrinsic dignity of each individual member of the
community is enhanced by respecting the personal value of the ‘other’ as an ongoing and
relational interaction that emphasizes active engagement of all participants; relational autonomy
is not a ‘one and done’ attempt or a ‘one-sided action;’ it reaches beyond the self and reaches
toward the human potential of each member within families, communities, societies and
nations.25 When an over emphasis of absolute self-determination and absolute autonomy
dominates the cultural framework, the curtailing construct fails to recognize the relational and
social context of culpability; blaming, shaming and stigmatizing the individual, automatically
depletes appropriated freedoms, mutuality of human value, and equality of human worth.26
Societal hierarchies that separate worthiness of others through domination and isolation
escalates the risk of poor health outcomes. The underlying social causes of poor health outcomes
is known as negative determinants of health.27 Some of the negative determinants of health
include unequal access of education, nutrition, access to health provider treatment, community
support, and the social connectedness that could potentially decrease the risk of individual
vulnerability; vulnerability manifests itself within societies through dislocation, marginalization,
and stigmatization and therefore, incorrectly distorts human weakness through a framework of
absolute culpability of individuals alone.28 This social construct of perceived escalating
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deficiencies of individuals, perpetuates the disconnectedness of human potential in historical
proportions; one of the ways that this seemingly individualized dilemma manifests itself globally
is through the escalating crisis of addiction and substance use disorders.29 Human life for
individuals lies within a balancing continuum of growth, development, flourishing, and care for
one another, when human frailty becomes evident within this cyclic relationship with others and
the one who is frail is discarded or cast aside, further vulnerability ensues; consequently, human
vulnerability requires reliability upon others during these normal times of waxing and waning
need from the moment of birth, throughout life, until death.
The constructs of autonomy, servitude, and hierarchical structures of dominance have a
deep historicity that precedes the current discussion of the bioethical discourse on the protection
of human subjects and the biomedical principle of respect for autonomy; additionally, the
principle of the right for autonomy never intended to obliterate the importance of connection and
their benefits within human relationships. Therefore, it is necessary to investigate the historical
significance of autonomy through the framework of intrinsic rights of individuals, respect for
autonomy. Autonomy as a relational element that promotes the self-actualization of all
individuals, autonomy is achieved through reciprocal relationships, during the physiological
elements of impaired neurological functioning, one requires an increase in relational connection.
The focus on relational autonomy versus absolute autonomy can improve individual potential
and minimize the vulnerability and frailty of individuals through the growth of supporting
interdependency of one another.30
Autonomy through the framework of intrinsic rights of individuals, takes a look at
constructs of individual freedoms and individual agency. Individual freedom takes a look at how
one’s liberty is achieved despite controlling influences or dominance and personal agency takes a
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look at the ability of the person to make precise, purposeful and decisional actions as a result of
higher level executive brain functioning.31 The overarching or popular judgement made toward
individuals who struggle with addiction and substance use disorders are commonly regarded as
persons who make free and autonomous choices. Consequently, those who suffer with addiction
and substance use disorders are additionally claimed to be autonomous individuals who are
uninhibitedly capable of managing their own substance use dysfunction and as people who are
able to autonomously manage their own medical care.
Yet, this view is biologically and socially problematic and has dangerously increased
individual and societal harms. Science now knows and understands that the pathology of
addiction impairs the brains normally functioning processes that constitute elements of
individual agency, freedom and autonomy. Higher level executive functioning and agency is
drastically impaired as a result of the controlling influences of the substance’s effect on intrinsic
reward mechanisms, which results in disordered, harmful, and oftentimes deadly miscalculated
human survival responses.32 Claiming that the person with substance use disorder is a fully
functional agent who has the full capacity to manage health outcomes is a fictional element that
perpetuates the problematic trajectory of pathological harms associated with addiction;
additionally, this incorrect assumption is problematic in relation to the principle of respect for
autonomy.33
The principle of respect for autonomy requires that healthcare providers and researchers
respect the autonomous actions and decisions of the ‘other.’34 This respect for autonomy also
identifies that the health care provider must explicitly provide comprehensive education and
assess the patient’s ability to understand the essential information regarding the treatment and
intervention plans, in an attempt to protect patients from harm; patients who are vulnerable

86

because of altering levels of consciousness, or who lack decisional capacity may not have the
capability to cognitively or consciously make health care decisions.35 Therefore, the respect for
autonomy must also consider the nuances of how incapacity to make higher level functioning
decisions potentiates harms for individuals. With the drastic increase in neurocognitive
impairments in disease states, such as dementia, Alzheimer’s disease, and addiction, patients are
at an increased risk of harm to self and others, while seemingly ‘acting’ autonomously.36
Therefore, applying precautionary assistance in decision making for those diagnosed with
substance use disorders and addiction through elements of relational autonomy and protection
from increasing vulnerability and harms associated with neurocognitive pathology is highly
recommended.
Autonomy as a relational element, illuminates the elements of holistic respect of the other
by promoting self-actualization, empowerment, and decreasing susceptibility or vulnerability of
individuals through reciprocal relationships.37 The cultural transition from relationships toward
elements of absolute autonomy occurred as a result of the idealization that free choice surpasses
all ‘other’ essential elements of contemporary life; however, Mill’s harm theory more than sixty
years ago, asserts that altering the actions of individuals should logically occur only for reasons
that seek protection of harms toward self and toward another.38 Additionally, autonomy should
also consider the nuances of how individual actions and decisions are effected by impaired
neurocognitive functioning and how it relates negatively or positively to others socially, how it
relates to the epigenetic landscape, and how it relates to the impact of conscious or unconscious
interactions with others in order to enhance the holistic determination of benefits.39
Mill’s harm principle should be a good starting point in order to illuminate the current
understanding of the protection of harms for individuals, of the protection of communities and in

87

order to understand how to positively affect outcomes for those who experience substance use
disorders and addiction; culturally and socially individuals have been permitted to drink alcohol
and consume addictive drugs, as an act of an individual right or as an element of selfdetermination, despite the known trajectory of individual and societal harm. Public policy and
laws are currently aimed at protecting the safety of those affected by substance misuse through
the implementation of what is known as a public health measure of ‘least restrictive means’; the
least restrictive means principle or least coercive means principle is aimed at achieving health
goals through policy implementation that utilizes low level restrictions for individuals first and
then moves toward implementation of increased individual restrictive means as harms increase.40
Examples of public policy and laws, which aims to decrease harms through means of the
least restrictive means principle, include drinking and driving laws, setting standards of alcohol
and cigarette purchasing ages, and by implementing mandatory methadone program treatment
interventions for rehabilitation and incarcerating those found with illicit drug position.41
Unfortunately, elements to protect families and communities from the deleterious effects of
escalating harms of addiction and substance use disorders occur through legislative measures for
individuals who misuse substance, without addressing the more personal and private level of
harms through paradigms of care, despite the historical and debilitating harms that have persisted
through time for loved ones, families, and communities.’42
Relational autonomy would not only ensure the restorative wholeness for the patient who
exhibits impaired neurological consciousness states with addiction, but would reciprocally
protect others from the psychological, physiological, and epigenetic sequela of associated harms,
which have become evident. Consequently, elements of impaired neurological consciousness for
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those with addiction potentiate impaired relationship to self, and to others, while increasing
vulnerability, impairing autonomy and exacerbating frailty.

a. Autonomy and Frailty
Vulnerability and frailty are intrinsic elements of the human condition; contemporary
medicine, public policy and health care professionals recognize that despite scientific advances
physiological, psychological, and social constructs of wellness and prosperity are not infinite
characteristics of being. As a result of abuses toward individuals who are vulnerable, medical
practice, medical research, and the implementation of bioethical practices recognizes that the
intrinsic value of each person is the essential element, as a pivotal way to insure respect for
human subjects and patients during sickness, hospitalization, and vulnerability.43 Technological
advances, vulnerability, and physiological disease states more commonly result in complications
that can chronically increase loss of physical functioning, loss of cognitive functioning, and can
increase frailty and dependency states; therefore, increasing the need to recognize the benefits of
‘the principle of respect for autonomy, must include and evaluate the restrictions of persisting the
absolute autonomy framework and examine the actuality of the beneficial aspects of relational
autonomy’ in order to decrease the risk for consequential vulnerability.’44
The definition of vulnerability is a growing construct in application within the bioethical
discourse; the broadening nature of the term can provide different themes of usage for
individuals, groups and societies; hence, making the concept more difficult to comprehensively
define.45 According to Schroader and Gefenas, vulnerability and human frailty is defined as,
‘individuals and groups of individuals that have an assured likelihood of being subjected to
probable harms, while also lacking the ability to defend or protect oneself;’ additionally, the
public health nursing literature expresses the concept of vulnerability by linking the construct ‘as
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a continuum state of dependency on healthcare providers for the management of establishing
health care goals, interventions and outcomes.’46
Constructs of absolute autonomy increase the vulnerability potential for susceptible
individuals through isolation and decreasing access to knowledge in decision making processes
that can increase the risk for harms for an already underserved population; furthermore, when the
hierarchical constructs of social systems are not equal for all members of society, disparate and
unethical management of care can result unnoticed.47 Social determinants of health are not equal
from person to person and this simple fact must not be disregarded. When one considers the
nuances of vulnerability and how current views of autonomous decision-making processes are
made in health care, a parallel assessment of the essential elements of vulnerability must laterally
evaluate how the known inequality negatively influences individual health and wellness. The
seemingly obvious conclusions and assumptions may be unintentionally hidden because of
personal and professional biases, which justify the disparity, by assigning individual fault or
blame; this justification, which hides one’s culpability is identified as an ethical blind spot.48
The principle of respect for autonomy was implemented to provide guidelines for health
care professionals to consider all individual patient rights during research or health care decisionmaking processes; the guidelines sought to dissolve paternalism and implement a standard of
care that promotes a positive obligation of physicians to respect a patient’s values of care,
decisional capacity, maintain confidentiality, maintain veracity to obtain free willed consent for
treatment, and to help patients make informed health care decisions through educational
initiatives sought the dignity of individuals.49 However, all patients do not possess the same
capacity to make autonomous choices; and yet, determining incompetency and assigning
surrogate decision-making in healthcare becomes a difficult and imperfect task.50 Frequently,
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those who are not competent to make decisions neuro-cognitively or psychologically appear
competent, and may not be adequately assessed; thus allowing the perpetuation of harm to self
and others, without appropriate, compassionate, and professional intervention and care.51
In an attempt to avoid paternalism, perhaps unnecessary priority has been placed on
allowing individual autonomy and individual decision making despite known and associated
harms by asserting that patients are permitted to ‘make bad decisions’ resulting in isolation,
elevated risk of physiological progression of harms, resulting in escalating vulnerability, frailty,
loss of consciousness, and ultimately directly cause exponential harms on others; consequently, a
reconceptualization of how absolute autonomy should be transitioned into an improved
reciprocal framework of relational and authentic caring interdependence is needed for the
management of care for those who suffer the neurocognitive consequences and pathology of
addiction and substance use dysfunction. Healthcare providers, family and societies must
potentiate an improved model of care delivery, for those who suffer with altered consciousness,
neurocognitive impairment and disease states.
The neurocognitive alterations associated with neurocircuitry changes in addiction and
substance use disorders certainly increase vulnerability for those who are predisposed to
addiction; additionally, by the very nature of an addiction or substance use disorder diagnosis,
patients are potentially silenced, through fear of blame and stigmatization, which further widens
the gap between ethical management of care interventions that are so necessary in improving
patient and societal outcomes.52 Strengthening support through relational and attentive decisionmaking potentiates improvement in care by eliminating ethical blind spots and decreasing the
disparate ethical gap between autonomy, vulnerability and frailty. Subsequently, failing to
consider the specificity of how the application of absolute autonomy principles potentially
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increase the risk of vulnerability for those with substance use disorders and addiction requires a
careful examination of behavioral and applied ethics; behavioral and applied ethics seeks to
comprehensively examine how social problem affect escalating harms on the individual level,
organizational and societal level.
Health care providers are professionals who should strive to provide care and health care
management interventions with the patient’s best interests and best intentions as their primary
duty. Yet, understanding how individual behavioral influences professional responses and
therefore organizational treatment processes as it relates to those who suffer with addiction and
substance use dysfunction along with the acknowledged societal biases must be closely
examined. The differences between autonomy and frailty or autonomy and vulnerability is never
a result from single responses of individuals; but rather, it is a result of an ethical response that
fails to acknowledge that society can influence the continuation of harms and blindly respond in
ways that are detrimental to individuals and society.53 Only focusing on the narrowing constructs
of individual autonomous actions and decision making for those who are known to have neurocognitive impairment from addiction, refuses to acknowledge the deep seeded cultural biases that
unknowingly or unintentionally widens the unlikely development of a social and organizational
acceptable frameworks of care. Developing a responsible and professional framework of care
must seek to decrease premature mortality, morbidity, vulnerability, and frailty for those at
greatest risk.
The management of care for those diagnosed with addiction and substance use disorders
looms in the shadows of societal and organizational structures; bounded ethicality, examines
how double standards and opposing intentions and actions impact individual ethical judgements,
organizational processes and societal policies, which seek to uncover the psychological processes
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that result in unethical behavior.54 In order to recognize the inter-connected responsibility of
action that seeks to decrease vulnerability for individuals, the ethical analysis must identify the
ethics gaps associated with autonomy and vulnerability. The ethics gaps are closely associated
with human biases, conflicts of interests, and processes, which begin to accept unethical actions
as socially acceptable processes; the unnecessary and premature death of tens of thousands of
people, due to substance use disorders without receiving adequate medical and societal support,
is an example of unethical management of care processes that occur as a result of ethical fading.
Ethical fading occurs as a result of unnoticed processes and actions despite resultant harms and
an inability to recognize such harms as a result of inaction.55
Behavioral ethics and an ethics of care take a look at how bounded ethicality and ethical
fading continue to harm those with substance use disorders and addiction; an ethics of care
illuminates the ethical blind spots that have perpetuated the negative health outcomes for those
susceptible to substance use disorders and addiction. An ethics of care integrates behavioral
responses that seeks to establish a paradigmatic shift in the management of care for those with
addiction; an ethics of care seeks to expose the blind spots and identify the ethical fading in order
to decrease the widening gap that is exponentially increasing harms and vulnerability for those
with substance use disorders and addiction. An ethics of care identifies the distinction between
interdependency, independency and dependency in order to establish the benefits of relational
autonomy and the relational need for behavioral responsiveness of professionals.56

b. Independency and Dependency.
From infancy through old age, from psychological dysfunction through superlative
intellectual functioning, from physiological disability through optimal health the construct of
relational autonomy recognizes that vulnerability and frailty is nurtured and sustained through
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the interdependent actions of ‘others’ through relationships; yet, current application that seeks to
describe human functioning, focuses on absolute independence and the negative aspects of
dependency.57 The principle of autonomy in healthcare places importance on the independent
nature of one’s ability or one’s capacity to make health related decisions, oftentimes separate
from complex relational decision making processes. Absolute individual autonomy in healthcare
decision-making is problematic for the patient who experiences addiction dysfunction due to the
physiological symptoms and resultant social isolation that predominates for this disparate
population.
As a result, it is important to examine the linguistic meaning, distinctions, and
relationships between the functional use related to the terminology of dependency, independency
and inter-dependency as it is applied within complexities of contemporary healthcare decisionmaking. Dependency is historically thought upon as a negative state of human existence and
independency is viewed upon in a much more positive light; even though, the reality of the
human condition embodies waxing and waning of vulnerability and fluctuating levels of interdependence and dependency. Therefore, dependency presents within complex constructs and
causes, while also existing in many forms, such as physiological, cognitive, emotional, moral,
economic, political and social dependency, etc; the description of dependency has historically
been associated with negative traits that are associated with individual fault and deficiency.58
Constructs of independency are highlighted as highly favorable states, which recognizes
that optimal physiological, cognitive, emotional, moral, economic, and political states are
universal goals and the most desirable state of individual functioning; thus, ascribing autonomy
and independency as the ultimate goal to be achieved for each productive member of society.
This construct portrays that independent and autonomous individuals are the normal and desired
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state of human striving, thriving and potential; leaving out the essence and the normalcy found
within human relationships, connections and empowerment of supportive human constructs of
care. Care embraces help for the other in times of need, through concrete actions that promote
human interdependence; care, through commitment, empathy, and presence, combine a vision
for equality of worth, despite dependent states and seeks to make a positive difference in the
lives of those in need.59
Those who struggle with the physiological, psychological, neurocognitive, social,
economic and political effects of substance use disorders and addiction are not only paralyzed
with the physical effects of dependent need, but they are severely affected by the structural,
societal, and the behavioral effects of societal constructs of dependency as well.60 Reversal of the
isolating tendencies could slowly dissipate if values of reciprocity, connectedness, empowerment
and interdependency replaced personal and spiritual emptiness that isolation and
disconnectedness exacerbates; the continued societal alienation that ascribes autonomous nature
of blame directly toward individuals only increases the disdainful influences of societal neglect
and isolation that results.61
Bounded ethicality as terminology within a behavioral ethics framework seeks to explain
the bondage that occurs when the refusal of acknowledging that one’s actions and decisions
result in harmful outcomes for others.62 Societal constructs of marginalization, isolation and
individual blame for substance use disorders and addiction have resulted in overt harms to those
who suffer; yet, political, social, and even professional constructs of addiction management
continue to adhere to and cling to antiquated terminology and constructs of substance use policy,
laws, and care that focus on individual blame without carefully reflecting upon relational
culpability.
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Epidemiological studies that review outcomes for substance use disorders and addiction,
associated with marginalization, isolation and discrimination strongly indicate that the escalating
harms from the current political, legal and healthcare policy are perpetuating the increase in
mortality and morbidity for individuals with addiction dysfunction.63 Historical references to this
phenomenon include, historical times of dislocation and stress, such as during the United States
(U.S.) solders Vietnam conflict, the dislocation of the aborigines in Canada, the dislocation of
native Americans in the U.S., the dislocation of African slaves in the U.S., and the dislocation of
the Jewish families in Nazi Germany.64 Facilitating individual autonomy requires the
establishment of supportive relationships through interdependency; therefore, the imperative to
re-conceptualize the application of respect for autonomy in health care requires demystifying the
exclusivity of individual choice as an absolute and autonomous choice to be addicted and
embrace a true respect of individual autonomy by recognizing bondage, and embracing
interdependency and empowerment of ‘others.’65
Unfortunately, the current cultural and societal precedence of believing that those with
substance use disorders possess free will and free choice to autonomously direct all healthrelated decisions only perpetuates individual and population harms; for patients who have
confirmed substance use disorders and addiction the neurobiological, neurocircuitry and
executive functioning dysfunction perpetuates complications through the continuum of substance
use disorders and sociocultural environmental interactions.66 Despite, the scientifically
confirmed physiological changes, the current cultural belief or understanding of vulnerability for
those with substance use disorders is often disregarded and blatantly ignored; it also indicates
and implies that a certain hesitancy exists for professionals and family members to initiate
interventions and care, because of the social stigma, which pervades actions that seek ‘to actively
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restrict the actions or behaviors of the one with substance use disorder’ as a violation of the
respect of autonomy.
The implication of allowing patients to harm self, continues to suggest that it is an
individual’s right to make poor choices; hence, implying that the action of substance use is
merely a matter of executive functioning decision-making choices, or absolute individual free
will and therefore indicative of individual moral culpability. The hesitancy to impose
professional practice interventions for those with neurocognitive dysfunction is feared and
therefore, professional interventions are delayed and/or completely omitted. Additional,
‘treatment’ rationalization is further presupposes, that if legal and punitive sanctions are
imposed, then individuals will voluntarily improve their decision-making ability and choose to
not self-administer an illicit and addictive drug; and therefore, will be motivated to
autonomously and willfully cease consumption of addictive substance. Yet, this presupposition is
delusional, because substance use disorders and addiction dysfunction directly impairs decisional
capacity through the activation of stress surfeit/ reward deficit dysfunction that further impairs
executive functioning of the prefrontal cortex through neurocognitive and neurocircuitry
alterations as previously discussed.
The social constructs, which seek to protect individual human life, through relational and
interdependent states, are abandoned willfully by families and communities despite the
individual, consequential and relational bondage that alienates individuals, from families and
relationships. Care ethics focuses on the responsibility of relationships during concrete
circumstances that exist in the focus of daily activities and actions; therefore, care ethics requires
taking a look at human behavior, which supersedes rights, rules, formal and abstract systems of
thought, and universal or unbending principles.67 Care ethics reflectively analyses actions and
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behaviors that can potentially eliminate all forms of physical, societal, and economic
dependencies that are known to limit human flourishing, while seeking to invigorate human
flourishing and lived potential.68
An ethics of care recognizes that self-sufficiency influences dependency states; those
who possess economic resources, despite addiction, may appear less vulnerable than those who
lack financial resources. However, all individuals despite societal and economic positions would
still possess physiological dependency, due to the pathology of neurocognitive impairment and
remain at risk for harms. Economic self-sufficiency, which can purchase care during vulnerable
physiological states does not constitute an example of absolute autonomy and independence; it
only represents economic independence. Similarly, patients who suffer from addiction and
poverty, manifest multiple levels of societal, economic and physical dependency and struggle
with insurmountable stress to meet basic physiological human needs and are at increased risk of
harms that result in risk for substance use disorders.69 The plight of those with substance use
disorders and addiction are generally more vulnerable to economic dependency, through poverty
and homelessness and consequently, suffer increasing neglect and severity of disparities of
care.70
Unfortunately, addiction is perceived as a ‘self-inflicted’ dependency state and research,
indicates that all states of dependency are negatively perceived; however, self-inflicted
dependency states are particularly stigmatized, heightening the consequence of abandonment.71
According to Dean and Rogers’s, Economic and Social Research Study, he found that states of
dependency were popularly portrayed during times of childhood, old age, or periods of disease
and illnesses with periods of increased frailty, isolation, or emotional helplessness.72 As a result,
outcomes of perceived dependency were viewed upon within the context of two prototypical
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levels of understanding. The first view, identified dependency as both a potential state that was
unavoidable and/or as a state that was self-infliction; hence, asserting deliberative judgement
regarding either the acceptance or blame toward the loss of independence and choice to be a
burden or to be dependent.73 The second group did not assign blame upon those who developed
specific conditions that resulted in a dependent state; rather, the second group agreed upon the
universal nature of dependence on one another.74 Regrettably, the stigma associated with
dependency persists.
Additionally, personal independence is projected as the standardized normative state,
while, dependency is often projected as either a personal tragedy or as an abnormal or deviant
societal state. Dependency is often perceived as a deviance, which is viewed upon culturally as
an abnormal state; yet, the dependency of obtaining food from farmers or distributers for the
reliance of nourishment is perceived as a socially acceptable dependency. Yet, the dependency
for the need of care from another is often times associated with moral blame, fault and
weakness.75 Adding to the particular nuances of dependency, substance use disorders and
addictions are perceived as self-inflicting harms, which projects exceedingly harsh and negative
judgements from society upon the other. The complex layering of the social constructs of
dependency, inflicts elements of stigma and negative self-worth upon patients, perpetuating the
escalation of substance use harms and obstructs reliance on others for help and care.
Unprecedented and relentless insistence that effective personal strength, independence,
autonomy, and self-sufficiency dominate human existence would continue to heighten
dominance of a hierarchical constructs that place individual moral culpability of all disease
states, without acknowledging that the bounded ethicality of those who write the laws and
policies dominate social and health care policy contribute to those harms; bounded ethicality

99

would fail to reflect upon the intrinsic dignity and care of each patient and would fail to reflect
upon the societal harms that are perpetuated by denying that the intrinsic dignity of each person
exists. The perpetuation of harms associated with addiction and substance use disorders must not
be further subjected to the escalating harms associated with isolation and stigmatization by solely
blaming individuals; an ethics of care requires the practice of virtue that recognizes the
importance of relational responsiveness of professionals in order to empower the relational
autonomy of patients who are inflicted with vulnerable cognitive and physical manifestations of
disease.76
Isolation, marginalization, criminalization, and discrimination is proven to be unable to
reverse the trajectory of harms associated with neurocircuitry and neurocognitive changes that
are associated with substance use disorders and addiction; albeit, an ethics of care attempts to
build relational autonomy and interdependency for patients, empowering responsive and
relational reaction from professional in order to acknowledge that through a framework of
professional processes and actions that seek to build programs that respect the dignity of all
persons aims to reverse the trajectory of harms associated with substance use disorders and
addiction.

3.2 Relational Autonomy of Patients.
Moral agency refers to the capacity to act as a moral agent, meaning that the individual is
capable to make moral judgments.77 Moral agency and moral status are terms utilized in
bioethics to refer to human rights; moral status and rights of individuals are assigned to all
human beings by the very nature of their human condition.78 The human condition bespeaks
moral respect. However, historically this respect for human life is not consistently or universally
honored. Moral respect is translated in bioethics by the very essence that constitutes the reality of
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the human subject; thus, recognizing that despite cognitive changes, despite, marginalization of
relationships, despite loss of physical functioning, the characteristics of humanness remain
constant.79 Once components of inherent dignity of an individual or of a population’s humanness
are removed, atrocities occur against those deemed less than human. Moral agency, despite its
individual nature, recognizes that moral status remains a construct of relationships; and as a
result, absolute autonomy, which is independent of relationships, is a fallible misconception, by
the very nature of the true essences of human dependency, frailty and vulnerability.80
Freedoms and rights of individual persons are determined within the social cultures and
constructs that they are developed; an ethics of care validates the moral agency of all members of
the community on a continuum of care.81 Meaning, that at different periods of life, all individuals
fluctuate on the continuum of vulnerability, on the continuum of possessing decisional capacity,
and the continuum need for care; current democracy frameworks portray images of individuality,
independence, and autonomy above all rights, without acknowledging the importance of the
interdependent nature of social relationships and the empowering essence of relational
autonomy.82 Constructs of vulnerability, disability, frailty and dependency upon others for care
increasing ignore the giftedness and value of individual collaboration and support from relational
and community structures.83
An ethics of care enhances the moral agency of the patient through enlightening the
frameworks of relationship and recognizing the intrinsic worth of each person, despite perceived
imperfections in character; concepts of non-relational models of care for those diagnosed with
dependency and addiction disorders in health care cannot manage the disorder effectively, as
evidenced by the escalating harms of that criminalizing and stigmatizing individuals and
populations has caused.84 An ethics of care promotes a closer look at moral agency without
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disconnecting individuals from the relational constructs that acknowledge the necessity of
relational autonomy throughout the lifespan; the goal is to promote the responsible autonomy of
the patient through relational support, when, where, and how it is appropriate.85 Health care
providers that embrace constructs of relational autonomy promote moral agency through
responsiveness, responsibility, competency and actions that seek education, prevention,
empowerment and wellness; the current constructs of criminalization, assigning absolute moral
responsibility, while ignoring the constructs of societal and community culpability, cultivates
isolation, disconnection, and the deleterious effects of individual stress states and persistence of
generational harm and susceptibility.86
Bounded ethicality also applies to patients who are diagnosed with addiction and
substance use disorders who personally refuse to admit to individual culpability or refuse to
acknowledge the harms that result to others as a direct consequence of their harmful substance
use behavior; meaning that the one who is vulnerable to the deleterious consequences of
addiction, must also acknowledge the harms that their disease state ensues upon family,
community and future generations. Identifying one’s individual moral culpability of related harm
to others, identifies one’s own moral agency with the duel aim to seek care to decrease the
trajectory harms to self and others as it relates to individual pathology. Individuals must also to
seek to responsibly decrease the trajectory of biological, genetic and epigenetic harms for self,
family and future generations; an ethics of care holistically seeks to influence the relational
autonomy of individuals who suffer from substance use disorders and addiction by helping to
increase the patient’s ability to improve executive functioning, decrease stress response states
and to regain neurocognitive homeostasis.
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The snapshot of moral culpability must clearly seek identification of individual patient
responsibility in order to assist those afflicted to consciously decrease inflicting harm to self and
to others; each patient who suffers, must examine and reflect on their own individual
particularities, such as etiology, intentions, circumstances, and behaviors that precipitate one’s
behaviors and actions, which increase susceptibility to disease. Additionally, moral agency of the
person who is diagnosed with addiction and substance use disorders, must carefully examine the
nuances of moral agency and how to increase control of one’s own moral actions and one’s
responsible responses to those actions. Moral agency requires that the person possesses the
ability to reason, has the ability to use past experiences as a guide in decision-making, has the
ability to freely choose actions, and must have the ability to ‘know’ the consequences of those
actions; therefore, the person diagnosed with substance use disorders and addiction, must seek to
regain responsible responsiveness to their own situation.87
Building upon one’s own beneficial health outcomes, requires building a network of
interdependence with trusted family, friends, community and health care providers through
mechanisms that build one’s own moral agency through relational understanding of one’s own
limitations and weaknesses; additionally, improving outcomes through recognition of one’s need
to seek relationships of empowerment and acknowledging personal strengths and weaknesses,
through recognition of personal responsibility, responsiveness, reaction and wise action.88
Building a patient’s own moral agency through a framework of empowering interdependency
when diagnosed with substance use disorders and addiction would then require strategies to
improve a person’s ability to reason during each phase of the neurobiological cycle of substance
use disorder, ie binge/ intoxication stage, withdrawal/ negative effect stage, and pre-occupation/
anticipation stage. A patient with a substance use disorder and addiction is vulnerable as a

103

solitary moral agent to manage the trajectory of care for self without risking exponential harm to
self and others; as a result, implementing a relational model of reflective moral agency is
justified and recommended within an ethics of care model of care.
A relational model of care for substance use disorders would implement a relational
decision-making model that applies all of the criteria of moral agency to the patient’s substance
use circumstances. An example of care includes, utilizing relational illumination of past
experiences as a catalyst for applying guided health decision making interventions and goals.
Acknowledge that, according to the stage of substance use disorder, the patient may experience
the inability to freely choose immediate substance reward over chosen long term goal reward
outcomes, due to physiological and neurocognitive impairment; hence, requiring relational
intervention and standardized treatment protocols to decrease harms to individuals, families, and
communities is suggested. Lastly, because individuals with substance use disorders and addiction
cannot always cognitively choose between long term consequences versus short term rewards of
actions, relational support and interdependent systems of decisional care is required to identify
deleterious long term consequences and implement surrogate decision making protocols.
Implementing relational support is an essential care element in order to empower individual
growth toward personal responsiveness, personal reaction, and wise action through supportive
measures of relational responsibility.

a. Responsiveness and Reaction.
Factors that influence responsiveness and reaction to one’s substance use disorder
continuum of dysfunction or disease, requires that individual who suffer are guided into a
journey of recovery. This journey requires personal reflection and responsibility in ‘managing’
their personal wellness program, but it also requires expedient professional support that includes
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daily, weekly, or monthly medication assisted treatment (MAT) and psychosocial counseling
support.89 The decision to seek recovery support has the potential to improve neurocircuitry and
neurocognitive responses; however, immediate guidance is paramount during substance use
disorder continuum. Patients ability to alter the trajectory of harms occurs through professional
relationships and scientific treatment plans that seek to de-escalate substance use and harms
along the particular ‘place’ of dysfunction; fortunately, by further improving individual agency
through MAT and psychosocial counseling, reciprocity and interdependency can help protect the
one vulnerable through the appropriately responsive treatment paradigms. As a result, future
escalations in dysfunction can decrease, once a professional relationship is established.
Independent, responsiveness to one’s susceptibility of harms associated with substance
use disorder has not traditionally been effective for individuals, families or communities;
therefore, everyday decision- making and particularly decision-making during states of illness
exacerbation and increased vulnerability require higher levels of supportive and relational
interactions with others. Recognizing that depending upon the severity level of the substance use
disorder, variable methods of supportive care and assessment is paramount for the
implementation of successful intervention. Unfortunately, within the current addiction
management structure, individuals who are diagnosed with substance use disorders are making
health care decisions alone, in silence or within unsupportive and fearful encounters with the law
and others. Unsupportive encounters increase isolation, stress states and further impairs
resilience, and individual coping ability; increased stress states, escalate agitation, aggression,
hopelessness, and further perpetuate chaotic social environments, which often results from
negative expressions of bias, and disapproval toward the one diagnosed with dysfunction. Hence,
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perpetuating further health disparities, escalating risk for patient harms, decreasing access to care
and further facilitates the loss of trusting relationships.90
Additionally, health disparities reflect a higher burden of susceptibility for individuals to
disease and addiction; populations that remain at the greatest risk for addiction disorders include
the genetically predisposed and socially isolated.91 Therefore, individual access and education
initiatives, should seek individual responsiveness, provide education initiatives that teach
responsible, and reciprocal responses to risks through grass roots initiatives that seek to empower
those most at risk and marginalized. Identifying and teaching social determinants of care seek to
empower individuals, families and communities in order to develop relational strategies of care
for the most disparate of communities in order to decrease risk for the individuals who are most
vulnerable, by seeking to decrease hostile environments, and promote positive relational
strategies that seek prevention and recovery.92 Changing the management of care paradigm to
embrace a relational and accessible public health model of care, versus a crisis management of
care model would actively seek to help advocate for individual wellness and prevention
initiatives before harms occur.
As a result of addiction science and evidenced based practice initiatives, individual and
professional reaction strategies should implement relational treatment interventions that seek to
improve an individual’s reciprocal response and actions by decreasing associated risks during
each stage of the substance use disorder continuum; hence, protecting essential connections for
individuals throughout the substance use continuum. Responding to the specific pathophysiological behavioral responses during the binge/ intoxication stage could include individual
recognition for MAT or administration of pharmaceutical agents that increase adverse responses
to substance, such as flushing, nausea and vomiting; responding to the specific patho-
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physiological behavioral responses during the negative/ withdrawal stage, individuals could
fearlessly seek pharmaceutical agents to decrease the relentless stress and anxiety responses.
Additional psychosocial counseling could be sought, along with family and community lead
mindfulness training interventions; lastly, responding to preoccupation/ anticipation stage may
require distraction techniques, psychotherapy, or involvement in social outreach initiatives.93
As a direct result of inattentiveness and unresponsiveness of societal structures of care
and failure of professionals to implement reciprocal relationships of care for patients, the current
perpetuation of isolation of individuals results in human neglect and disempowerment for those
with substance use disorders. This unfortunate trajectory of substance use disorder management
of care paradigm, is a direct result of hierarchical power imbalances within the social constructs
of care between the care provider and the care receiver; placing the provider of care and social
structures in a dominant position over the one with neurocognitive dysfunction and dependency,
this hierarchical power position of dominance will always perpetuate individual harms.94
This current management of care paradigm, continues to places individual blame solely
on persons, claiming complete moral agency and moral culpability upon the individual.
Unfortunately, due to bounded ethicality, social culpability is not universally recognized;
resistance often times lies within refusal to reflect upon social culpability that predisposes
individuals to dependency states, such as physical dependency, economic dependency and
psychosocial dependency through constructs of marginalization, labeling, and developing
dehumanizing constructs of unworthiness of the ‘other’.
Yet, the continued perceptions of societal blame and the evolutionary persistence that
human frailty is a result or subjection to self-inflicted harms increasingly impacts the
commodification of health care services through insurance payment refusals or insurance
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liability; therefore, by commodifying care, blameworthy disease states are increasingly seeing
restriction to care or restrictions to access of care; in some instances omission of services are
seen as, necessary consequences of deviant and self-harming behavior as a result of availability
of scarce resources.95 Assigning moral blame for the development of disease states, such as
obesity, diabetes, hypertension, cardiac disease, mental health disorders, sexually transmitted
diseases, lung cancer from cigarette smoking, cirrhosis from alcohol consumption, addiction and
substance use disorders, opens up gross infringements upon human rights and openly denies the
vulnerability of the human condition.96 Human rights violations of this kind that purport
authoritative judgments that impair human freedoms to access of health care interventions and
treatment grossly impact human protections, which increase vulnerability, violate intrinsic
dignity of persons and should be viewed upon with trepidation and great concern.97
Until social constructs of care admit responsibility through reflection and responsiveness,
harms for individuals will persist. An ethics of care supports reciprocal and relational actions of
attentiveness and responsiveness with the goal to recognizing the complexity of individual and
societal agency and culpability. Through dissemination of education initiatives, awareness of
physiological and biological disorder trajectory associated with the understanding of
neurobiological, genetic and sociocultural consequences of dysfunction, an improved awareness
of complex physiological, psychological and societal influences on individual harms and stigma
may dissipate. Embracing the scientific evidence and developing a plan that attempts to reverse
the adverse consequences of neglect and isolation, requires patient and professional courage to
express assertive action that facilitates improved coping strategies along with the commitment to
persevere responsibly through the commitment of responsive and reciprocal relationships, that
actualize individual, professional and societal responsibility through treatment paradigms that

108

recognize universal responsibility to prevent dependency, and to promote care through the
application of advancing science and wisdom.98

c. Responsibility and Wise Action.
An ethics of care combines professional and patient responsibility in the management of
disease and illness as a central category of practice and virtue; overriding market systems, which
often times commodify individuals and populations and aim to decree policies that place moral
judgments upon individuals, which have negatively impacted the professional responsibility of
care that should seek the prioritization of professionally care to vulnerable populations in ways
that meet the physical, emotional, psychosocial needs of those who suffer with substance use
disorders and addiction.99 Care seeks to make distinctions that market systems fail to provide. An
ethic of care’s focus should seek to empower and enlarges the scope of individual and
professional duty, through characteristics of virtue and practice that illuminates a comprehensive
nature of wellness facilitation. Care enhances the traditional role of deontological or professional
obligation roles by holistically including not only required professional actions and duties, but by
infusing authentic caring intentions.100 Relational, empathetic, and inclusiveness of purpose
during patient encounters serve to function through methods that empower personal, social, and
environmental constructs of health.101
An ethics of care through practice and care, enlarges the scope of one’s personal and
professional responsibility and duty, because it implements an intentional, thought filled,
conscientious, and virtuous processes of interacting with one another. An ethics of care enlarges
one’s deontological role to oneself and to one another by placing care above justice; current
management of substance use disorders and addiction, have placed justice in the dominant
position that overrides care as the dominant human need. Patriarchal dominance in current
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political and social systems place the unequal value of autonomy, duty and rules over the value
of care, sensitivity, and needs of individuals with dependency, vulnerability, and weakness;
therefore, it is not surprising that individuals are set up to struggle against the dominant
framework of justice.
Many opponents of an ethics of care and many care theorists have debated, whether or
not, an ethics of care has the comprehensive ability to encompass elements of justice within the
ethics of care’s moral theory model. Virginia Held and Eva Feder Kittay support the
presupposition that care practices rightly include characteristics of justice, which certainly
enhance individual agency and responsibility; however, care places an emphasis of distinctive
relational aspects of care, versus individual nature of autonomy.102 They also conclude that
although actual care practices should incorporate both elemental aspects of care and justice, an
ethics of care rightly embodies different priorities over justice; which suggests an imperative to
alter the current paradigmatic approach in the management of substance use disorders and
addiction from a framework of justice to a framework of care, which should seek to
comprehensively characterize patient and professional obligations, responsibilities and duties.
Responsibility for one’s substance use disorder and addiction, within a justice framework
has the primary aim to exemplify legal culpability through legislative efforts to improve law
enforcement for those who are deviant or in opposition to the created laws; this was the aim and
the purpose on ‘The war on drugs.’103 The focus on justice, is to create, laws, find fault in
individual actions and to ‘bring to justice’ those who are deviant to those laws, as an effort to
prevent individual and societal harms; hence, the primary value is justice.104 On the other hand,
responsibility for one’s substance use disorder and addiction dysfunction, within an ethics of care
framework, has the primary aim to broaden the nature of dysfunction into relational elements
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that examine an improved comprehensive and holistic paradigm of thought.105 Justice, duty and
responsibility certainly remain important elements of care; however, the primary value becomes
care over justice, because caring relations should invoke trust and consideration of the wellness
of others.106 The current justice paradigm management for substance use disorders and addiction
dysfunction has invoked the antithetical components of care, which are characterized by fear,
isolation, abandonment and loss of trust.
Therefore, the combination of professional and patient centered commitment to health
and wellbeing is actualized through the implementation of individualized, social, and cultural
education initiatives that focuses on care, responsibility, and justice; value on justice alone, does
not alter the trajectory of harms. A commitment to continuous learning programs that are
formulated on contractual respect and relational competencies that seek to recognize the goals
and values of patients, their social support systems, their communities, and their health care
providers, aims to build relationships through care, concern and mutual responsiveness of both
the patient, while also addressing the broader social concerns.107 Supporting patients through
treatment plans include formulation of life style modifications that enhance sobriety, validation
of a need to decrease identified vulnerabilities and triggers, and creation of a comprehensive plan
that aims to enhance personal and social strengths of supports.108
To enhance patient understanding of the multidimensional physiological, psychological,
genetic, epigenetic, social and environmental factors that interplay with the risk, the progression,
and the exacerbations of addiction dysfunction, it is important that the patient is educated on the
complexities of addiction through a reconceptualization of disease; this includes illuminating
vulnerabilities and empowering patients to persevere through setbacks and difficulties, without
fear of punitive consequences; additionally, wise action includes visually providing the patient
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with concrete evidence that dependency and addiction results in self-inflicted brain dysfunction.
Consequently, it is imperative to provide education, regarding the hopeful evidence that this
trajectory of dysfunction can improve with treatment interventions. Wise action for the patient
includes taking responsible steps to reverse trajectory of dysfunction, reconceptualization of selfimage, discontinuation of self-blame, yet empowered by the courage of recovery, refocusing and
re-identifying with one’s intrinsic self-worth and dignity.109

3.3 Relational Responsiveness of Professionals.
Individual patient responsiveness and reaction to illness, disability and disease states can
be highly influenced by the social constructs of culture and environment; therefore, it becomes a
professional imperative for health care providers to remain scientifically and socially attentive to
the responsiveness and reaction of individuals with a vast potential of disease states, illness and
disability. Responsiveness, attentiveness and reaction for the management of care for those
diagnosed with substance use disorders and addiction through the framework of an ethics of care
requires prompt help establishing a strong trust and interdependence between the one who
requires the help and the one who provides the help. This means that the interdependency in care
is void of power hierarchies; the responsiveness is mutually exclusive for both the care recipient
and the professional care provider.110
Professional responsiveness and reaction to those with any disease state, requires a
reciprocal and attentive professional response in order to implement educational initiatives that
seek to help decrease the risk of each person’s potential harms that would increase the trajectory
of risks for that individual: additionally, professional responsiveness and intervention in the
management of substance use disorders and addiction should seek to improve the patient’s
response to illness, to improve social support systems, to provide coping strategies whose goal is
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to increase neurocognitive functioning and decrease triggers that potentiate the escalation of the
continuum of harms.111 By implementing professional interventions such as therapeutic
communication and empathetic responses, along with MAT and counseling would allow the
important role of prompt treatment with scientific principles of care, in order to decrease
individual vulnerability, without negative withholding of care because of negative biases,
associated blame and stigma.112
Processes of professional responsibility must include maintenance of professional
competencies through education initiatives that identify patients obstacles to the treatment plan,
management during negative patient response interactions, instructions on de-escalation of
negative responses, activation of positive coping strategies, and promoting professional
assessment recognition that responsibility includes awareness of one’s own potential negative
responsiveness to patients, in order to embrace the virtues of care and support to patients,
without succumbing to personal biases, discrimination, paternalism and parochialism 113 The
present day health care system is often times disconnected to the value of relational
responsibility and responsiveness of patients; this disconnectedness exemplifies the potential for
power imbalances that can silently overshadow the needs of care for those diagnosed with
addiction disorders.114 The relational responsibility of professionals includes identifying the
unique manifestations of each patient present within the continuum of substance use disorders; it
is the health care professional’s responsibility to remain attentive and responsiveness to the
individual patient’s genetic, biological, epigenetic, and sociocultural circumstances in order to
help formulate initiatives that preserves individual and generational integrity.
Responsive and responsible prevention and treatment strategies must be implemented to
address the complex nature of substance use disorders and addiction; unfortunately, scientific
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and social delineations have segmented agreement about etiology. The segmentation of etiology
results in fragmented and separate approaches to prevention strategies, treatment plans, and
research initiatives; by separating the evidence, rather than integrating a comprehensive
framework of the interwoven components of substance use disorders and addiction, the crisis of
consistent and empathetic professional addiction management ensues.115
Health care systems and providers of care have a unique responsibility and ability to
respond to the global challenge of the escalating rise of substance use disorders and addiction;
health care providers have the unique ability to understand, to conduct research, disseminate the
scientific findings and change societal constructs that perpetuate the etiological causes of
addiction disorders while also understanding how to collaborate in complex care systems for
paradigmatic management changes.116 Healthcare providers have an overarching and global
responsibility to re-evaluate the current system of care to decrease the stigma, marginalization
and disparities that increase the continuum of substance use disorder dysfunction progression;
while also being on the forefront of aggressive treatment initiatives that seek to save lifes.117 This
initiative requires recognition that professional silence is a result of ethics avoidance and
inattentiveness that violates the fundamental principles of human dignity and essence of a
professional responsibility of care.118
According to the ethics of care framework, implementing the moral qualities of
responsiveness, attentiveness, responsibility, competence, and integrity of care, requires paying
attention to the innate human need of the ‘other’ who does not ‘know and requires help;’
professional attentiveness, requires responsiveness that results in care that is based upon
scientific evidence and research, with the aim to improve patient responsiveness and reaction to
their own disease state and physiological struggles in order to promote the security of self,
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family, and the community. An additional professional focus should advocate for altering the
sociocultural environments that increase stress for those who struggle with poverty, economic
dependency, physical, and cognitive dependency that can further fluctuate decisional capacity to
use substances as a coping strategy for the burdens of societal neglect and struggle.119
The current healthcare industry is required to remain responsive to the needs of all
persons, especially those with neurocognitive dysfunction and fluctuating decisional capacity;
additionally, members of the community should become supportive and responsive to the needs
of the most vulnerable. The marginalized and impoverished have increased comorbidities of
disease resultant from stress, decreased nutritional states, and other epigenetic influences that
alter health awareness and access to educational public health preventative support.120 Healthcare
markets further widen health disparities for those who are at risk for substance use disorders and
addiction. Populations that are unable to pay for health care services are victims of limited access
to market system that further isolates, marginalizes and ignore those in greatest need; as a result,
perpetuating disparities of care and risk for substance use disorders addiction.121
Therefore, the industrialization of primary market systems, focuses the attention and the
wellbeing of individuals through the commodification of people’s ability to pay for services;
therefore, when people are viewed as a means to make money, those who have little access to
insurance and economic resources become disproportionately unable to obtain access to care,
negatively affecting the wellbeing of individuals and entire social communities through
constructs of inattentiveness and unprotected responsiveness of the most frail and underserved.122
Relational responsiveness of professionals seeks to actively respond to the need of those
who suffer with economic, sociocultural, and physiological causes of dependency resultant with
substance use disorders and addiction.123 Embracing an ethics of care as a responsive moral
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ethics framework, requires adherence to an understanding that the essence of each person is a
moral connection of humanity by the very essence of the related nature of human dignity.124
Empowering individual is just one identifying role in assisting the development of affective
treatment strategies. Professional responsiveness motivates the recognition of the giftedness of
individuals despite the sequela of harms caused by a disease trajectory, an ethics of care demands
professional responsibility and attention to the moral qualities to treat all patients with the utmost
dignity and respect; this dignity is actualized in human empowerment and relational support for
those who suffer from the physiological consequences of substance use disorders and addiction.

a. Professional Attentiveness and Treatment with Dignity.
An ethics of care requires professional responsiveness and attentiveness that recognizes
the complexities of illness through interconnected manifestations that include the physical, the
social, the environmental and the psychological aspects that affect the chronicity of dysfunction
and disease; an ethics of care calls for the incorporation of attentiveness and relational autonomy
that holistically embodies dignity for each person, despite dependency, vulnerability or any
characteristic that invokes negative responses from society Recognizing the value of each person
is at the heart of the moral framework of an ethics of care. Therefore, relational autonomy does
not compartmentalize individuals because of individual physiological disease processes, from the
social determinants of health or from the negative psychosocial responses of disease, but rather
recognizes that chronic disorders such as substance use disorders and addiction are a result of a
spectrum dysfunction and progression; management demands upon holistic, comprehensive and
relational approaches that meet the needs of individuals without devaluing personhood.125
Professional attentiveness requires the development of a relational and participatory plan that
identifies the inadequacies of the present management of care; partnering concepts of relational
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autonomy and professional attentiveness potentiates a paradigm of care that increases the dignity
of care for those who are most marginalized.126
Humans are sensitive beings that remain vulnerable throughout a lifetime, requiring the
sustenance and development of relationships, companionships, and connectedness. Professional
attentiveness recognizes that principles of human flourishing, actualization, and wellbeing are
associated with the incorporation of holistic care paradigms that include the promotion of human
dignity and respectful development throughout the lifespan.127 Professional codes of ethics
promote optimal care to individuals and communities, despite disease, diagnosis, race, gender or
sexual orientation.128 Unfortunately, aspects of stigma and marginalization still abound in the
treatment of addiction dysfunction, often times unnoticed due to bounded ethicality and ethical
fading; the current social constructs of care in substance use disorders and addiction management
must embrace concepts of dignity for all human life.129 Substance use disorders and mental
health disorders are not exempt from the fundamental principles of inherent dignity in healthcare.
Professionals must embrace the fundamental principles of inherent dignity for all
individuals, despite opposing views, values, or life choices; attentiveness, requires an adherence
to models of care that promote understanding, enhances relationship, facilitates responsibility,
encourages accountability, and incorporates safe and equitable elements of care.130 Incorporating
authentic implementation of dignity for those with substance use disorder and addiction
dysfunction, must directly improve access to care, by influencing social constructs of ethical
behavior change; attention to authentic professional values of attentiveness, recognizes that
human dignity treats all persons with respect and care by facilitating care relationships, through
embracing care as a deep and fundamental value.131 Professional responsibility, seeks to improve
social and professional responsiveness to those who are vulnerable by aiming to unite and heal
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versus separating and dividing.132 Professional attentiveness enhances the lens of responsibility
and illuminates skills necessary to provide professional competency.
Implementing an ethics of care and relational decision-making decreases patient
vulnerability and improves individual dignity through relational respects, of acceptance and care.
All persons, by nature of their humanity, are fundamentally vulnerable and dependent upon
‘others;’ social constructs of family, community, and healthcare organizations can either produce
positive care environments or negative care environments.133 Positive care environments that
decrease vulnerability, empower relational autonomy, and ameliorate individuals through the
promotion of wellbeing and intrinsic value embody the essence of human dignity holistically in
clinical practice; this includes the respect for the giftedness and value of those who suffer from
substance use disorders, addiction and other neuropsychological diseases.134
The United Nations Educational, Scientific, and Cultural Organization’s (UNESCO)’s
Universal Declaration on Bioethics and Human Rights, asserts that the respect for human
vulnerability and personal integrity should be respectfully considered in the care of all
persons.135 This care consideration includes persons with dependency and cognitive dysfunction
that impairs the ability to make sound executive functional decisions because of neurocircuitry
dysfunction related to substance misuse. Intrinsic dignity of persons is expressed through
acceptance of individual limitations through amelioration of individual strengths that can be
actualized through relational empowerment; relational empowerment and dignity recognizes that
the values and the views of the persons who are vulnerable, require assistance when making
decisions, encourages the person to be as self-supporting as possible, and assists with surrogate
decision-making in order to help avoid harms for persons when aiming to decrease harms.
Aiming to decrease harms because of impaired decisional capacity include the patient in the
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decision-making process as often as possible, clear individual goals of treatment are respected in
all decision-making circumstances.136
According to the standards of the Patient Self-Determination Act, patients cannot be fordestined or predetermined as incompetent decision-makers because of an ascribed physiological
or asserted medical diagnosis; however, it is an ethical imperative to preserve individual dignity
when a patient is at risk for harms to self or other because of poor decisional capacity.
Implementation of a care paradigm that seeks to avoid harms associated with vulnerabilities as a
result of decreased cognition, decreased rationality, and alterations in thought processes are
essential components of substance use disorder and addiction management that have not
previously been considered as normal elements of care.137 The particularities of the task at hand
are monumental and a relational approach to care must incorporate strategic implementation
process that strongly supports individual dignity, by the application of authentic professional
responsibility and competencies.

b. Responsibility and Competency.
Incorporating responsibility and competency in professional interactions requires the
incorporation of professional standards and objectivity without eliminating the relational
elements of care.138 It should be the goal of the professional to follow standards of clinical
practice that include attentiveness to the needs of the patient utilizing evidence based practice
standards that may separate the perceived biases of the caregiver, in order to provide the optimal
care of the patient.139 Professional responsibility includes incorporating the synthesis of
professional knowledge, acting objectively for the benefit of the patient, disregarding ones’ own
personal or negative judgment regarding the patient while implementing the care of the ‘other’
with fidelity and compassion.140
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Patients entrust that professionals will maintain responsible and competent care in their
interactions with patients by practicing and adhering to high moral standards that provide
unwavering attention to moral values and professional codes of practice; patients anticipate that
professionals will practice with integrity and trustworthiness.141 This requires that professionals
act with fidelity, transparency, respect for informed decision-making, incorporation of individual
rights, and the inclusion of the principles of beneficence, and non-maleficence during all patient
interactions.142 Professionals that seek to maximize the value and dignity of the patient must also
include the sharing the contributory causes of substance use disorders and addiction dysfunction
to patients in order to include appropriate education strategies that integrate addiction etiology,
epidemiology, neurobiology of disease, genetic and epigenetic pre-disposition, so that patients,
families and communities are truly informed; incorporation of scientific knowledge for patients,
potentially revolutionize the management of care for this disparate population, because it
validates a model of care that eliminates the focus on intrinsic personal failures and blame and
enables a more constructive paradigm of relational responsibility between health and wellness,
versus debilitating self-destruction.143
United States healthcare systems have primarily focused on individual autonomous rights
of patients through constructs of decisional competence determinations of patients by
professionals; however, responsibility in an ethics of care clearly displays the role of human
flourishing as a priority within the nature of relational structures.144 A collaborative model of an
ethics of care recognizes that supportive and relational decision-making models improve
individual and system outcomes, decreases risk for patient harms and heightens the interdependency and interconnectedness of social supports.145 Minimizing the vulnerability and
harms for those with substance use disorders, addiction and the often times resultant
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neurocircuitry and neurocognitive disability that impairs executive functioning capacity of
individuals by increasing the associated harms of substance use; assessing the quality of
improved consent processes, assessing the quality of treatment outcomes, and assessing the
development of processes that support relational decision-making potentiate the enhancement of
human dignity for those with addiction. Therefore, it is the responsibility of professionals to seek
processes of care that improve relational outcomes through implementation of shared decisionmaking by improving competence for those with increased vulnerability who are at risk to inflict
harm to self, harm to families, and harm to future generationally through changes that seek
optimal health for all.146
Responsibility of action as an ethics of care value, does not solely focus on subscribed
duties or obligations; within an ethics of care paradigm, responsibility embodies the care
philosophy which embraces outreach to ‘others.’147 Outreach to others is a professional
responsibility in the management of care to those diagnosed with substance use disorders,
addiction and neuropsychological illness, must understand that the collaborative path of care
requires implementation of continuous assessment of patient understanding, assessment of
patient centered goals and values, incorporation of participatory communication with others,
attentiveness to adhering to the values and goals of patients, validation of vulnerabilities, and a
commitment to eliminate barriers of care, which could impact patients and social supports
negatively.148
It must be additionally noted, that implementation of professional responsibility of this
magnitude, requires organizational support systems and policy structures, that empower
professionals to gain the competencies to implement supportive, relational and collaborative care
to patients and families.149 Professional competencies in the delivery of care for patients
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diagnosed with substance use disorders and addiction dysfunction require that professionals
manage the delivery of care through a thorough understanding of the rights of persons with
dependency and disability.150 Professional competence is attained through continuous reception
of training and educational information that strengthens professional practice; professional
competency is evaluated by organizational and professional standards of practice guidelines and
aligns with the overarching concepts of professional ethical standards.151 Professional ethical
standards of practice are required to be adhered to during the management of care for those
diagnosed with both impaired cognitive disease and for those diagnosed with impaired physical
disease.
Therefore, it is the responsibility of care providers to implement relational decisionmaking care guidelines that incorporate mental health policy and disability policy standards in
everyday practice.152 Providing appropriate services to patients diagnosed with substance use
disorders and addiction include anticipating continuous re-assessment and re-evaluation to
ensuring that sliding scale capacity assessments are strongly considered in relational aspects of
care and decision-making. Ensuring that futuristic decision-making is respected for those with
neurocognitive changes and potential trajectories of care associated with neurological crisis and
chronic deterioration are considered. This inclusive responsibility of re-assessing and reevaluating patients is a process that professionals must clearly identify within the Patient SelfDetermination Act; it is clearly stated, that all patients should be informed about the right to
prepare advanced directives regarding the desired trajectory of their personal care.153Application
of preparing relational decision-making directives in the management of care for substance use
disorders and addiction have not been previously implemented; however, presents an exciting
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care element that seeks to decrease the current trajectory of harms to the enormous number of
patients and families affected by the current international addiction epidemic.
Responsibility to implement quality initiatives that enhance awareness to actualize
maximum decision-making potential for those with fluctuating cognitive impairments related to
substance use disorders and addiction is necessary; hence a reconceptualization of previous legal
mandate and criminalization of addiction is warranted; additionally, bioethical principles that
address the roles and duties of proxy or surrogate decision-making must be fully explicated
within the framework of the unique patient circumstance in substance use disorders, mental
health dysfunction with addiction and the neuropsychological manifestations of fluctuating levels
of cognitive ability. Proxy and surrogate decision-making guidelines often emphasize the
responsibility of the appointed decision-maker for patients during end-of-life decision-making;
however, the application of proxy decision-making for a person with fluctuating competency as a
result of substance use disorders and addiction within a framework of an ethics of care adds a
layer of relational decision making, dispelling the myth of an ‘all or nothing’ appointment of
surrogate decision-making proxy for those with neurocognitive dysfunction with addiction and
substance use disorders.154
Therefore, a supportive and relational decision-making implementation process becomes
a process of professional responsibility and adherence to professional competencies; allowing
persons with substance use disorders and altered cognitive ability that imposes a risk of selfharms, seeks to maximize individual decision-making without being subjected to the paternalistic
decisions of others. Professional responsibility requires that patients are assisted in expressing
values and wishes in the management of healthcare related decisions, prior to times of insistent
self-harm through substance misuse.155
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Chapter 4 Consent in Addiction Disorders
Obtaining informed consent for patients diagnosed with substance use disorders and
addiction disorders is problematic because the assessment in determining individual autonomous
decisional-capacity does not meet the standards of the informed consent criteria. Obtaining
informed consent for patients who experience chronic neurological changes that impede
executive cognitive functioning violates the historical elements of informed consent that sought
to protect individuals from harms. Applying the elements of obtaining informed consent and
assessing decisional capacity for patients who experience chronic substance use disorder and
addiction, requires a careful analytical examination of the process, which seeks to investigate the
known neurological changes that restrict adequate adherence to the elements of informed
consent; the elements of informed consent include the analysis of the following criteria, first determination of individual competency; second, maintaining voluntariness of individual; third,
ensuring adequate disclosure; fourth, assessing individual capacity of understanding complex
disease processes and treatment interventions and lastly, determining the individual’s capacity to
assess risks and benefits of complex health information.1
Determining competency for consent for the medical treatment for patients diagnosed
with substance use disorders and addiction, an understanding of the confirmed neurocognitive
functioning changes must be carefully examined, because of the resultant physiological
influences that alter executive functioning abilities; as a result, a careful analysis that seeks to
determine the connection between how the escalating neurological dysfunction and
neurocircuitry changes respond to stress states is paramount. It is a professional obligation to
implement a holistic and ethical plan of care that adequately discloses the treatment plan,

136

assesses patient competency, determines voluntariness, assesses the capacity for understanding
complex nature of substance use and addiction as a disease, and carefully assesses the ability of
the patient’s ability to assess risks and benefits of behavior and treatment.2
In order to comprehensively evaluate all of the essential elements of consent for those
diagnosed with substance use disorders and addiction, professionals should assess and recognize
the fluctuating stages of the substance use continuum. Meaning assessment is continuous,
relational and varying; determining an individual’s competency for substance use and addiction
management takes longer than the determination of an instantaneous authoritative judgement of
the ‘other.’ The professional team must seek to recognize the manifestations of neurocognitive
and neurocircuitry dysfunction, understand the neuropathology, must recognized intrinsic
reward/ stress responses and aim to decrease escalating physiological harms and often times
hidden harms, such as psychological, spiritual, and existential suffering.3
Despite clear bioethical standards that require a systematic and comprehensive method of
obtaining informed consent, traditional processes of obtaining consent for patients who suffer
from substance use disorder and addiction continues to ignore the particularities of the spectrum
of substance use disorders. Hence, perpetuating an increase in the associated neurobiological
complications that often times result in loss of human life. Startling increases in mortality and
morbidity result; death as a result of preventable accidents is now the third leading causes of
deaths in the United States.4 Substance use and addiction is one of the leading causes of the
occurrences classified as preventable accidents.5 Utilizing an ethics of care seeks to repair
autonomy and authentic self-determination by incorporating relational decision-making
processes through the actualization of individuals through community support, through the
empowerment of relationships, and through prevention and wellness initiatives, that recognizes
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the multifactorial processes, that necessities individual, social and cultural responsibility and
culpability of harms.6
The constructs of an absolute autonomy model, which highlights isolation, blame and
stigma for those who suffer from addiction and substance use only instills perpetual vulnerability
and escalating harms; consequently, developing an improved informed consent processes for
treatment of substance use disorders and addiction requires implementing methods, which clearly
address the states of altered consciousness and cognitive impairments that occur both acutely and
chronically as a result of substance use. An ethics of care, seeks a professional response that
acknowledges the nuances of substance use and addiction when applig the criteria of informed
consent; once, the criteria of substance use disorder continuum and addiction have been
validated, a relational and shared decision-making mode of informed consent processes should
be initiated.
Shared patient, professional and surrogate decision-making, ensures the implementation
of professional partnership initiatives that respond scientifically to improve individual autonomy
by improving decisional capacity and shared decision-making ability to individuals, despite the
neuropathology of dysfunction; partnership links individual vulnerability to the strength of
holistic management strategies.7 Improving neurocognitive functioning for those who suffer
from substance use disorders and addiction is made possible by utilizing treatment interventions
that adequately develop relationships of care for the patient, family, and community; the
development of relationships of care eliminates the authoritative and paternalistic paradigms that
result in radical neglect of dysfunction and disease, based upon out dated constructs of fear and
repulsion associated with the ‘unknowing’ of how to manage what seems to be a self-induced
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state of altered consciousness. The advances in technology and science can provide the evidence
that begin to dispel the myths associated with blame and weakness of character for individuals.

4.1 Altered Consciousness and Relational Decision-making.
Consciousness is often thought of through constructs that are separate from the actual
functioning components of the brain; however, consciousness and neurological functioning are
intimately connected on a biological and cellular level.8 On a fundamental level the relationship
between consciousness and neurological functioning are simply described within the elements of
an awake state of being.9 In health care, level of consciousness is measured by determining
potential complication of neurological functioning through the determination of assessing the
level of consciousness by measurement scales; the spectrum of consciousness fluctuates as
waxing and waning states that occur during sleep, during illness, during injury, during
anesthesia, psychological responses, or during accidental loss of consciousness resultant from
substance use, etc.10
Additionally, consciousness means more than simply an awake state. Consciousness also
attempts to explain the ‘awareness’ of self, awareness in relationships with others, and awareness
of one’s spacial presence in time and place.11 Consciousness experiences the complexities within
interactions, processes, and environments, through multifaceted interpretations of creating
meaning through neurological functioning; consciousness requires executive functioning and
complex decision making ability.12 The state of consciousness also includes personal subjective
experiences and how those experiences occur reciprocally with self and with others. During
substance use and addiction, states of consciousness are altered with self and with others, due to
the specific nature and neurological effects of each substance used; Elizabeth Hirshman’s
phenomenology of addiction research describes the altered state of consciousness as an extreme
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emotional and rational thought that deconstructs self and relationships through disordered,
illogical, and destructive states that are described through an inauthenticity to self.13
However, consciousness is not restricted to the limitations of wakefulness or awareness;
rather consciousness indicates the overall functioning of the human ‘brain’ and how it responds
inclusively through biological functioning of the entire person through the complexities of the
human nervous system.14 The neurobiology of consciousness is now able to trace the
characteristic patterns of neural circuitry and hence neural activity, that occur during conscious
and unconscious states within individual brains; yet, experiences seem intrinsically private and
personal, which are more complex than neuronal activity alone and difficult to share through
explanations of the spoken word linguistically .15 Individual experiences are intricately
determined by both the objective and subjective responses of human encounters; to make matters
more complex, neuronal experience responses are drastically altered through the chronic
consumption of substances. Physiological and behavioral responses to these substances resort to
intrinsic protective responses that seek to preserve reward pathways, that mistakenly link
substance use with the urgency of survivability; hence, intrinsically altering perceived threats of
safety to self, and creating tension between the subconscious version of the authentic self.16
The negative/ withdraw stage of addiction, contributes to the development of
inauthenticity for individuals. Authenticity is described as being honest to one’s self, being
trustworthy and reliable to one’s self; unfortunately, as a result of the neurological changes that
seek to increase survivability and reward seeking behavior an inauthentic identity develops,
hidden and shadowed in silence.17 The shadowed silence of inauthenticity causes existential
suffering for those who experience substance use disorders and addiction.18 The public opinion,
which reflects the projection of blame and stigma, only heightens the shadows of blame and self-
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loathing, which incorrectly places an emotionally heavy burden upon individuals, escalating
stress and further impairing executive functioning states, which further impairs the ability of the
individual to act authentically and autonomously.
The neurobiological changes, which occur in patients during the acute and chronic stages
of substance use disorder and addiction dysfunction interferes with the individual’s neurological
functional capacity; the changes in the hippocampus directly influence the impairment of short
and long-term memory functioning and directly influence changes in the mesolimbic dopamine
reward system by altering the neurotransmission of reward and survival seeking pathology.19
Impaired neurotransmission, impaired neurological functional capacity, and changes in reward
seeking functioning interferes with the patient’s ability to understand complex health information
and to rationally consider the long term consequences of substance use harms and medical
management of care benefits. The escalating short term stress responses, which motivate the
survival reward circuitry functioning will intrinsically take precedence over executive decisionmaking functional ability; impairment affects rational understanding of long term medical
treatment goals and blocks decisional capacity that is necessary to adequately determine the risks
and benefits of treatment versus continued substance misuse.20
Additionally, genes that are extensively exposed to cocaine specifically reveal
mitochondrial membrane changes that are associated with altered hypothalamic pituitary adrenal
axis system responses that further alter genetic expression, affecting glucose and metabolism
regulation, in response to escalating stress.21 The epigenetic consequences of stress on future
generations is staggering, indicating that the seemingly autonomous decisions of individuals
deleteriously affects the future health and wellbeing of not only the individual, but the cellular
expression and methylation stress responses of immediate offspring and future generations.22
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Seemingly the conscious and autonomous decisions of individuals negatively effects decisionmaking, and overall wellbeing and health due to harmful neurological responses, which affect
decisional capacity for self and for future generations.
The American Psychiatric Association (APA) and the Diagnostic and Statistical Manual
(DSM-V) of the American Psychiatric Association’s fifth (5th) edition criteria defines
dependency as an uncontrollable craving and an inability to stop using a substance despite
repeated spoken desire to cease usage of substance; the criteria further includes that substance
use disorders are categorized as a chronic spectrum disorder that begins with dependency
fluctuates between remissions, relapses and climaxes with the acuity of addiction. Individuals
who experience this spectrum disorder often verbalizes a desire to stop use of substance, but
makes the non-rational choice to continue use of substance; the complexity of addiction
pathology affects neurological functioning of the brain through the stages of binge/ intoxication,
withdrawal/ negative effect, and preoccupation/ anticipation stages.23 The scientific evidence
supports that the processes that cause physiological dysfunction in substance use disorders and
addiction alters consciousness, cognition and alters decisional capacity; thus, turning a blind eye
and advocating for the autonomous rights of patients by stating, ‘that patients are ‘allowed’ to
make poor decisions when they fall within the spectrum disorder of substance use dysfunction’
certainly exhibits an overt neglect for the respect of human dignity.
Robert M. Veatch, reflectively suggests that the notion of informed consent, requires a
transition to a more modern and revolutionary conceptual development; recommending that the
components of informed consent that seeks the theoretical ‘good’ for patients should be reexamined.24 The transition toward a reconceptualization of the informed consent criteria and
theoretical ‘good’ for patients in healthcare cannot narrowly focus on generic check-box criteria
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and processes of informed consent; rather, each patient’s condition must be carefully examined
within the socio-cultural, particularities of disease, support, and resources available for each
associated circumstance. The particularities for the treatment for those diagnosed with substance
use disorders and addiction disorders must seek to decrease the risk of vulnerability associated
with isolation, alterations in consciousness and impaired decisional capacity. The reinterpretation
of informed consent for substance use disorders, must seek to implement processes, which seek
to restore authentic identity and restore consciousness, which will as a result increase
competency, improve self-determination, and restore autonomy of individuals through constructs
of partnerships and relational decision-making.

a. Criteria for Consent: Autonomy and Self-determination.
Modern bioethics, medicine and science have unintentionally through reductionism,
deductive reasoning and the quest to heighten the dignity of individual persons placed an
impossible burden and value on autonomous decision-making.25 In the application of healthcare
decision-making, the very definition of autonomy translates from the Greek interpretation that
recognizes the importance ‘of self-ruling’ principles and concepts.26 It is interesting to note, that
the original interpretation of autonomy identifies the self-ruling of city-states not the sole selfrule of individuals. With the advancement of modern biological science and democratic
government establishments an increasingly reductionist interpretation of autonomy and its
application to healthcare decision-making has evolved; as a result, the limited scope of
individuality has wrongly led to the increased risk of harms that for those who are suffer from
substance use disorders and addiction, further widening the gap of care, as a result of fear and
isolation, in decision-making practice and process.
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Historically, informed consent processes were implemented as a way to protect
vulnerable research subjects from harm as a result of human experimentation; often times,
physicians and researchers lacked transparency for those who were not informed regarding the
nature of medical treatment or research.27 It was common for patients to passively accept the
hierarchical and paternalistic care of physicians without full participation, knowledge or
understanding of the plan of care; therefore, implementing standards of informed consent
became a revolutionary way to encourage patient participation in their plan of care. Constructs,
which encourage patients to participate as partners in their own plan of care, requires grassroots
health related education initiatives and higher level executive neurological functioning ability for
individual patient participation; the conundrum is further complicated when an honest analysis
identifies that all patients do not possess the complex reasoning skills necessary to ‘partner’ with
professionals who are scientifically trained and educated. This understanding, necessities the
importance to implement relational decision-making models of care that extends beyond the
medical community and acknowledges the multifaceted, holistic and relational nature of family,
social, and cultural supports.28
The bioethical criteria necessary for obtaining consent in health care requires that the
patient has capacity to make autonomous decisions, this ability to make one’s own decisions is
paramount for self-determination. Self-determination, is more specifically defined as the
universal right of individuals to determine their economic, cultural and social development.29
Competency in health care decision-making identifies a patient’s ability to understand health
related information and then be able to express personal values related to treatment choices,
consistently over time; additionally, the ability to understand health related information should
be synthesized in the expression of desired outcomes for care without coercion.30
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During different periods of one’s life, personal ability to perform tasks, including
decision-making, fluctuates from periods of independence to periods of increased dependency on
others for decision-making; optimal development that promotes autonomous decision-making
requires acquiring interdependent knowledge from others in order to increase foundational
wellbeing and to decrease vulnerability through family or community structures.31 Therefore,
autonomy and self-determination is a relational process shaped by the accumulation of
knowledge, which is shared through support of family, healthcare providers, and communities.32
The legal criterion of competency, presupposes that the individual who seemingly makes
a conscious decision to consume alcohol or illegal drugs is acting autonomously; however, the
physiological determination of deciding a patient’s capacity in order to make clinical decisions
should not confuse the legal linguistics of decision-making, with the scientific and neurological
application of evidence based decision-making.33 Historically, maintaining that patients who are
diagnosed with substance use disorders and addiction meet the decisional capacity criteria
necessary for self-regulation and self-governance during their medical management of care is not
scientifically justified. Therefore, patients who are diagnosed with substance use disorders and
addiction require application of a revolutionary standard of professional practice and care that
truly differentiates autonomous decisional capacity versus physiological alterations in
neurological functioning that is affected by genetics, epigenetics, and neurotransmission
alterations due to substance.34
Application of an interpersonal, professional, and relational system in decision-making is
necessary to enhance the social nature of empowering personal autonomy and decision-making.35
The central proponents of individual autonomy have rightly heightened the bioethical principle
of ‘respect for autonomy.’ The bioethical principle emphasizes the intrinsic value and dignity of
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all persons, by placing intrinsic value of each person against constructs of discrimination and
stigmatization for marginalized individuals, communities and populations; the respect for
autonomy principle recognizes that all persons have the fundamental right to rationally choose
one’s own trajectory in life, including medical treatment and care in relation to one’s individual
values and beliefs.36 Additionally, healthcare professionals commonly seek to include in practice
the bioethical principle of beneficence, which rightly prioritizes seeking the positive good for
patients during management of care; providing the good for patients, has often times resulted in
paternalistic decision-making of practitioners without considering the individual goals and values
of the patient.37 Developing partnerships through shared decision-making models of care, seeks
to embrace patient centered goals and values, while also preventing harms associated with
neurological dysfunction; placing absolute autonomy in its rightful place through the support of
relationships, or a relational autonomy standard.
More specifically, the bioethical principle of autonomy focuses ‘on the respect for
autonomy’ by ‘normal choosers’ in regard to their actions of intentionality, comprehension, and
understanding; those who suffer from substance use disorders and addiction are not cognitively
or neurologically normal choosers. Respect for autonomy is actualized by healthcare providers
when a patient’s perspectives, values, and wishes are acknowledged, implemented and adhered
to by their healthcare providers; yet, if known cognitive or neurological impairments are overtly
manifested and are ignored by practitioners, then escalation in vulnerability is inevitable for this
disparate population, that suffers from substance use disorder and addiction.38
The delineation to respect autonomous individual responses to decision-making is
justified in patients who possess normal decisional capacity; however, the process is confounded
when patients are unable to adequately understand health information, express or communicate
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care preferences, regulate projected consequences or understanding of treatment interventions,
and has difficulty rationalizing care, risks and benefits of care; this conundrum of decisionmaking as it relates to determining the competency of persons who demonstrate altered levels of
consciousness, as a result of substance use disorders and addiction, requires a comprehensive and
systematic evaluation.39
Decision making for patients who experience altered levels of consciousness as a result
of progressive dementia or complications from neuropsychological factors are commonly
determined incompetent and are eligible to receive support from surrogate or proxy decisionmakers.40 Cognitive examinations and assessment of decisional capacity is routinely completed;
as a result, many hospitals and practitioners, utilize a simple psychiatric consultation process to
accomplish this goal.41 Yet, this oversimplification of obtaining a psychiatric consult is not the
best way to determine cognitive capacity in patients who suffer from substance use disorders and
addiction and often times results in a subjective and paternalistic decision patterns based upon
‘best interest’ standards.42
The best interest standard in health care, identifies that when a patient is unable to freely
choose a medical trajectory of care, then physicians and health care practitioners are required to
implement the best interest standards of care for that patient; concurrently, when a patient is
deemed incompetent to make their own health decisions, a surrogate decision-maker is assigned
to make decisions for the patient and is expected to adhere to the same standard of care.43 When
autonomous decision-making ability is lost by persons because of declining neurological
functioning, bioethicists have implemented forms of surrogate decision-making processes
through application of subjective and objective judgment standards; consequently, implementing
a systematic process for determining decisional competency, while navigating through the
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variable levels of consciousness and cognition changes in substance use disorders seeks to
comprehensively improve supportive decisional care.44 However, best interest standards cannot
occur in isolation, without ‘knowing’ the values of patients, families, and community.
Collaborative and relational decision-making is an approach that includes professional
expertise, requires family participation, and an inclusion of what is known of the patients
expressed desires or values of care.45 Within the traditional surrogate decision-making role, the
proxy or surrogate is charged with determining healthcare decisions for the patient, based upon
what is known to be the previously expressed desires or wishes as they would have been related
to healthcare treatment and interventions.46 When the patient’s interests and values are unknown,
the best interest standard can be implemented; decisions are made because they are in the best
interest of the patient, meaning, surrogates or proxies are not permitted by law to reject treatment
interventions that would not be beneficial to that patient.47
Vulnerable populations, such as those diagnosed with mental health disorders, substance
use disorders, and any other patient who is determined to have decreased levels of consciousness,
and those diagnosed with neurodegenerative diseases require collaborative, responsible, and
professional advocacy interventions that implement decision-making through relational and
professional advocacy plans of care; relational and professional advocacy plans should be
implemented for those who have altered levels of decisional capacity, altered abilities to
communicate those abilities, and insufficient resources or family support.48 Therefore,
implementing an ethics of care maximizes the relational aspects of decisional care for those who
require support from professionals, family, and society.
Family members or proxy decision-makers often times verbalize concerns that they are
inadequately prepared to make substitute decisions; additionally, professional healthcare
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providers feel that limited clinical standards or guidelines of care have yet to be fully developed
in order to offer improved professional development strategies that seek supportive and
empowering consent processes for those diagnosed with neurocognitive impairments, substance
use disorders and addiction.49 This conversation and establishment of guidelines must supersede
the care of those diagnosed with substance use disorders and addiction. Health care professionals
have an obligation to advocate for the avoidance of harms, implement treatment interventions
that seek to enhance positive coping strategies, and advocate for avoidance of neglect associated
with impaired decisional capacity for those who suffer from the harms associated with the
physiological coercive processes that hijack neurological functioning of those who are inflicted
by substance use disorders and addiction.50 Consent processes in the management of care for
those who are diagnosed with substance use disorders and addiction, must seek to revolutionize
best practice standards by implementing a relational alternative to consent through a paradigm of
authentic care and shared decision making strategies that include preventative and harm
reduction education initiatives, developed for individuals, family, healthcare practitioners, and
entire social communities.

b. Shared Decision-making: Developing a Treatment/ Social Plan.
Allowing individual and autonomous decision-making in the management of care for
patients diagnosed with substance use disorders and addiction has not improved the outcomes for
this epidemic.51 The most severe form of the continuum of substance use disorders is addiction;
addiction is complicated by the intrinsic and coercive nature of the substance’s ability to alter
cellular functioning, impact epigenetic and biological functioning, and severely alter cognitive
and neurological processes; managing the coercive nature of substance use requires a relational
supportive development of a holistic and comprehensive treatment plan that must include
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community and social empowerment. Furthermore, the current social structure of criminalization
for those who suffer from substance use disorders and addiction only serves to alienate and
isolate individuals from supportive social environments, family, and communities. Social
constructs of marginalization and stigma must disintegrate; hence, aiming to alter the epigenetic
consequences of dysfunction from one generation to the next.52 It is time to holistically develop
strategies that comprehensively manages all aspects of substance use disorders in order to
decrease harms through relationship, shared decision making and community collaboration.
Because the progression of the chronic continuum of substance use disorders and
addiction progressively impedes the voluntariness of actions for individuals and thus inflicts its
learned behavioral perpetuation for subsequent generations of individuals, while also continuing
the intrinsic pathology risk of cellular methylation and adverse cellular responses, which
influences generational cellular expression during periods of stress and illness, it becomes an
ethical imperative to initiate a paradigmatic and revolutionary treatment program that includes a
social plan to prevent further individual and consequential societal harms. This can be
accomplished by avoiding alienation, marginalization, isolation, and dislocation of patients
through the development of evidenced based treatment programs that are not discriminatory and
reflect a relational paradigm of care.53
Developing a shared decision-making model of care requires developing components of
care that implement strategies that seek to decrease vulnerability, paternalism, hierarchical power
imbalances and violations of individual human rights. As a result, the current framework that
only identifies, individual moral culpability, by not acknowledging or examining the
comprehensive and communal nature of the rise in substance users disorders and addiction
nationally, fails to reflectively consider the evidence that supports the pathophysiological,

150

neurological, and social constructs that continue to escalate harms, disability and death.54 The
unrealistic assumption, that addiction is a freely chosen path in life blatantly ignores the
supportive scientific evidence of pathology; as a result, the extreme neglect of persons, despite
the APA’s DSM-V criteria that clearly illuminates the neurological pathology that substance use
disorders and addiction continues despite the frequently verbalized desire, by many to cease
consumption55.
Professional practice interventions, pharmaceutical interventions, collaborative treatment
modalities, and holistic interventions that aim to heal existential and spiritual suffering have
resulted in improved outcomes for patients and families; therefore, the hesitancy to develop
alternative health care treatment options as a result of misinterpreted and narrow constructs of
autonomy as it relates to substance use disorders and addiction appears to be a grave violation of
the Universal Declaration of Human rights. Article one, states: ‘all human beings are endowed
with reason and conscience and should act toward one another in the spirit of brotherhood.’
Perpetuating human harms, through antiquated authoritative punishment strategies is no longer
an acceptable management of care process; perpetuating harms increases vulnerability and
suffering for this disparate population.56
Developing a shared decision making model for the management of care for patients
diagnosed with substance use disorders and addiction, seeks the development of an alternative
method of obtaining informed consent, through an essence of a common spirit or relational
partnerships that seek harm reduction and prevention strategy implementation.57 The
development of an alternative method of an informed consent process should clearly articulate
the importance of shared decision making and the development of individual treatment options;
but the criteria must also incorporate a social plan of support, through empowerment, guidance
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and hope.58 The development of relational criteria is essential, versus the solitude associated with
a disease model of care and isolation of a criminalization model of care that instills barriers to
individual decision making through constructs of fear, rejection and marginalization.59
By addressing the particularities associated with the neurobiological pathology, which
causes the neurocognitive dysfunction associated with the continuum of substance use disorders
and addiction, pathways of recovery can materialize when compassionate and relational
education initiatives are established.60 Utilizing elements of surrogate decision making is helpful;
yet, extrapolating elements of transparency, empowerment, and collaboration in the development
of practical, measurable and realistic goal setting must also be established. Criteria of effective
surrogate decision making in the management of care for substance use disorders and addiction,
must include a compassionate educational based treatment initiatives that teach prevention and
harm reduction strategies.61
The experiences of individuals, family members, and communities who are affected by
the devastating effects and the struggle of loved ones who are diagnosed with substance use
disorders and addiction continues to escalate in numbers. The manifestations of existential
suffering and the struggle of those who are diagnosed, negatively affects family and friends as
they witness the neurocognitive loss of relationship with a loved one who suffers from substance
use disorder and addiction; this emotionally draining loss can negatively affects the entire family,
and community, through emotions such as depression, helplessness and anxiety with the
seemingly unexplainable trajectory of dysfunction and minimal professional and societal
support.62
Additionally, associated family members are often times labeled with the same stigma,
shame and blame that plagues the one diagnosed with addiction; therefore, perpetuating
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detachment, neglect and abandonment for those who suffer. Developing a model of care that
seeks empowerment, healing, and support aims to project a framework of care that weaves
together the human values of respect, dignity and social justice. Implementing ethical values
provide a comprehensive framework of care that seek the actualization of attentive, responsive,
and accountable professional behaviors that honor and respect the development of realistic
patient goals that implement strategies and interventions that actively seek to prevent harms and
improve health outcomes for individuals, families and communities, through a comprehensive
and relational interpretation of competency for consent.63
4.2 A Relational Interpretation of Competency for Consent.
Current management of chronic disease states such as hypertension (HTN), coronary
artery disease (CAD), chronic obstructive pulmonary disease (COPD), type II diabetes mellitus
(DM), obesity and human immunodeficiency virus (HIV) all entail management of care
paradigms that included shared decision making regarding diet, exercise, pharmaceutical
interventions mindfulness programs and other health related prevention strategies in the
management of physiological disease processes that are also caused by complex cellular, genetic,
and environmental factors; treatment does not result in isolation, marginalization, and social
alienation. When a patient diagnosed with diabetes continues to consume foods high in sugar,
rather than alienate, marginalized and discriminate, programs attempt to include interventions
that support behavioral modification, interventions that identify psychological support, offer
alternative pharmacological management strategies, and offer alternative services to avoid
progression of etiological advances of chronic disease and heritability.64
The professional call to action requires application of a responsive health care
environments that identify that the cognitive dysfunction of addiction should not negate the
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provision of the same evidenced based practice and care, as provided in other chronic and
complex inherited diseases; unfortunately, due to the nature of perceived blame of disease choice
and negative nature of cognitive impairment, current practice perpetuates progression of
chronicity, suffering, and death.65 It was not so long ago, that similar stigma, alienation, and
marginalization occurred for infectious disease states such as leprosy and HIV. Both of which
were associated with individual moral failure and culpability.
The relational interpretation of determining competency for consent in the management
of care for patients diagnosed with addiction disorders requires the support of healthcare
providers that recognizes that those who are diagnosed with impaired cognition and impaired
executive neurological functioning should not be expected to medically manage their own
trajectory of care.66 The reinterpretation of consent in the management of care of addiction
disorders requires a commitment of professionals to eradicate the socially embedded culture of
blame, shame, and isolation by teaching prevention strategies, instructing responsibility and
personal ownership of susceptibility of disease, and teaching strategies that optimize human
flourishing and potential.67
This initiative requires the development of individual patient strategies that acknowledge
human potential and flourishing within the individuals given circumstances, focusing not on
negative and perceived faults, but on individual drive and strength that potentiates hope and
recovery.68 This hope of recovery is not achieved through isolation, marginalization and
discrimination, but through respectful education strategies that patiently discuss the
physiological processes that cause impaired decision making for those who suffer from substance
use disorders and addiction.69 Once the physiological elements that contribute to individual
impaired decision making is taught and understood by the patient, initiatives that seek to improve
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the journey of neurocognitive functioning can begin. A partnership that is grounded upon shared
decision making is initiated through initiatives that include the unique perspectives, values, and
needs of each patient.70
Eliminating paternalistic and authoritative measures of professional coercion is
paramount to the success of the patient’s improved competency and repair of developing
autonomous decision making capabilities. Professionals must begin to embrace the perspective
that medical and healthcare initiatives are ill prepared to implement best practice standards
without knowing the particularities of the unique perspectives of individual patient values and
circumstances; however, this does not negate the professional responsibility to openly share long
term trajectory of risks and harms to patients, families and communities.71 The new approach to
informed consent must consider the nuances of patient choice, values and goals in order to
develop authentic and caring partnerships.72

a. Impaired Decision-making.
Identifying impaired decisional capacity in addiction disorders is challenging,
unpredictable, fluctuating and progressive or regressive in nature; the substance use disorder
determination is often considered through the lens of a spectrum disorder, with substance
dependency being the preliminary state of the dysfunction and addiction being the acute and
most severe progression.73 Therefore, the disorder requires application of skilled assessment
strategies to determine, at which stage or progression of neurological and cognitive dysfunction
the patient is currently experiencing; this assessment should include a comprehensive
professional evaluation assessment, completion of the MacArthur Competence Assessment, and
examining the results of periodic nuclear imaging scans to diagnostically determine impaired
decisional capacity.74
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Additionally, an empathetic approach that seeks the values of care, such as attentiveness
and responsiveness are necessary to ensure treatment with dignity and respect for the ‘other,’
despite neurological vulnerability.75 Professionals must recognize that decisional capacity and
decision making in addiction is fluctuating, it cannot be managed as a stagnant entity of the
treatment plan and it would be negligent to not comprehensively assess with a detail to due
diligent considerations of the known neurological fluctuations. During substance use disorders,
capacity fluctuations occur between periods of improved understanding during remission and
stability and drastically impaired capacity during times of chronicity and exacerbation.76
Until recently, the ability to gaze into the operational components of the brain’s phases of
neurological functioning was unimaginable; yet, presently the discovery of imaging processes,
which enable practitioners to view the brains perfusion and neurocircuitry activity is possible.77
This imaging helps practitioners see hypoactive, hyperactive, and normal activity of a person’s
neurological brain functioning; this technology revolutionizes the care for patients after
neurological insults, such as from strokes, epilepsy, psychiatric illnesses, traumatic brain injury,
or with the progression of Alzheimer’s disease.78 This technology also has the ability to
revolutionize the care of those who suffer from substance use disorders and addiction.79 This
technology is called single photon emission computed tomography (SPECT) scans along with
the use of computed tomography (CT) scans, is known as a SPECT-CT scan.80
This visualization can now support the individualized management of care components
necessary to validate and support the clustering of symptoms associated with the deterioration of
functioning from substance use disorders and addiction.81 Why is this important? Because the
alterations in decisional capacity and the nuances of the particularities of brain dysfunction must
be treated according to individual necessity. Through brain imaging studies, the nuances of

156

addiction, criminalization, isolation, escalation of stress states, increased emotional anxiety can
clearly validate the negative impact on brain functioning, health and decisional capacity.82
Impaired decisional capacity in the management of care for those with substance use
disorders and addiction is a serious conundrum of care that has been neglectfully unaddressed
medically, socially, culturally and politically; unfortunately, not identifying the problem has only
escalated in individual and societal harms. Creating inaccurate constructs of unfounded
presuppositions that claim addiction is associated ‘as a freely chosen component of the will’ by
claiming that the user consumes in order to seek euphoria is unfounded. The proliferation of this
over simplified fallacy of addiction can no longer confirm addiction as a weak moral resolve of
individuals; the perpetuation of this inaccuracy is neglectful and unethical and can no longer be
utilized as rational justification for allowing the perpetuation of harms associated with those who
suffer as capable to manage their own trajectory of care.
In 1947, after a series of investigations, the sociologist Alfred Lindesmith noted in his
book entitled, Opiate Addiction, that those who used opioids sought to relieve the negative
physiological withdrawal states of distress and the escalating stress responses that occurred after
utilization of substance, rather than freely choosing the use substance for the attainment of
euphoria.83 Now with the availability of supportive SPECT-CT scan imaging, the deleterious
effects of substance use disorders can no longer be disputed as a disorder of moral weakness and
individual culpability; behavioral, emotional, cognition and psychological impairments result in
pathological brain dysfunction that impairs normal neurological functioning that clearly includes
impairment in cognitive processing.
The individual circumstances that create substance use disorder and addiction are
different from person to person; additionally, the methodology to restore impaired decision
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making, once substance use disorders and addiction results is equally complex. Yet, the notion to
restore competency and decision making ability for those with substance use disorders and
addiction is often spoken in terms of individual responsibility, implying the notion that the
recovery from inflicting harm on self and others is freely chosen and therefore must be
individually resolved.84 This notion that suggests that a person with substance use disorders and
addiction is fully competent, and solely responsible for making competent decisional claims to
prevent harms is unfounded. Therefore, implementing programs that seek to relationally restore
competency and consciousness associated with the neurological and neurocircuitry harms
associated with addiction are necessary.
Determining the particularities of impaired decision making in substance use disorders
and addiction can benefit from the investigative inquiry of the neurosciences and in particular
neuro-ethics; technological imaging, indicates that neuronal activity involved with the processing
of large amounts of information, is impaired during intense emotional states, trauma, infections,
environmental toxins and drugs.85 Investigative utilization of the information should seek to
create concrete neurological guidelines in determining competency for decision making for those
diagnosed with substance use disorders and addiction. Currently, the determination of obtaining
an assessment for those with potentially impaired decision making ability is commonly evaluated
through the examination of the components of a person’s understanding, expression of choice,
appreciation of those choices and reasoning ability through the utilization of the MacArthur
Competence Assessment Tool. (MacCAT-T).86However, the utilization of this assessment tool is
rarely, if ever utilized in the determination of competency for those with substance use disorders
and addiction. Additionally, new technologically advanced imaging scans should be used to
guide the implantation of determining decisional capacity.
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Emotional intelligence and emotional responses have also been determined to impact the
beneficial or detrimental components in decision-making processes; without balanced and
sustainable emotional responses, decision-making capacity has been found to be significantly
altered.87 Therefore indicating that both cognitive and emotional abilities are necessary to
sufficiently participate in informed consent understanding, adds yet another layer of complexity
as it relates to the nuances of impaired decision-making for those with substance use disorders.
Human emotions are characterized generally through complex mechanisms of incentive feelings,
biological factors of intensity, which can be characterized through enculturation or socially
learned characteristics.88
Identifying the importance of human emotion and cognition in the process of assessing
impaired decisional capacity for those who suffer from substance use disorders and addiction
becomes the essential elements necessary in determining the ethical implications of utilizing a
relational process for informed consent and decision-making. Examining the psychological and
neural properties of the cognitive ability during decision making processes for those with
substance use disorders is relevant as it closely correlates to determining accurate and
accountable assessments as it relates to impaired decisional capacity, negative emotional
responses, and the stress of the negative withdrawal stage of addiction.89
Emotional states are effected by either the physiological processes of sympathetic
nervous system (SNS) responses or parasympathetic nervous system (PSNS) responses;
sympathetic nervous system responses invoke physiological excitatory states, which are
manifested by flight or fight responses and the parasympathetic nervous system responses
induces feelings of peace, contentment and relaxation. Negative, stress states further induce
impairments in emotional response, which impedes functioning of the prefrontal cortex, clearly
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potentiating impairment of cognition, negatively effecting executive functioning ability and
negatively effects actions and impulses as a result of dysregulation of those emotions.90
Dr. Bruce Lipton, brilliantly witnesses the results of both positive and negative emotions
as they influenced the failures and success of his struggling medical students in his work entitled,
The Biology of Belief. By studying the work of Candace Pert’s Molecules of Emotion, both Pert
and Lipton unlock the scientific evidence that reveal an organism’s ability to communicate
through intracellular organism responses, that either induce human growth states or initiate
human protection or organism survival states.91 States of protection, invoke the stress response or
the organism activation of the sympathetic nervous system response. Alternatively, human
growth states rely on nutrition, harmony, synergy of cellular functioning and supportive
relationships; during stress states alterations in cognitive brain functioning decreases and during
times of growth, cognitive functioning improves and develops in harmony with others.92
Therefore, examining programs that seek to decrease stress responses and improve
emotional responsiveness that increases the ability to improve competency through relational
decision making processes, education and prevention strategies potentiate improved patient
outcomes. Because current decision-making guidelines fail to adequately measure decisional
capacity in patients’ diagnosed with the neurodegenerative effects of substance use disorders,
addiction and the associated mental health disorders it is recommended that collaborative
professional consent processes are created that require diligent checks and balances that seek to
preserve the dignity of those who suffer, through accurate and objective strategy implementation;
adequate assessment strategies should attempt to identify diagnostic and treatment plans that
seek to improve patient competency and seek to improve outcomes through enhanced
measurement criteria.93
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b. Improving Competency.
The neglect to develop affordable and accurate diagnostic testing for risk of dependency
dysfunction and the failure to develop affordable and accurate diagnostic testing to indicate
progression of disability of dependency dysfunction violates the very principle of respect and
dignity that seeks to protect autonomous rights that healthcare providers proclaim to protect;
therefore, clearly determining rationality and how it may determine free choice must be
evaluated. Rationality clearly identifies one’s ability to reason, based on calculation of objective
determination of facts, and then deliberating and acting according to those facts.94 Free choice is
associated with one’s voluntary decision, one’s own determination, one’s consent or assent
indicating free will and responsible rationality to make that choice.95
The neurological, biological and genetic processes that affect neurotransmission and
complex neurological functioning in cognitive rationality are visually recognized as functional
impairments on diagnostic imaging studies; additional scientific evidence supports that
purposeful ‘thinking’ behavior does not occur during substance use and addiction exacerbations.
Rather, addiction stages are affected by pathway stimulation or reward deficit mechanisms that
neurologically alter transmission pathways that result as habitual and ‘unthinking’ behavior.96
Placing credence on the ‘intactness’ of decisional capacity for individuals diagnosed with
substance use disorders and addiction, as if it were a reliable source of reliability, without
completing a comprehensive capacity assessment places the patient at an unprecedented risk for
harms and death.
The sympathetic nervous system activation that induces increased ‘organism-protection’
stress response states within the sub-conscious of those with addiction, overtly overrides
complex decisional neurological functioning by inadvertently hijacking individual awareness,
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creativity and consciousness, because of the perceived and urgent need to ‘protect self;’ when the
sympathetic nervous system overpowers the organism in order to seek the organism’s protection,
the functional components that support growth, development and human flourishing are greatly
impaired.97 Substance use disorders and addiction are fueled by overactive protection
mechanisms that escalate urgency for perceived survival needs, invoke fear, paranoia and
seemingly self-indulgent responses of manipulation for consumption of substance; yet, the
underlying reactive purpose is one of survival.
The quest to improve competency for patients who are diagnosed with substance use
disorders and addiction requires the development of a treatment plan that requires a cultural
paradigm shift that recognizes that substance use disorders and addiction occur because of
neurological pathway changes that alter motivational reward pathway dysfunction through
complex physiological states that solely seek organism survival. The outdated assumption that
substance use disorders and addiction represents a patient’s cognitive choice for self-harm can no
longer be classified as social deviance, and managed through methods of marginalization and
isolation.98
Assessment tools have been created with success to help manage care for patients and
families through shared decisional assessment of values in relationship to progressing and
deteriorating neurological and neurodegenerative dysfunction in patients diagnosed with
Parkinson’s disease and Alzheimer’s disease.99 Diagnostic assessment tools are necessary to
measure increasing risk of disease progression in all other chronic disease states, finding ways to
measure the resultant impaired competency in addiction is paramount; assessment tools that
could routinely be used to identify changes in decisional capacity in addiction disorders could
include laboratory tests that measure serum levels of illicit substances, laboratory tests that
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measure specific stress hormones and nuclear medicine brain scans that seek to provide objective
visual results, which show the confirmed physiological and neurological evidence of brain
dysfunction for both the individual, their families, and to the healthcare team.100
Implementing processes to improve competency for those who suffer from substance use
disorders and addiction requires application of a comprehensive biological, psychological, and
socially constructed paradigm of care that utilizes the elements of an ethics of care in order to reinterpret consent in the management of care for this neglected population. Elements of care seek
to improve human potential, actualization and growth; therefore, seeking to decrease the
perpetuation of the deleterious effects of stress states that are activated due to the perception that
individual survival is threatened. Management of care interventions, must seek mechanisms that
decrease sympathetic nervous system responses, which result in catecholamine and adrenal
hormone releases, that perpetuate the escalation of disease progression.101
In order to improve competency for patients who are diagnosed with substance use
disorders and addiction specific components must be identified to improve the neurological
functioning that is impacted across the spectrum of substance use disorders and during each of
the stages of addiction; additionally, measurable assessment tools that accurately determine
competency in health care decision-making that parallel the examination of the biological criteria
during each stage of the addiction cycle must be comprehensively identified. Substance use
disorders and addiction are associated with the following criteria: 1. Individual verbalizes
consistent desire to decrease or discontinue use, without success. 2. The individual spends an
extraordinary amount of time seeking, using and recovering from substance use. 3. Individuals
daily routines revolve completely around the substance. 4. Individual craving is persistent and
associated with allostatic changes in the individuals neurocircuitry alterations in the brains
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reward structures; identification of improved competency cannot be determined until the criteria
above is resolved.102
When implementing strategies to assess competency, the health care practitioner is
required to determine if the patient has the ability to understand health information and if the
patient has the ability to understand the consequences of their health decisions.103 This process is
not accurately determined for patients who suffer from substance use disorders and addiction;
however, it can be accomplished through the systematic assessment of changes with ‘The Aid to
Capacity Evaluation’ (ACE), ‘The MacArthur Competence Assessment Tool for Treatment’
(MacCAT-T) and through SPECT-CT imaging evaluations during the various stages of
substance use disorders and addiction. The MacCAT-T, is particularly helpful because it
provides the patient the opportunity to ‘write out’ or verbalize their understanding of diagnosis,
features of disorder, trajectory of disorder, and address understanding of interventions, discuss
benefits and risks of treatment and to discuss alternate treatment options.104
By instructing the patient who is diagnosed with substance use disorder and addiction to
periodically reflect about their comprehensive understanding of their disease progression, reflect
upon their understanding their disorder, their treatment goals, assess their benefits and risks
associated with progression of substance use, and understand the benefits and risks of treatment
interventions and alternate treatment interventions, enables family and professionals to while
carefully document and determine consistency of understanding over time of those choices.105
By documenting patients written or verbal responses, practitioners are able to assess the
understanding of findings; additionally, detailed assessments that evaluate if the decision-making
process is affected by adverse or beneficial consequences, by assessing if patient’s are unable to
respond to open ended questions, to determine if patient’s require prompting, to assess if the
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patient is affected by cognitive signs of guilt, shame, punishment, hopelessness, delusions or
psychosis or if the patient’s decisions are influenced coercively by ‘drive’ to use substance
during negative withdrawal states.106
Additionally, by diagnostically evaluating nuclear medicine SPECT-CT scan results,
concrete visual neurological dysfunction can be measured and utilized in determining severity of
progression of incompetency over time. Conversely, if a SPECT-CT scan results show visual
brain functioning improvement and the patient is able to consistently document an understanding
of health-related information and synthesize the expression of desired outcomes without coercion
of substance, as a result of improving standardized assessment criteria, then identification of
improved competency can be determined.107 In order to implement the above mentioned
competency assessment process, the establishment of professional and family interpretation of
informed consent becomes an essential element in the patient’s plan of care. This relational
process of determining competency, initiating shared decision making, and implementing a
treatment plan that requires the engagement of the patient, family, community and health care
professionals, developing partnerships and shared decision making can radically improve the
outcomes strategies that seek benefits over risks, improve interventions that support neurological
healing, versus radically neglecting individual needs by allowing the continuation of impaired
decisional capacity to dictate harms to vulnerable populations.
4.3 A Relational Interpretation of Coercion by Professionals.
According to an ethics of care, human nature is empowered by the relational response
with others; hence, growth, development, empowerment and actualization of individuals are the
primary focus and goals of all relationships.108 Coercion on the other hand is defined as
influencing another with the use of physical or psychological threats.109 Healthcare professionals
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in the management of care for patients who are diagnosed with substance use disorders and
addiction, do not seek to restrain patient’s decisional capacity through coercive means; rather,
health care professionals influence decisional outcomes out of respect of human dignity, when
patients lack the decisional capacity to prevent harms to self.110
When cells and organisms are left within toxic environmental states, abnormal cellular
isolation and apoptosis result; similarly, when people are negatively influenced by environmental
factors that are toxic to the welfare of individuals and future generations, illness, isolation and
death occur.111 The current management of care strategy for substance use disorders and
addiction must reflect upon the perpetuation of toxic and stressful environments in which it
almost unknowingly persists, perpetuating human harms, illness and death. Statistics reported by
the World Health Organization (WHO), indicated that in 2014 alcohol related deaths exceeded
three million persons globally and that ‘other’ substance related deaths exceeded over fifteen
million; additionally, according to the 2014 National Institute of Health (NIH)’s statistics and the
National Institute on Drug Abuse’s National Survey on Drug Use and Health (NSDUH) more
than nine percent of America’s total population directly consumes illicit drugs every month.112
The national reports clearly indicate that substance use disorders and addiction are not the
result of personal and individual failure, but rather a culmination of societal dysfunction that has
also become an economic burden that exceeds over two hundred and twenty three billion dollars
annually; the crisis clearly indicates that the continuation of individual marginalization and
blame heightens the need to radically disempower the trajectory of harms that are potentiated by
present day management dysfunction.113
A call for action is required; implementation of strategies that embrace individual,
professional and universal responsibility includes application of scientific knowledge, provisions
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of treatment plans that are not punitive, and relational support initiatives that seek to improve
competency, cognition and neurological functioning through plans of care that seek responsive
and attentive interventions that recognized the intrinsic dignity of the vulnerable ‘other.’114 A call
for professional and societal support requires empathetic disease management that seeks the
prevention of harms through the implementation of care guidelines that provide positive
influences over individual behavior; prevention strategies, through the lens of partnerships and
health promotion intervention techniques, which affect behavior is ethically justifiable, even
when these healthcare actions illicit rational reflection and professional persuasion.115
Professional persuasion is often viewed as disrespecting autonomy and free will in patient
decision making and has been negatively affected through the historical harms associated with
previous association with disregard to human rights through paternalism, professional
manipulation, and methods of health care coercion; however, utilization of positive persuasion
constructs of physician management of care paradigms, requires a closer evaluation as it relates
to normative constructs of care for those who are diagnosed with substance use disorders and
addiction. Taking a closer look at how, initiatives to influence behavior to enhance personal
autonomy, may occasionally necessitate protections from harm in certain instances in order to
‘repair’ neuropsychological aspects of repairing the will, and empowering elements of relational
protection and human flourishing.116
Phrasing the influences of scientific evidence as it relates to seeking wellness initiatives
must realistically illuminate the social construct of harms that negatively and assuredly illicit
intrinsic and toxic environmental effects on populations through the oftentimes unspoken
coercive influences of social constructs of consumerism and behavior marketing constructs that
unknowingly and negatively influence the health of individuals and populations.117 Coercive,
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societal influences that value consumer agents as a means to attain exponential wealth, influence
consumerism of products without fully informing the consumer of risks; as a matter of fact, the
opposite is true, the marketing strategies purposefully appeal to parasympathetic nervous system
activation and reward seeking behavior, which cognitively associates consumerism with feel
good hormones, social acceptance, elimination of suffering, and improvement of a quality of life,
and promises the attainment of unattainable euphoria.118
Addiction consumerism and behavior marketing constructs understand the physiological
human tendencies of reward mechanisms, the understanding of the intrinsic human longing for
food, love, belonging, and the power of influencing strong rewards and instincts for an ideal and
unattainable desire of complete satisfaction; consumerism and economic marketing strategies
actively influence the lure of personal actions that contribute to substance use disorders and
behaviors that produce huge profits for alcohol, food, tobacco, cannabinoid, and pharmaceutical
organizations, by capitalizing on human vulnerability and desires without considering the cost of
human life.119 Societal influences of marketing coercion do not consider the implicit autonomy
of individuals; rather, marketing coercion seeks embellishment of the imagination in order to
enhance the influences of superlative desires.120 On the other hand, health care professionals and
paradigms of care that seek disease prevention, health promotion, and methods to improve
neuropsychological aspects of autonomy and decision making in order to ‘undo’ the harms
associated with the complex constructs of commodified coercion are not in violation of
normative ethical values necessary for ethical deliberation and processing.
Therefore, health care constructs that seek to respect individual autonomy of patients who
are diagnosed with substance use disorders and addiction utilize their professional education and
understanding of pathology to positively influence improved goal related outcomes, not as a
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means to inflict coercive harms upon another; but rather, to influence decisional capacity that
seeks health promotion, prevention of executive functioning dysfunction, empowerment of
optimal brain health, and educational initiatives that enhance information processing, improve
understanding of emotions and desires understanding that relationally supportive environments
realistically improve health benefits and decrease risks of long-term harms associated with
substance use and addiction.
a. A call for Partnership Versus Radical Neglect
To reverse the consequences of social neglect in the management of care for patients
diagnosed with substance use disorders and addiction requires the development of professional
and relational partnerships in the management of care to restore optimal, authentic and truly
autonomous decision-making, which promotes individual flourishing; restoring executive
functioning ability and reversing the trajectory of neurological dysfunction for those diagnosed
with substance use disorders and addiction would potentiate a decrease in disease related
comorbidities and alter transgenerational risk of heritability. The call for the development of a
national healthcare improvement plan, seeks the utilization of professional commitment
influencing optimal health promotion strategies, which decrease the rising incidence of substance
use disorders and addiction globally; it is a call to reverse the consequences of societal neglect
and to reverse the deleterious consequences of neurocircuitry and physiologically disordered
reward seeking dysfunction, which results in the loss of human capacity for decision-making.
Initiatives that seek to minimize poor outcomes of disease continuums have previously
helped to decrease mortality and morbidity, enhance the quality of human life despite chronic
disease states, disseminate educational initiatives that seek health promotion, and provide
implementation of aggressive public health prevention strategies that improve patient outcomes;
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examples include the national and global public health initiatives that have been able to
significantly decrease new onset of disease and minimize disease progression in the management
of patients diagnosed with human immunodeficiency virus (HIV) and acquired
immunodeficiency syndrome (AIDS).121 HIV is a chronic spectrum disorder disease state, that
begins with viral infection that effect destructive pathology to normal human immune responses
and culminates in severity with the development of AIDS comorbidities and death; similarly,
substance use disorders begins with dependency that effect destructive pathology to normal
neurological functioning and culminates in severity with addiction comorbidities and death.
With the implementation of complex professional and public health initiatives to
decrease the stigma and marginalization associated with HIV and AIDS diagnosis, fear and the
associated stigma began to decrease. Additionally, the public health initiatives utilized health
promotion strategies sought the dissemination of prevention strategies in order to decrease the
transmission of the virus; concurrently, they also sought methods, which decreased the virus’s
ability to replicate and further destroy the normal functioning of the patient’s immune response.
By seeking methods that were able to alter the destructive progression of the virus effects on the
patient’s (host’s) immune response, the progression toward the obliteration of T-lymphocyte
production was improved, progression toward a diagnosis of acquired immunodeficiency
syndrome (AIDS) halted, and a new model of health promotion was able to decrease the risk of
the severity of disease progression.122
As a result epidemiology studies indicate a twenty nine percent decrease in AIDS related
deaths during the eight year period after the public health initiatives were implemented; an
additional thirty three percent decrease in new HIV infections occurred, and a fifty two percent
decrease in pediatric HIV infections were associated with the direct result of global healthcare
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strategy improvement implementation and preventative education initiative plans.123 Relational
constructs of care that include patients, family, and community seek to decrease stigma,
marginalization, and disease progression through evidenced based practices that understand
physiological constructs of the chronicity of disease and pathological dysfunction. Through
public health initiatives and relational educational intervention implementation, individual and
public understanding and trust in healthcare providers can empower a comprehensive change in
the trajectory of harms associated with inadequate knowledge, fear and misunderstanding of the
chronic spectrum disease progression.124
Supporting a similar plan of care for substance use disorders and addiction requires
embracing an ethics of care framework that seeks to eliminate the stigma of blame and unjust
moral branding; through implementation of professional duty and responsiveness, new care
guidelines can implement operative and functional diagnostic criteria, through the development
of harm reduction strategies that clearly outline guidelines of care that disempower the illinformed, eradicate vulnerability and decrease the exploitation of those susceptible to cognitive
impairment.125 Management of neurological dysfunction should not be linked to legal mandates
of treatment interventions, such as obtained with incarcerations and criminal sentencing of those
diagnosed with substance use disorder and addiction; but rather, management of care should be
linked with a compassionate and comprehensive treatment initiative that functions to promote
wellness, eradicate despair and shame, and offer hope for the reversal of the unnecessary
suffering.126
Relational constructs that seek to decrease stigma, improve health outcomes and promote
educational initiatives to decrease progression of disease decreases harms and empowers
relational constructs of consent for treatment; relational constructs of care that seeks the
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neurological enhancement of the will of the other seeks to increase cognition and executive
functioning for those caught in the cycle of neurological dysfunction, empathetic and
compassionate application that seeks to reverse the trajectory of neurological harm
acknowledges the dignity of those who have been radically marginalized and neglected.127
Understanding that social constructs of criminalization and marginalization creates fear,
isolation and impedes the construction of relational elements of care and trust, destroys the
essential elements of the physician-patient relationship.128 The constructs of relationship
improves consent processes for patients, health care providers, treatment centers, community
support and family; elements of consent must continue to promote transparency, promotion of
best interests, and full disclosure of the benefits and risks of proposed treatment plan, through
supportive and trusting relationships that seek to repair neurological pathways that empower
authentic relational autonomous decision-making through relational constructs of care.129
Despite the professional’s competency as it relates to the complex understanding of the
neurological dysfunction of substance use disorders and addiction; the professional is not the
sole decision maker. The health care provider cannot arbitrarily and intrinsically ‘know’ the
complex circumstances of each patient’s trajectory of substance use disorders, addiction and the
intrinsic beliefs, values, suffering and circumstances of each individual person.130 Additionally,
Paul Ramsey articulates that the patient physician relationship is an association of trust, fidelity
and honesty; thus, indicating that the relationship must place the patient at the center of the
decision-making.131 However, as previously discussed, the nuances related to competency,
understanding, neuropsychological circumstances that invoke grave potential for personal,
transgenerational, and societal harms as it relates to the impaired decisional capacity for those
diagnosed with substance use disorders and addiction, requires an added component of relational
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participation of family and community standards of care. Including the relational aspects of care
is commonly utilized as a vital conceptual framework of care within health care environments;
‘person and family centered’ care paradigms have existed routinely for pediatric populations, and
adults who have fluctuating and deteriorating neurological functioning. Advocating for the
inclusion of patients, families, and community centered in decisional support, engages in a
comprehensively holistic attempt to ensure the development of interventions and treatment plan
that meets the particularities of each circumstance.132
A call for patient, family, community and health care provider partnership seeks to ensure
optimal paradigms of care initiatives by eliminating constructs of radical neglect that dominate
the historical contextual management of care paradigms that currently exist. By implementing a
systems approach to care and by implementing a public health prevention of disease progression
strategies outcomes can improve outcomes through collective responsibility for the benefit of
future generations and society. Elements of obtaining informed consent, require a comprehensive
and thorough evaluation method, which help to determine a comprehensive understanding of
how the intervention, treatment and outcome management of care plans relate to human benefit
and human risk for increased harms. Developing an honest reflection of the current plan of care
programs for substance use disorders and addiction is necessary; improving benefits and
eliminating unnecessary risks are paramount in the management of care for the management of
care for this public health epidemic.
b. Assessing Benefit-risk Ratio.
Epidemiological studies must be analyzed to properly identify benefit-risk ratio in the
determination of initiating an endeavor that seeks to consider a re-interpretation of consent in the
management of care for those diagnosed with substance use disorders and addiction. Assessing
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benefit-risk-ratio begins with a reflective analysis of national statistics that adequately portray
the escalating societal problems related to substance use disorders and addiction; it is always the
desire of health care and bioethics to seek methods that avoid human rights violations and
decrease vulnerability through the trajectory of potential harms, related to treatment
interventions.133 Therefore, analyzing the effectiveness of current treatment programs and
outdated and harmful constructs of informed consent for patients diagnosed with substance use
disorders and addiction as they relate to outcome and disease trajectory is paramount.134 It is also
necessary to assess for the need of a reformative implementation of care paradigms that continue
to harm, marginalize, devalue, and discriminate substance use disorders as a rational choice; it is
time to incorporate comprehensive and holistic disease management approaches that align with
evidence based practice actions and cooperative empowerment of the ‘other’, through
nondiscriminatory and transparent plans of care that seek to decrease individual and societal
risks, by incorporating interventions that decrease known variables of harms.135
Physicians and primary care practitioners are unable to determine the expected short term
and long term benefits and harms associated with treatment interventions to individuals and
families in every instance; however, the physician or practitioner has experience in anticipation
of procedural or intervention related risks for harms or benefits and they are obligated to share
their knowledge with patients and families in a comprehensive, transparent, and knowledgeable
inclusiveness.136 It is important to keep in mind that risks and harms are uniquely evaluated by
the values and perceptions of individuals and families. The practitioner who authoritatively
declares absolute claim to optimal benefits for another, is not reflectively participating in
partnership.137
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Therefore, it is important to clearly define all terms, diagnosis, treatment plans,
interventions and expected outcomes to the patient diagnosed with substance use disorders and
addiction; it is also important to discuss minimal risks, greater risks and direct benefits of
treatment plan in relationship to the chronicity of dysfunction.138 Because of alterations in
executive functioning processing, it is important to discuss aspects of minimal risks to the patient
and the family. Minimal risks include feelings and emotional responses that present in
physiological withdrawal discomforts, psychological negative reward responses with negative
emotions such as anger, indignation, depression, embarrassments and feelings of privacy and
confidentiality concerns regarding one’s psychological or moral perception of ‘others.’139
Similar considerations are necessary when determining participation in research, with
patients who have increased vulnerability because of impaired decisional capacity. The
overarching goal includes the inclusion of two circumstances in order to promote optimal
consideration for the neurocognitive dysfunction that increases risk for vulnerability: first,
interventions must include relatively assured prospective benefits and secondly, the interventions
should only impose minimal risks as mentioned above.140 Perhaps more accurately, patients who
are diagnosed with substance use disorders and addiction, who demonstrate alterations in ability
to provide competency in decisional capacity and require relational components of decision
making requires an assessment of benefits, burdens, and risk versus strictly just a benefits and
risk assessment. The determination of assessing benefits, burdens and risks for those who are
diagnosed with substance use disorders and addiction require innovative bioethical assessment
strategies that carefully extrapolate the nuances of vulnerability as they relate to risks of
authoritative and paternalistic influences or the continuation of societal harms and neglect.141
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For example, implementing health promotion strategies that seek to decrease harms as it
relates to the substance use disorder continuum from dependency to addiction seeks the
decreased progression from the physiological state that induces withdrawal of substance
symptoms to the progression of chronic relapsing binge/ intoxication, withdrawal/ negative
effect, and preoccupation/ anticipation stage manifest as addiction. By halting the chronic and
unnecessary progression of neurobiological and neurocircuitry abnormal changes in the brain
that result in the progression of escalating risks, comorbidities and death, outcome interventions
can achieve higher levels of health and wellness. Implementation of treatment strategies may
impose ‘burdensome’ manifestations, but repair and restore normal functioning of the patient’s
neurological decisional capacity functioning. By seeking methods that are able to alter the
destructive progression of neurological impairment effects of addiction, neurological
improvement can decrease the deleterious consequences of advancing substance use disorder
dysfunction. It remains imperative to distinguish between substance use disorder progression of
risks that result in neurological impairment, multi-organ dysfunction, and death versus treatment
intervention burdens that invoke consequences of disease dysfunction, but improve benefits of
autonomy and decisional capacity.
Implementing relational consent paradigms of care must evaluate outcomes of care, as
they relate to neglected treatment plans, which leaves patients alone in decision-making, despite
the known neurological and decisional capacity dysfunction for those individuals. With relational
consent paradigms of care, objective and thoughtful consideration of the pathophysiological
responses of addiction that certainly impedes individual decision-making capability, replaces
abandonment with relational considerations of care. Continued monitoring of substance use
disorder and addiction outcomes, through the evaluation of elevated risks, burdens, and benefits
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of recovery, relapse, and comorbidities of physiological and psychological disease states, require
the implementation of improvement paradigms that alter comprehensive management of care
initiatives by truly considering the nuances of neurological dysfunction in addiction.
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Chapter 5: A Relational Paradigm for the Management of Care.
An ethics of care seeks to carefully consider and treat the comprehensive elements of
substance use disorders and the underlying causes that increase risk of progression from chronic
substance use states toward advanced progression of dysfunction to addiction; additionally, an
ethics of care seeks to decrease the comorbidities associated with the culmination of complex
physiologic, psychiatric, and social complexities. An ethics of care seeks to unravel the
hierarchical constructs that label substance use disorders and addiction as the result of the
oversimplification of human actions and moral culpability; as a result of the outdated constructs,
individuals sustain harsh and deleterious consequences. Therefore the practice of applying an
absolute moral culpability toward the individual alone, is no longer justified; the justification
judgement paradigm neatly offers concrete, rigid, immoveable and propositional human
solutions to a perceived individualistic human problem, by labeling the actions that culminate
into addiction as sinful and morally disdaining.1 Constructs of care must facilitate an
understanding of the social magnitude of the problem through careful reflection and the
collection of gathering inclusive and comprehensive evidence in order to appropriately analyze
the interventions, which are necessary to institute a relational and empowering plan of care.
The goal is to implement a relational paradigm of care framework that responds to the
complexities of substance use disorders and addiction by seeking to change the justification
judgement paradigm of care into an authentic and responsive management of care process, which
treats all people with dignity and respect. A paradigm of care seeks to deconstruct the theory that
supports the justification judgement paradigm of care and treatment for substance use disorders
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and addiction, by clearly and emphatically highlighting that the oversimplification of declaring
that the sole fault belongs to individuals without considering the scientific biological, epigenetic
and societal consequences of addiction and substance use disorders; maintaining a narrow
perspective is irresponsible and neglectful. A relational paradigm of care seeks to authenticate a
holistic and responsive management of care framework, which recognizes the social
consequences that increase the risk of substance use disorders and addiction for individuals
because of cultural discrimination, stigmatization, and environmental factors, which are closely
aligned with the development of other disease states as indicated by the social determinants of
health.2 Improving the treatment of all persons equally by implementing health promotion
priorities and disease prevention strategies for disparate populations is essential.
Implementing an ethics of care as a relational management of care paradigm,
incorporates the holistic care approach of patients who are diagnosed with other physiological
disease states, such as cardiovascular disease, hypertension, and diabetes mellitus by responding
to the scientific evidence, by acknowledging the complex biological, genetic and epigenetic
consequences of disease that can increase the incidences of harm to patients and populations;
implementing prevention and harm reduction strategies, while also considering the nuances of
each patient’s circumstantial, cultural and environmental risks, which can progress into
escalating harms and contribute to comorbidities of disease and increase mortality are
considerations of a responsible plan of care.3
The recognition and identification that the current hierarchical justification and
judgement paradigm of care for substance use disorders and addiction has grave individual and
societal consequences related to the trajectory of escalating harms elucidates the ethical
imperative to apply caring and evidenced based practice initiatives consistently in the plan of
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care; the implementation of responsive interventions, such as through the development of
destigmatizing language modifications that seeks to eliminate the unnecessary suffering and
preventable escalation of vulnerabilities for patients with substance use disorders and addiction
provides the necessary and preliminary constructs for the paradigm shift.4 Language has the
influential potential to help change perceptions and to facilitate human responsive behavior
changes as it relates to improving understanding and acceptance of the pathophysiological
alterations and effects of substance use disorders and addiction, when mismanaged.5
Management of care within an ethics of care framework requires the implementation of
strategies that decrease suffering, decrease harms and decrease vulnerabilities, which are
associated with the neurobiological, neuroimmune, and abnormal stress state response processes,
that impact behavioral responses and influence social factors, which exacerbate physiological
and psychological states; the hierarchical justification judgement paradigm of care consequently
results in the dehumanization of the ‘other.’ Dehumanization has the ability to de-actualize and
impair human flourishing; the management of care shift must include innovative treatment
modalities that seeks to repair the integrity of those diagnosed with substance use disorders and
addiction, through the implementation of therapeutic plans, which validate the need for relational
consent paradigms, positive behavior modification programs, neurological enhancement
interventions, and alter impaired genetic expression. Modalities of care, such as neurological
enhancement, pharmacogenomics interventions, and immunotherapies, could potentiate the
reciprocal well-being of the ‘other.’6
In order to influence effective change, relational collaboration and utilization of inclusive
language must be instituted to successfully alter the current negative language associated with
the harms of the current epidemic of substance abuse and addiction; utilizing non-biased
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language, implementing relational consent processes, re-developing paradigmatic treatment
protocols that aim to restore relationships, to development prevention programs, to implement
reduction of harm strategies, and an to overhaul and reform policies and programs are
necessary.7
Cultivating an empathetic, compassionate, and relational connectedness for individuals
who suffer from the sequela of substance use disorders, addiction, and chronicity of symptoms
requires the implementation of comprehensive development strategies that seek to improve the
understanding and application of how the differences of neurocognitive and neurological
functioning is expressed and validated in the framework of neurodiversity; by using the term
neurodiversity, the ability to reframe the language and illuminate the use stating, ‘impaired
neurological and impaired neurocognitive functioning’ is actualized through the lens of
neurodiversity. The language of neurodiversity provides a linguistic framework that rationally
understands that all brains function is intrinsically differently; yet, not necessarily impaired.8
Recognizing that despite differences, all human life is treated respectfully, regardless of
one’s neurological functioning. This diversity acceptance results in accepting differences in
others despite the variability of human physiological states or conditions; differences in
appearances, such as facial features, skin color, body types and body size are no longer
acceptable reasons to discriminate, stigmatize and marginalize. Yet, the perpetuation of stigma
and discrimination persists for the neurological and cognitively diverse, especially in desperate
populations who suffer from substance use disorders and addiction.
Additionally, investigating treatment modalities that aim to enhance the neurological
potential for patients who experience neurological reward mechanism reorganization, may seek
neuroplasticity enhancement and neurocognitive-repair through innovative methods or
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interventions in order to decrease the societal constructs of harms, which further isolates
individuals. Recognizing neurodiversity, potentiates improvement initiatives, which seek to alter
the negative social determinants of health for vulnerable patient populations; the language of
neurodiversity leads to collaborative measures that are supportive of relational consent
implementation and shared decision making processes.9
The term neurotypical provides the overarching description that seeks to assuredly
describe a ‘normal’ brain. However, the neurological development of each person’s brain is an
intricate process of genetic and environmental factors that rapidly grow and develop from
conception to early childhood; each person’s brain forms their own complex networks of
functioning, dependent upon factors, such as early stress, neglect, abuse and poverty.10 The brain
functions and grows from the age of zero until three through a combination of genetic and
environmental factors; early on in life, the brain is strongly effected by genetic influences and as
the child grows and experiences interactions in life, the environment and the experiences help to
shape the brain’s functioning.11 Therefore, examining how neurotypical diversity potentiates
improved neurological functioning in substance use disorders, addiction, and recovery is an
interesting and descriptive way, which can perhaps identify early preventative strategies for
addiction through parenting education and continue to support the process, which can decrease
the construct of stigma related to early vulnerability.
The neurodiversity movement was initiated as a result of the exponential increase in
patients diagnosed with autism spectrum disorders and the association of disability stereotyping,
as it identified the neurobiological influences and differences that are uniquely associated with
children who are diagnosed with the spectrum disorder.12 The movement seeks to establish the
understanding of neurodiversity as a relational, responsive, and empathetic construct, which is
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necessary in developing meaningful and productive lives for those who learn and behave
differently than the ‘typical’ child; the movement seeks to bring value and equality for those who
experience neurological differences by providing supportive and inclusive accommodations that
seek human flourishing.13
Establishing an understanding of the unique characteristics of each person’s brain
development through neurodiversity constructs of care has the potential to empower and support
all patients who experience the neuropsychiatric, neurocognitive, neurobiological and
physiological brain alterations and differences, influenced by events that lead to substance use
disorders and addiction.14 In order to comprehensively embrace the construct of neurodiversity in
substance use disorders and addiction management, treatment paradigms must respect the
experiences of the ‘other’ as a vulnerable human and not as a problem to be fixed.15
Understanding that neurological development is a construct of the complex interplay between
biology, genetics, experiences, behavioral responses and environmental stimuli, assists to
illuminate the need to consider the particularities of the ‘other’ consistently, rather than dismiss
the person as a result of dysfunction pathology and constructs of justification judgment
paradigms of care.16
5.1 Substance Use Disorders Comorbidities in a Relational Context.
Substance use disorders and addiction have relevant societal consequences, as evident by
the rapidly increasing mortality and morbidity epidemiology studies; additionally, the awareness
that substance use disorders and addiction are chronic disease states is also evident and
scientifically determined. Yet opponents of the disease model of addiction, persists with the
claim that because persons are inaccurately influenced by the constructs of the disease model,
purposeful and long term motivation to one changing behavior impedes one’s personal journey
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toward health; therefore, the person remains caught in the perpetual cycle of substance use and
addiction.17 As a result of the opposition to the disease model of addiction, Maia Szalavitz,
introduces the framework of addiction as a developmental disorder, versus a neurological or
physiological progression of disease, without comprehensively considering the American
Psychiatric Association’s, Diagnostic and Statistical Manual V’s Editions diagnostic criteria.18
Still others claim that addiction is simply a habitual, behavioral and learning disorder that results
through the operative effects of reward and punishment through the unconscious preferences
and repeated demonstration of actions of the subject.19
As previously indicated substance use disorders and addiction are multifactorial,
biological, neurocognitive, and neurocircuitry disease states that present as a result of
polygenetic, epigenetic and transgenerational effect that are influenced by social determinants of
health, such as poverty. Despite the complexity of the multivariate elements of addiction, both
individual and societal consequences are well known through the results of public health
statistics; concurrently, most all chronic disease states, including addiction, manifest for
individuals and communities in relationship with cultural and social determinants of health.20
And most chronic disease states do not present exactly the same way in every patient; yet, the
diagnostic criteria remains evident, despite diversity of personal presentation.
Additionally, by classifying addiction as a behavioral or developmental disorder, the
perpetuation of prescribing individual blame, without recognizing the epigenetic consequences is
at risk. The perpetuation of assigning an individual with a behavioral or developmental
dysfunction, justifies the judgement and blame paradigm, which additionally justifies blame and
stigma for the co-existing psychological and physiological comorbidities such as anxiety, stress,
depression, personality disorders, hypertension, liver dysfunction and pancreatitis; yet, this
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perpetuation of the justification of judgement, further escalates harms developmentally,
behaviorally and cognitively, while also, increasing the harms associated with psychological
health.21
It is true, that substance use disorders and addiction directly affects the overall health of
communities through escalations of relational conflicts, ‘increased risk-taking’ behavior,
violence, crime, and poverty.22 Social determinants of health clearly identify how environments,
families, communities, and relationships can positively or negatively influence health, learning,
communication skills, and holistic abilities to navigate through human vulnerabilities. Therefore,
the relational context of an ethics of care paradigm includes health promotion and disease
prevention strategies that meet people where they are, with the goal to improve the outcomes for
individuals, families and communities; an ethics of care meets the human condition of
vulnerability, dysfunction and disease living environments and in the particularities of human
circumstances.23
An ethics of care functions by knowing that the ‘actualization of the other’ or the ability
to obtain optimal human thriving must move beyond the narrow constructs of moral judgements
and justifications; an ethics of care does not seek to determine the justification of the actions for
the one who is cared for as the ethical focus. Rather, an ethics of care focuses on the natural
human obligation to evaluate situations qualitatively and comprehensively in order to see the
intrinsic and extrinsic factors that potentiate harm for the ‘other’; an ethics of care does not seek
to determine the causal culpability of placing moral judgement on another as if people were
commodified as an equation to be solved algebraically.24 An ethics of care considers the
particularities of ‘being’ human and seeks ways to empower the other through relationship.

196

As a result, an ethics of care considers all elemental causes of substance use disorders and
addiction dysfunction, by remembering to place the person in relational context with others and
by remembering that vulnerability is a universal human characteristic. Therefore, acknowledging
that all health disease states predispose persons to increased susceptibility to physiological and
psychological harms must be stated as an objective scientific norm and not as a subjective
determination or a moral claim; by firmly ‘naming’ substance use disorders and addiction as a
disease, the paradigm of care seeks to dissipate flawed moral reasoning that deconstructs human
worth and value through circumstantial evidence, without regard or acknowledgement of the
complexities of each individual’s situation.
Through the incorporation of an ethics of care re-establishing the repair of relationships,
enhances social connections and incorporates educational initiatives that empower an
improvement of health outcomes for individuals and communities; an ethics of care paradigm
must seek to incorporate management of care goals that enhance psychological well-being,
enhance neurological functioning, decrease disease progression, improve developmental
actualization, and improve neural plasticity in order to help promote behavioral modification
through shared decision-making and the implementation of caring interventions that repair
personhood and self-actualization.25
Shared decision making seeks to decrease the risk of biological harms, decrease
neuroimmune dysfunction, decrease problematic psychological dysfunction, prevent the societal
increases in crime, and seeks to decrease and prevent escalating risk of accidental death and
injury; repairing areas of the brain that are effected by the deleterious consequences that increase
mortality include the hippocampus, amygdala, insula, prefrontal, anterior, posterior cingulate,
and somatosensory areas.26 By reflectively analyzing a root cause analysis of the substance use
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disorder and addiction conundrum, an ethics of care must carefully examine how psychiatric,
neuroimmune, inflammatory comorbidities of substance use disorders and addiction often times
overshadow and divert the focus of care away from the affective treatment for substance use
disorders and addiction itself. Acute care management of health consequences, such as treating
the comorbidities and the complexities of substance use disorders and addiction tend to
reactively seek rapid and instantaneous medical management of care priorities; yet, an ethics of
care seeks long term, gradual, and holistically patient paradigms of care that seek authentic and
relational care methods in order to strengthen human relationships and minimize human
vulnerability.27
Holistic management, inclusively strives to decrease the psychiatric and physiological
comorbidities of substance use disorders and addiction, by recognizing that the problem cannot
be acutely, objectively and problematically solved through constructs of historical systems of
criminalization, justification, judgement and blame; an ethics of care must not separate self and
others, an ethics of care must be drawn into the other, must nurture the other, and must protect
the other by initiating actions that contribute to the wellbeing of another inclusively. These
actions seek to identify the elements of neurodiversity, which effect the psychiatric,
neuroimmune, and inflammatory comorbidities of addiction.

a. Psychiatric Comorbidities.
Substance use disorders and addiction are closely associated with concomitant
psychological and neuroimmune dysfunction, which is known as the tri-morbidity of addiction/
dependency.28 Common psychiatric dysfunctions include, depressive, anxiety, personality and
bipolar disorders; concomitant disease states, such a neuroimmune disorders, psychiatric
dysfunction and addiction increases the risk and vulnerability of dysfunction and places the
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individual at greater risk for harm and death.29 Additionally, environmental influences, such as
prenatal/ antenatal exposure to substance, prenatal stress, physical abuse, psychological abuse,
post-traumatic stress disorders (PTSD), poverty, and dislocation, have the potential to influence
harm to individuals and future generations through epigenetic heritability factors.30 Due to the
unique and complex interrelated dysfunction of neurotransmitter and neuroendocrine functioning
complications may arise from excessive secretion of catecholamines, such as norepinephrine and
epinephrine; additional alterations in neurotransmitter functioning of dopamine, serotonin, and
gamma-amminobutryic acid (GABA) can further contribution to the psychological aspects of
dysfunction that persists for patients because of the increasing the risk of misdiagnosis,
increasing the risk of biased and dismissive care, which increases the continuation of the misuse
of substances and addiction by impairing an individual’s comprehensive treatment plan
development.31
The additional etiological complexities of substance use disorders and addiction, include
the effects of the social constructs and criminalization paradigm, which are closely associated
with the further perpetuation of isolation, marginalization and ongoing stress responses;
additionally, the escalating risk of concurrent comorbidities of physiological and genetic
susceptibility as it relates to the intrinsic genetic expression, further increases the risk of chronic
dysfunction and episodic exacerbations caused by the body’s inability to maintain homeostasis.
The body’s internal environmental genetic expression malfunctions, further alter
neurotransmitter functioning, causing dysregulation of mood, alterations in sympathetic and
parasympathetic nervous system responses, potentiate impaired inflammatory processes,
exacerbate cognitive dysregulation, effect cardiac and respiratory dysfunction, which can
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culminate in overwhelming organism impairments that negatively affect human psychological
health, actualization, and flourishing.32
In order to adequately monitor and evaluate chronic disease states, methods of psychiatric
and addiction dysfunction evaluations are desperately needed; thankfully, even though
evaluation methods have been almost nonexistent to the present day, current methods of brain
imaging are now becoming available through visual radiological imaging scans, magnetic
resonance imaging (MRI) scans, and single proton emission computed tomography (SPECT)
scans.33 Additional advances in genetics, biological functioning, and diagnostic testing is now
available to measure alterations of histones, proteins, and specific cytokines that influence
genetic expression.34 Additional evidence is needed to determine the role the hypothalamic
pituitary adrenal axis (HPA) functioning responses to the intricacies of neurological circuitry
functioning and how it relates to the chemical communication of the endocrine, immune, and
psychiatric functioning effects in patients who suffer from substance use disorders and addiction.
Greater understanding of the brain body connection in relationship to stress, genetic expression,
heritability, environmental and nutritional influences potentiate an ability to implement
interventions that seek to decrease the psychiatric comorbidities associated with substance use
disorders and addiction.
Evaluating depressive, anxiety, personality and bipolar disorders requires an examination
of the additional effects that stigmatizing and marginalization inflicts upon person’s who suffer
from psychiatric disorder diagnoses; concurrent exacerbations of anxiety and depression are
common affective states in patient who suffer from substance use disorders and addiction.
Aspects of socio-cultural stigma contribute to the morbidity associated with addiction and
psychiatric disorders. As a result, stigma increases the psychological suffering for individuals
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contributing to spiritual and existential suffering that further perpetuates intrinsic imbalances in
homeostasis and contributes to cellular inflammatory processes that further impair neurological
functioning.35
Inflicting social and cultural isolation and stigma upon another has deep Judeo-Christian
roots related to adopting the cultural justification for labeling individuals who are different,
unclean, and sinful, for fear of inflicting potential harms upon individuals and the community;
therefore the justification to judge the ‘other’ as unclean, infectious, or sinful and remove them
from the community, because of the risk of harms to ‘another’ became an ethical standard and
often times perceived as one’s duty within societal culture.36 Excluding those who exhibited
undesirable physical or psychological characteristics from the community as a response to
factors that included fear of social disruptions, fear of potential transmission of communicable
disease and fear of psychological or spiritual harms, alienated individuals from community
support.37 The justification to label another through the hierarchically proclamation of prominent
language, must be re-evaluated. By implementing neurodiversity awareness strategies in the
management of care substance use disorders and associated psychological comorbidities,
constructs that perpetuate anxiety, depression, personality disorders, bipolar disorders, posttraumatic stress disorders, for those with substance use disorders and addiction, becomes an
essential starting point.
The effects of modern society, through industrialization and dislocation have separated
families, communities and relational constructs that increase interpersonal connections between
people, families, and communities; increasing the opportunity for increased feelings of isolation,
fear, loneliness, anxiety, depression and vulnerability.38 A deep existential longing for authentic,
and loving relationships often times exist for those diagnosed with substance use disorders and
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addiction; yet, the reflection of the one with substance use disorders and addiction mirror the
culmination of emptiness, loneliness, and longing for the resolution of dissected and impaired
relationships.39 By implementing an ethics of care, the restorative qualities of acknowledging and
repairing relationships becomes the essential priority.
Additionally, the comorbidities of psychiatric disorders in the management of care with
substance use disorders and addiction, coincide with the association of impaired epigenetic
expression of abnormal stress responses, that result because of difficulties and strains in
everyday living; consequently, manifestations of stress as it results from contemporary living are
often times stabilized and minimalized through family and community support systems.40
However, the stabilization of social support systems for patients who are diagnosed with
psychiatric disorders, substance use disorders and addiction are at an increased risk for
experiencing strained family relationships, abusive relationships, and increased past traumatic
experiences, which increase the likelihood of decreased relational, community, and social
supports, increasing the likelihood of the perpetuation of anxiety, and depression.41 The largest
indicator for predicting the likelihood of the development of twelve to seventeen year olds to
experience substance use disorders in the United States include correlating psychological distress
states and major depression; public health initiatives that seek to decrease the risk of early
substance use disorders highly recommends advocacy programs that seek the integration of
behavioral health paradigms that teach risks and coping strategies. Behavioral health paradigms
recommend that adequate initiatives to address the disparities of care must provide
confidentiality and guarantee that patients will receive care, without judgment.42
A growing understanding of the relationship between stress and substance use disorders
and addiction is becoming evident; concurrently, stress is associated with many other
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pathophysiological disease states, such as cardiovascular disease, gastrointestinal ulcerations,
Cushing’s Syndrome, hypertension, and psychiatric disorders.43 Yet, the correlation to
empathetically treat the psychological components that increase the risk for substance use
disorders or that perpetuate the continuation of substance use, requires an intensive
implementation of education to decrease stigma and discrimination and program development
for mental health resilience training initiatives.44
Physiological balance or homeostasis is normally sought through the regulation of
physiological and psychological functioning. A normal hypothalamus-pituitary-adrenal axis
neuroendocrine functioning response initiates stimulation of the hormone adrenocorticotrophic
hormone (ACTH) from the hypothalamus in response to circulating cortisol levels, which then
stimulates the anterior pituitary in order to increase the secretion of ACTH, which activates the
secretion of glucocorticoids, from the adrenal cortex, as the normal activation of situational
stress response.45 This normal stress response is activated in conjunction with the sympathetic
nervous system to intrinsically protect the person during an imminent life or death threat. The
perceived threat to the intrinsic survivability of the person was designed to occur as a fleetingly
temporary response.
Yet, for people who experience chronic neglect, chronic abuse as a child, who experience
chronic physical, sexual, or psychological abuse at any time during life, or those who experience
post-traumatic stress from an illness, accident, violence, crime, chronic states of stress can
initiate the harmful consequences that impact psychological and physiological health.46 Chronic
states of stress, which increase excess adrenal hormone secretion have negative effects on the
homeostasis of psychological functioning.
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The impaired response of elevated serum cortisol levels influence, stress states that
include elevations in heart rate, elevations in blood pressure, elevations in serum glucose levels,
elevations in serum dopamine, and changes in serotonin levels that result in manifestations of
increased cognitive awareness initially from the elevations of glucose and dopamine during the
initial threat; however, as a result of chronic elevations of stress hormones, such as epinephrine,
norepinephrine, glucocorticoids, glucose, aldosterone, anti-diuretic hormone and cortisol levels
remain elevated, causing complications that include increased capillary permeability, sustained
inflammatory processes, decreased immune responses, and psychological states that include
irritation, anxiety and depression.47 The complexities of fluctuating stress hormones and the
interaction of illicit substance further impairs the excretion and reward mechanisms of dopamine,
glucocorticoids, cortisol; thus further impairing the homeostasis of neurotransmitter functioning
that can result in labile psychological periods of anxiety, somnolence, or depression.
Additionally, the fluctuations in neurotransmitters in relation to the pathology of addiction
greatly effects moods, motivation, and aggression.48
The negative reward/ withdrawal stage of addiction, enhances the neurotransmitter
release of epinephrine and norepinephrine, which increases the effects of the psychological
exaggerated responses and increased risk of psychosis and mania through the chronic elevations
of the corticotrophin releasing hormone (CRH), adrenocorticotrophic (ACTH) hormone release
that increased the adrenal secretion of glucocorticoids, or cortisol, which sustain the stress
response states; additional release of catecholamines from the adrenal gland, fluctuations in
dopamine, and decreases in the parasympathetic nervous system responses that are unable to
induce calming states and homeostasis contributes to the negative behavioral responses that are
so difficult to empathetically manage during the care of substance use disorders, and addiction.49
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The escalation of these adverse psychological responses of abnormal stress and substance
use states, increases the stress and reactive repulsion of ‘others’ to therapeutically respond to the
care of the patient in a comprehensive, holistic and caring way; hence, the perpetuation of stigma
and marginalization.50 From an ethics of care perspective, the management of the deleterious
effects of the neurocognitive dysfunction that perpetuates the negative consequences of the stress
response and the negative reward - withdrawal stage of addiction requires special care that seeks
to restore homeostasis and personhood. An ethics of care understands that the existential
suffering and the psychological comorbidities of substance use disorders and addiction, respond
through the repair of relationships; it understands that marginalization and stigmatization
escalates the perpetuation of the deleterious psychiatric effects of addiction.51 Therefore, the care
provider actively seeks to implement relational interventions that empower the integrity of the
individual, restores personhood, attempts to relieve vulnerability through constructs of hope for
healing and self-transformation of the other by seeking to respond to the traumas, stress, abuse,
dislocation, hurt and longing of the ‘other’ in order to restore dignity.52
b. Neuroimmune/ Inflammatory Comorbidities.
Normal neuroendocrine sympathetic nervous system responses to chronic stress result in
sustained release of inflammatory mediators that increase risk of systemic alterations in
circulation, hormonal release, and organ functioning; sustained stress states have been clearly
indicated to also increase the risk of cardiovascular disease, neuroendocrine dysfunction,
autoimmune dysfunction, cancer, liver, pancreatic disease states, and increased risk for substance
use disorders and addiction dysfunction.53 Additionally, effects of stress further complicates the
trajectory and spectrum of harms associated with the neuropsychological risks of impaired
cognition, which can escalate the risk of fluctuating anxiety and depression, while also
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progressing the risk of acute sympathetic nervous system responses leading to cardiovascular
stress, tachyarrhythmia, and circulatory system collapse.54 Additionally, substance use disorders
and excessive consumption of alcohol and illicit substances, increase the risk for the activation of
internal immune communication or signaling of proteins called cytokines.55
Neuroimmunity is the study of the relationship of the interconnected physiological effects
related to the functioning of the relationship between the immune system and the central nervous
system; the complexities of the interaction between the brain, the nervous system, and the
immune responses are just beginning to be understood. Immune cells of the brain are called
microglia, just like other immune cells of the body, the body’s natural immune defenses seeks to
keep the organism free from intrinsic harms associated with external invasion of viruses,
bacteria, and other potentially damaging antigens, constant surveillance of external harms is
completed through the complex cellular communication system of the nervous system and the
cells of the immune system.56 Microglia are the primary macrophage or white blood cell of the
brain; the additional job of the microglia, includes debris cleaning, or phagocytosis. The
Inflammatory response intricately works to maintain homeostasis within the entire organism;
however, the brain and the neurological system obtains special immune protections.
As previously indicated increased stress hormone states deleteriously influences
increased chronic inflammatory states and decreases the body’s ability to illicit an optimal
immune response; additionally, the perpetual exposure of neurological changing substances, such
as alcohol can further increase the risk of disordered neuroimmune functioning.57 After exposure
to alcohol and illicit substances, microglia and monocytes illicit communication with proinflammatory communicator proteins called cytokines in order to illicit protective immune
responses effected by the elevated brain stress states, elicited by exposure of substance. The
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neurological system facilitates the activation of microglia proliferation within regions of the
brain; this stress response increases capillary permeability and can contribute to the neurological
functioning and cognitive changes that result from the increased inflammatory neuropathology.
Dr. Daniel Amen’s research is able to produce vivid pictures of how the increases in the
impaired neurocircuitry and impaired circulation pathways portray in an unhealthy brain after the
chronic exposure to substances as a result of addiction; the brain visually appears as cottage
cheese, showing missing matter and empty spaces, which disable optimal functioning, perfusion
and oxygenation.58
Additional immune responses that are effected by the microglia and monocyte
communication signaling of the protein communicator’s or cytokines include communication to
other body systems, such as increased communication to the the gastrointestinal tract and the
liver; the pro-inflammatory cytokine signaling in the gastrointestinal (GI) tract and the liver
attempts to decrease the the risk of translocation of GI bacteria, which is initiated after sustained
stress responses. Further increases in the proliferation of inflammatory mediators, continue to
increase the systemic secretion of glucocorticoid hormones, which can continue to contribute to
the escalating neuro-adaptive psychological responses, which include anxiety, psychosis and
depression. As a result, additional chronic inflammatory dysfunction occurs in the liver and the
pancreas. The inflammatory processes that occur in the liver and the pancreas with the chronic
exposure to alcohol and illicit substances include the risk of esophageal varices, coagulopathies,
hypermetabolic states, hepatitis, and pancreatitis.59
The inter-related effects of the neuroimmune and the inflammatory response potentiates
the perpetuation the abnormal increases of sustained corticotropin releasing hormone and
sustained corticotropin releasing factors, which ultimately result in sustained serum cortisol
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levels, which affect entire organism homeostasis. The corticotropin releasing factor (CRF) and
corticotropin releasing hormone (CRH) are regulated by the encoding of the CRH gene; the CRH
gene is primarily responsible for stress regulation. The CRH gene is often times associated with
familiar heritability of transgenerational excessive genetic expression tendencies; studies indicate
that environmental and epigenetic influences potentiate an increase in cellular communication
sensitivity for excessive stress, fight and flight responses, by increasing the heritability of
substance use disorders and stress states though the effects of abnormal immune marker
functioning.60
Additional neurotransmitter release of excessive catecholamines, such as epinephrine
and norepinephrine accentuates the effects of the hypothalamic-pituitary-adrenal axis functioning
that results in additional excess secretion of glucocorticoids, mineralocorticoids, anti-diuretic
hormone and androgens that can negatively cause fluid and electrolyte imbalances; the end
result, increases the risk of sustained physiological impairments of circulation, perfusion, and
oxygenation systemically, which causes abnormal vasoconstriction, cardiovascular disease,
atherosclerosis, hypertension, abnormal glucose regulation, insulin resistance that results in
hyperglycemia, hyperlipidemia, and diabetes.61 Additional abnormal neuroimmune responses
result in leukopenia, delayed wound healing, increased risk for cancer, infections and sepsis.62
Inflammatory mediators when properly functioning within an organism are instrumental
in maintaining internal homeostasis; however, when excessive, abnormal and sustained release
of pro-inflammatory mediator activation occurs, the chronic inflammatory response can actually
harm the organism through an array of cellular and hematological complications; as stated
previously, after long term chronicity of substance use and immune dysfunction, complications
include end organ failure as a result of, glucose dysregulation, and abnormal inflammatory states,

208

which permanently increases stretching and resistance of specific organ cells. The primary cause
of pancreatitis or inflammation of the pancreas is excessive use of alcohol; additionally, a
leading cause of liver dysfunction, hepatomegaly, ascites, hepatic encephalopathy, hepatitis C
virus (HCV) and cardiomegaly include excessive use of alcohol and unsafe use of illicit drugs.63
As a result of further Gastrointestinal (GI) complications and increased systemic capillary
permeability, translocation of gastrointestinal bacteria predisposes the patient with substance use
disorders and addiction for sepsis, septic shock and death; this state of risk for translocation of
bacteria from the gut, compounds the risk for infections for patients already at high risk. Patients
are already at an increased risk for delayed wound healing, have an increased susceptibility to
infections, because of a decrease in white blood cell production, or leukopenia; additional
elements that continue to impair the immune response includes dehydration, and nutritional
deficits.64
Healthcare systems and providers of care can individually treat substance use disorders
and addiction through antiquated constructs of individual blame and through the disconnected
treatment modalities that only treat the isolated symptoms of acute disease exacerbations, with
disregard to the elevated incidence of the inflammatory effects on the neurological system that
ensues; however, this treatment methodology ultimately results in disregard of the integrity of
the patient.65 It is best to carefully consider the comprehensive neuroimmune response effects of
substance use disorders and addiction as it relates to the psychological and physiological
complications. The complications that correspond with the symptoms of impaired immune
activation, also influences the withdrawal-negative affect stage in the amygdala and the
preoccupation-anticipation stage of addiction, or craving stage in the pre-frontal cortex as
indicated by Crews, et. al.66 Additional considerations should evaluate how the activation of pro-
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inflammatory mediators impact the pro-inflammatory genetic and epigenetic expression of
neuroimmune cellular signaling which affects the transgenerational genetic expression from one
generation to another.67
Examining the influences of the neuroimmune and inflammatory responses that increase
the risk for physiological harms in relation to the complexities of stress, neurological function,
and the associated abnormal heritability of substance use disorders and addiction, requires
implementation of treatment modalities that consider the nuances of genetic neuroimmune risks,
while seeking to find genetic treatment modalities that aim to decrease over activation of the
neuroimmune stress states.68 Considerations must also seek to decrease the potential progression
of psychiatric and physiological dysfunction through the development of treatment modifications
that address the neuroimmune inflammatory states, in order to decrease the risk of comorbidities
of disease, which can destroy individual lives, families, and communities.
Further evaluation of the role that immune functioning and the excessive release of proinflammatory mediators negatively affect both the psychiatric and the systemic damage to the
heart, the gastrointestinal system, the liver and the pancreas all require application of scientific
understanding of the tri-morbidity of disease. The elements of substance use disorders, the
neuroimmune dysfunction and the associated psychiatric dysfunction that constitutes the
comprehensive aspects of the tri-morbidity addiction/ dependency is an often times an under
developed consideration in the management of care for those who suffer. Incorporating the
essential elements of the neuroimmmune and inflammatory comorbidities in relationship to the
complexities of substance use disorders and addiction requires application of professional
wisdom, attention and understanding; improving the understanding of the complex processes
requires the incorporation of concern that identifies the wellbeing of those who suffer from
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substance use disorders and addiction by decreasing vulnerabilities associated with the essential
and distinguishing aspect of the dysfunction.69
5.2 Relational Vulnerabilities of the Patient: Consent and Coercion.
Persons who suffer from substance use disorders and addiction have endured centuries of
negative health consequences, as a result of personal, physical and social neglect, because of a
simple and sad consequence, that societal constructs identify substance use disorders and
addiction as an individual and morally culpable condition.70 Hence, the perpetuation of isolation,
marginalization and discrimination, as decreed by a disordered hierarchical justification
judgement paradigm, which has placed abhorrent social and cultural biases toward the one with
addiction, which manifests as an exponential increase in existential psychological, physiological
and societal harms; the unfortunate trajectory of our current epidemic has occurred in part,
because of the confounding social, religious, cultural, political and health policy stagnation and
resistance to comprehensively applying a holistic implementation plan that bases the
management of care through scientific interventions that are focused through body, mind, spirit
and communal relationship with others in community.
This antiquated legal and health systems approach in the management of care for
substance use disorders and addiction continues to stringently adhere to the premise that
substance use disorders and addiction are disorders of individual choice and free will. This
approach will continue to impede improvement outcomes for those who suffer; additional social
requirements include, limiting the commodification of humans by limiting the coercive effects of
marketing systems that understand the financial gains as it relates to the vulnerability of persons
in relation to addictive substances. Public health models of care that seek initiatives to prevent
and decrease risk of substance use disorders and addiction, find it helpful to classify
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interventions on three levels, which include: the distributer of the substance or agent; the one
who is addicted or the host; and lastly, the community, or the environment, which includes either
the local national or international community.71
This information is helpful when evaluating the relational context of vulnerabilities and
the relational context of the potential layers of individual coercion. Solely focusing on autonomy,
decision-making, consent for treatment and health provider coercion as it relates to substance use
disorders and addiction is unwise and inconclusively focused; the holistic consideration of the
effects of coercion must focus on the outside influences and nature of societal market systems, or
the coercive effects inflicted by the distributers and the systematic and societal exploitation of
those who are most vulnerable.72 Market systems or agents value financial gains and profits over
the exploitation of vulnerable human hosts; market systems or agents perpetuate the continuation
of human harms to individuals, by understanding the intrinsic pathways of addiction, while
participating in the sustenance of public policy that assigns blame to individuals, while profiting
from market sales and dehumanization of the vulnerable.
Embracing the evidence that the debilitating physiology of the neurological dysfunction
of the increased risk for substance use disorders and addiction frequently exhausts individual
human potential to flourish, because of abnormal pathophysiological and genetic responses to
every day stress states, through the overwhelmingly abnormal inflammatory responses that
greatly impair decisional capacity appears to be a product of unintended adherence to the
disregard of human dignity.73 In health care, it appears that while striving to respect individual
autonomy, by declaring that patients have the right to consume substances and ‘make bad
decisions to use substances’, as though the coercive effects of the distributer and the environment
have little or no effect on the ‘host,’ devalues individual integrity, negates care for the other and
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withholds professional obligation to protect patients from the progression of disease and human
vulnerability.74
The professional values of care, such as connectedness, interdependency, responsiveness,
attentiveness, professional responsibility, wisdom and competency have unintentionally negated
to respect the authentic respect for human life for those who suffer from the complex
neurological sequela of dysfunction, by confusing neurological incompetency with competency
in a brain that is negatively affected by the systemic inflammatory and cellular response of
chronic stress states that are exponentially exacerbated by the commodification and social
constructs of hierarchical dominance, justification, and judgement. The host is exploited, while
the agent ensures considerable profit through coercion of social constructs of misinformation.75
The trajectory of systemic and chronic inflammatory mediator release in the body and
brain, greatly impairs a person’s ability to make autonomous decisions; as a matter of cellular
responses to stress and the genetic expression in response to stress, certain individuals who are at
high risk for substance use disorders and addiction are predisposed to the negative physiological
and biological effects of substances with just one exposure. This increased and misunderstood
response of the perpetuation and cycle of abnormal neuroimmune cellular expression after one
exposure of drug is often dismissed as simply a personal weakness and choice, even though the
biological coercive effect of the substance has been determined.76 A call to restore individual
understanding in regard to the need for relational interdependence, a call to enhance human
flourishing, and a call to adequately treat the physiological risks of dysfunction that result from
potential neurological and neuroimmune risk for the person with substance use disorders and
addiction heritability is long overdue.
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Legal constructs of the term, coercion is considered through the actions or processes to
which power is exerted on another person in order to receive a confession; however, coercion in
healthcare is utilized as a term, which considers the vulnerability of patients when experiencing
states of diminished autonomy during illness.77 Meaning, that one who is vulnerable in
healthcare, is coerced when implementing medical interventions against the person’s desired
will. It is commonly considered that autonomy is negatively impacted during states that impact
an individual’s mental health or psychological stability; hence, the concern that those who have
limited mental capacity are at increased risk for provider coercion in their management of care.78
The risk for institutional health care coercion in the management of care for those who are
diagnosed with mental health dysfunction is a concerning reality for those with a history of
psychiatric illnesses and mental health dysfunction.79
The management of care for those diagnosed with substance use disorders, addiction,
psychiatric dysfunction and mental health disorders have experienced exponential ethical
concerns in regards to exploitation, harms, and coercive authoritative management of care;
however, implementing plans of care that seek to respect the individual autonomy of persons are
indicated. Historical coercive and paternalistic practices, were justified in the management of
care for those who suffer with the psychiatric comorbidities of addiction as a result of a health
providers by claiming that paternalism ensured patient beneficence was justifiable.80 Yet, the
current constructs of care lean toward negating unwanted interference of professional
implementation or instituting a plan of care without the full and autonomous consent from the
patient for treatment. This inaction, which seemingly disregards the manifestations incapacity
criteria that the patient presents with is equally problematic.
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Through the implementation of a relational consent for treatment for substance use
disorders and addiction by initiating a framework of care, which is based upon the values of
relational interconnectedness and professionalism, care providers should seek to restore the
physiological neuroimmune homeostasis for the patient, by decreasing the trajectory of harms
induced by complex systemic inflammatory states, through the consequential impairment of
authentic autonomy states. Relational support, which facilitate comprehension and application of
the complexities of the abnormal and damaging neuroimmune state must manage the negative
effects to the brain. Applying elements of care, which decrease vulnerabilities, empower
personhood and repair consciousness must address the physiological coercive effects of stress
and substance use as it authentically relates to impaired neurological functioning; impaired
neurological functioning manifests through changes in affective psychological predisposition and
impairing decision making. The body’s normal response to stress states, neurological
dysfunction must be comprehensively considered.
Implementing paradigms of care that seek to decrease the risk for vulnerabilities though
relational consent processes must prioritize a unique understanding of the physiological
infractions of personal autonomy that occur for those with substance use disorders and addiction;
historically, two divergent anthropological frameworks for addiction management of care
influenced the medical and legal responses for those who are diagnosed with substance use
disorders and addiction. The anthropological frameworks include first the medical patient
anthropology and second the social client anthropology; Janssesn et, al describe the two
anthropologies as being incompatible with one another. Therefore, creating the justification to
identify the development of a third anthropology is necessary; an ethics of care asserts the
development of a third anthropological framework that embraces the relational aspect of the

215

medical patient anthropology, while also considering the interconnectedness of societal
influences that necessitate the dignity of the one who suffers. Through the development of an
anthropology framework that seeks to restore personhood, repair consciousness, eliminate the
hierarchical justification judgement paradigm that perpetuates individual and societal
vulnerabilities.81
a. Empowering Personhood, Repairing Consciousness.
Empowering personhood and repairing consciousness, begins with evaluating the two
opposing anthropologies of addiction and developing a new anthropology that seeks to reconcile
the differences. The medical patient anthropology, considers that the person who suffers from
substance use disorders and addiction is a person who inconsistently looks toward the health care
systems to assist with the unmanageable or acute escalations and exacerbations of the chronicity
of the physiological and psychological manifestations of disease; the medical patient encounter is
not relational and it is fragmented during periods of abstinence, exacerbations, and periods of
disconnection.82 The medical patient anthropology recognizes that the fluctuating capacity of the
patient’s ability to competently manage their trajectory of care is consistently limited; yet, the
anthropology recognizes its inability or it’s stagnation to implement real change for the patient,
because care is still negatively affected by the social constructs of the criminal justice system,
fear of the patient’s concern for criminal consequences and the perpetuating effects of social
stigma occur.83 Even within the medical patient anthropology, the patient is subject to the effects
of the hierarchical influences of the justification and judgement constructs that blame individuals
for the inability to remain abstinent or to completely cease the utilization of substance.84
Albeit, the social client anthropology does not recognize that the one with substance use
disorders or addiction is a patient who requires help with the trajectory of physiological and
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psychological disease state; rather, the social client anthropology lives in dichotomous tension
with the medical patient anthropology, believing that the one with addiction is a client and a
societal peer. The social client anthropology perpetuates the construct that the client is a
completely autonomous agent, rather than a ‘host’ and therefore morally culpable when utilizing
substance and therefore judged as wrongful and weak.85 Education initiatives that disseminate
the criteria that constitute an autonomous moral agent and that evaluates competence in
healthcare decision making is imperative. The careful evaluative elements of moral agency
require, first that the person has the ability to reason, has the ability to use past experiences as a
guide, has the ability to freely choose actions, and must ‘know’ or fully understand the
consequences of those actions.86 The ones who market substances, the ones who are the
distributive agent, must be held to the same accountability, before inflicting harms on vulnerable
hosts.
Historically, substance use disorders and addiction management case scenarios presented
with such diverse physiological complexities that at times seem impossible to describe or explain
outside of the language of moral intemperance, sin and culpability; however, current scientific
evidence can no longer allow the inadequate mismanagement and societal tensions to
unnecessarily impair the lives of those who are so tragically affected by the unreconciled
constructs of a social anthropology that refuses to embrace the medical, scientific and bioethical
constructs that seek to restore the rights of individuals and future generations; the bioethical
justification to empathetically adjust, accommodate and develop a merging anthropology for
those who suffer from substance use disorders and addiction seeks to restore both individual and
societal health by repairing the consciousness of society.
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Combining the medical patient anthropology and altering the social client anthropology
for the management of addiction through a revised anthropology that seeks to incorporate aspects
of the relational medical patient and through the constructs of a relational social human person
anthropology. This collaborative anthropology recognizes the need to embrace the specific
relational aspects of autonomy through empowerment, the redevelopment of repairing
competence and consciousness; because the one who suffers, suffers within a community from
the neurological, neuroimmune, neurocircuitry, and social impairments from substance use
disorders and addiction, which grossly impede the essential elements of meeting the standards of
individual agency and competency.87 Implementing relational consent paradigms and
incorporating shared responsibility potentiates restoration of personhood, restoration of
consciousness, restoration of improving individual competence ultimately seeks to restore
societal health.
Relational decision-making and paradigmatic reconstruction of informed consent
processes, and implementation of a relational management of care paradigm for those diagnosed
with substance use disorders and addiction is not coercive it is good healthcare and ameliorating
medical treatment. It is ethically justified to partner with patients, families and communities to
eradicate the current addiction epidemic, by revealing that the social elements of
commodification and exploitation of the vulnerable has exponentially harmed millions of lives
through the coercive measures of marketing, policy, and physiological effects of stress and
substance.88 In order to reverse the influences of the neurobiological, genetic, and epigenetic
consequences of the substance use disorders and addiction that have escalated the trajectory of
harms that impair personhood through the neuroinflammatory cellular mechanisms, restoration
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of cellular dysfunction can begin through developing a comprehensive and restorative process,
which seeks to restore physiological and societal homeostasis.89
As a result, relational decision making adjusts to the ever changing circumstances of the
one diagnosed with substance use disorders and addiction and allows persons to adapt to the
complex mechanisms and nuances of the neuroinflammatory and affective psychological
responses of the disease trajectory with assistance from others in order to avoid harm to self and
to others.90 Implementing measures of shared decision making, strengthens the construct of the
relational medical patient and social patient anthropology, by limiting the effects of the coercive
stress induced states of chronic substance use. Hence, the restoration of the one who suffers is
justifiable when avoidance of patient harms are evident, when patient choices substantiate harms,
when interventions improve patient outcomes, when interventions seek to improve public health
outcomes, and when implementation of interventions prevent the sequela of known disease
trajectory of harms in order to empower and restore human personhood and consciousness.91
Unlike many physiological disease states, substance use disorders and addiction are often
internalized states that produce powerful emotions of personal failure, that develop as a result of
repeated chronicity and acute exacerbations often times occur in opposition to one’s core values
and intrinsic vision of the self and consequently leads to disempowered personhood and
unexpected mental states; substance use and addiction progresses through altering levels of
conflicting consciousness.92 Hence, in order to discuss the earnest need to heal consciousness,
explaining the deleterious magnitude of impaired consciousness is necessary. The intensity of
personal, familial, and community suffering as a result of addictions’ grasp on altering levels of
consciousness for individuals must be reflectively and responsibly repaired through
implementing new treatment modalities utilizing strategies that heal physiological disease and
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empowers autonomy through relational connections. Like all medical interventions, balancing
benefit and risks of treatment are necessary.
Defining the concept of consciousness requires extrapolating the vastness of the concept.
Consciousness is often discussed through both scientific criteria perspectives and through the
complexities of metaphysical deliberation.93 Physiologically, the spectrum of understanding
consciousness can be simply examined through the lens of awake and sleeps states or through the
compounding nature of cognitive processes that relate to the complex abilities to process the
notion of self, environment, feelings, and decisions that constitute the unique nature of the
neurophysiological components of the mind-body experience that influences each individual
person’s life with others.94 The metaphysical and ontological aspects of consciousness are
emotionally unique for the satisfaction of the human desire to understand the intentionality or
non-intentionality of action of ‘being’ related to the self.95
Utilizing professional practice standard as guides to repair consciousness and restore
personhood for patients who experience the psychological and neurobiological harms to self
during addiction requires the implementation of relational decision making in order to benefit
patient well-being and improve physiological health.96 The overwhelming call for professional
responsibility to empower personhood and repair consciousness for those diagnosed with
addiction disorders is an insurmountable professional task, requiring the relational support of
patient, family, and community; communal provisions that are necessary in restoring personhood
and repairing consciousness must reconstruct the human spirit through restoring hope through resocialization and restoration of community acceptance.97 Professional responsibility require
incorporation of attunement and dignity management to validate individual worthiness and the
intrinsic need of human connectedness during vulnerability; navigating the responsibility of care
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includes empathetic processes to repair harms through respectful communication, health
promotion education, nonjudgmental and holistic care, and acknowledgment of the worth of each
patient.98
b. Decreasing Vulnerabilities.
Decreasing human vulnerabilities includes implementing care systems of connection,
knowledge transference, and supportive care environments; decreasing vulnerabilities for
individuals and populations afflicted with substance use disorders and addiction occurs with the
distribution of knowledge and programs that aim to decrease deleterious actions of care that
perpetuate marginalization and stigmatization.99 Additionally, Dr. Gabor Mate’s research on
substance use disorders and addiction clearly shows that vulnerability is heightened in all living
organisms when physiological and psychological isolation occurs; cellular and biological
synergy consistently results in strength of organism, whereas, when organisms and cells are
isolated from mutual cellular supports, the host is susceptible to disease, illness, and death is
likely to occur.100 When societies support the profits of the distributer over the management of
care of the host or person, similar increases occur in the susceptibility of disease, illness, and
death are imminent consequences.
Human vulnerability perpetuates when affirmation of perceived societal norms remain
unquestioned; unquestioned isolation, unquestioned dominance structures, and unquestioned
ethical systems that implement hierarchical justification judgement over another, increase social
systems that potentiate powerlessness, false normality, and result in persistent harms of the most
vulnerable ‘other.’ However, neurobiology, genetics and addiction science aims to restore the
unnecessary silence of suffering, aims to decrease vulnerabilities through implementing values of
care that increase individual hope, repair and reconstruct consciousness and re-empower
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personhood through innovative strategies that promote physiological, psychological, and
neurobiological restoration through social reintegration and non-stigmatized scientific disease
management care.101 Social reintegration requires a careful assessment in the determination of
respect for autonomy, personhood and competence. Restoration of hope and societal belonging is
required necessary.
Determining competency for consent begins with an honest evaluation of the criteria of
informed consent and then secondly includes the reconstruction of consent by incorporating
safeguards that protect persons diagnosed with substance use disorders and addiction through
relational decision-making processes and implementing contractual consent requirements for
those who are vulnerably affected by neurological impairment. The wellbeing of each
individual’s personal health is necessary, while implementing constructs of care that seek
individual integrity and neurological and neuroimmune stability; a relational consent paradigm
of this magnitude seeks assurances of family centered participation, avoidance of neglect,
empowerment for those with known neurological impairment and allows healthcare providers to
implement elements of relational care through patient and family centered consent processes that
seeks the relational integrity of all individuals.102
Decreasing vulnerabilities require a comprehensive evaluation for determining
competency for consent for healthcare decision-making for those who are diagnosed with
substance use disorders, addiction, and the neuroimmune sequela of the effects of sustained
inflammatory states, requires the application of a new anthropology of care; an anthropology of
care that values the integrity of individuals through the constructs of relationships, incorporates
insurances that the patient with substance use disorders and addiction maintain cognitive ability
to make health care decisions consistently over time, remain free intrinsic and extrinsic coercive
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influences of inflammatory neuroimmune effects of sustained substance induced stress states.
Are able to assess risks and benefits of decisions, while also understanding the long-term
consequences of those decisions.
The principle of double effect examines the analytical conceptualization of the essential
bioethical questions. Historically, the principle of the double effect has been successfully utilized
in the daily decision making considerations that healthcare providers are faced with in the age of
complexity and technological advances; however, the utilization of the principle of double effect
is useful for everyday decision making and toward evaluating the normative values of complex
implementation of health care interventions. The principle of the double effect incorporates four
essential normative criteria for considerations during the ethical decision making process. ‘They
include: 1.) The action must not be a bad or morally wrong action; 2.) The bad effect must not
cause the good effect; 3.) the agent must not intend the bad effect as an end to be sought; and
lastly, 4.) the bad effect, must not outweigh the good effect.’103
Implementing a relational consent process of decision making for the management of
care for those who suffer from the deleterious consequences of substance use disorders and
addiction seeks to facilitate a treatment paradigm shift that empowers personhood, repairs
consciousness and decreases vulnerability through the implementation of relational consent for
the management of care for substance use disorders and addiction. The first criterion examines
the duty of the one who acts.104 The action, which seeks to implement relational consent is not
morally objectionable; if the action sought the removal of all individual autonomy it would be an
objectionable action; however, the action, which seeks to implement relational consent confirms
the value and dignity of the individual and of the individual’s autonomy by seeking to restore
competency and autonomy through relationship. The action identifies the impaired biological
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mechanisms that impair the neurological ability to demonstrate competency and seeks to ensure
safeguards against the patient’s perpetuation of inflicting harms to self and to others. The first
condition is met.
The second criterion examines the sequence of consequences, from the action to the
actions effects.105 The action, which seeks to implement relational consent in the management of
substance use disorders and addiction, seeks to restore the individual’s ability to increase the
independent autonomous decisional capacity through medical interventions that decrease stress
states and neuroimmune psychological states that impair cognition, while implementing
constructs of relational empowerment, dissemination of educational knowledge, and societal
reintegration and belonging.106 The second condition is met, because the act’s effects given that
the neurological circumstances require the patient’s assistance in action; the action’s effect is not
the result of removing the decisional autonomy of the patient. The decisional autonomy is
already compromised.107
The third criterion examines the intention of the action; it has already been established
that through the implementation of relational consent, the intention of the healthcare
professionals is to restore and repair the harmful effects associated with neurimmune effects of
perpetual stress states.108 The health care professional does not intend or desire the bad effect of
the loss of autonomy, which causes impaired decision making; the healthcare professional
implements the relational consent process in order to restore competency.109 Lastly, the fourth
criterion exams that the bad effect or the action which seems to limit absolute autonomy of the
person for those diagnosed with substance use disorders addiction does not outweigh the good
effect of the goal to restore the limited and impaired neurocognitive functioning, which
negatively influences affective psychological states and executive functioning ability.
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By applying the principle of the double effect, the complexities of managing the
trajectory of care despite neurological impairment of the patient who is diagnosed with substance
use disorders and addiction improves the trajectory of outcomes, attempts to restore personhood,
decrease vulnerability and relieve the existential suffering of individuals and society. Substance
use disorders and addiction are associated with additional vulnerabilities, which include
psychological, spiritual or existential suffering; suffering of this nature is perpetuated when fears,
isolation, social withdrawal and hopelessness prevail.110 Implementing a comprehensive
understanding of competency, implementing relational consent processes and understanding the
justification or need to change the management of care attempts to restore personhood and repair
of consciousness, by additionally seeking the relational relief of suffering.
5.3 Relational Relief of Suffering: Patients, Professionals, and Society
Contemporary medical approaches of western medicine have a difficult time defining and
addressing the constructs of human suffering and its associated relationship with human
vulnerability. The multifactorial components of human suffering, pose complex and intrinsic
personal characteristics of perceived misfortune for individual patients. Suffering, according to
Eric Cassel, possesses the distinction of severe distress that actively deconstructs the wholeness
of the person.111 Whereas, pain, does not always deconstruct personal wholeness.112
Differentiating between and comparing between pain and suffering is necessary to adequately
evaluate the true depth and scope that suffering involves. Pain is routinely described as a
physiological process with a known etiology, pain can also be described as a subjective
experience of a physical ailment; pain is typically caused by known and unknown origins.113
However, medicine has objectified the pain experience, by routinely monitoring a
patient’s pain experience as the fifth vital sign; in hospital systems, nurses must document and
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measure a patient’s pain experience at least every four hours in the clinical setting.114 Assessing a
patient’s pain is a routine assessment. This assessment inclusion attempts to quantify the
patient’s experience of pain. The experience of pain is numerically numbered in order to provide
an accurate measurement of the intensity of pain, interventions are implemented to ‘remove’ the
pain, through administration of pharmacological agents, and lastly the pain is re-evaluated after
the intervention has been implemented to assess the physiological relief of the pain. The
numerical reductionism of the pain phenomenon, succinctly attempts to describe the pain
experience in order to effectively treat the phenomenon through pharmacological or alternative
treatment interventions.115
Conversely, suffering is largely ignored in clinical practice. Suffering cannot be reduced
to scientific objectification, so instead it conceptually hoovers in the recesses of a shadow or in
the patient’s personal experiences; suffering is, virtually unaddressed scientifically by modern
medicine.116 Suffering has the potential to infiltrate its anguish into all elements of the individual
human condition and experience, unnoticed; it’s often-silent assent potentiates negativity,
yearning, and destructive affects upon the one who suffers. Suffering is experienced physically,
emotionally, spiritually, and socially; suffering may progress slowly through time, or it may
rapidly destroy hopes and dreams for the future. Suffering may result from unresolved personal
conflict or suffering may result through unresolved chronicity of illness or pain.117 As suffering
progresses, personal direction and purpose is often lost; hence, the ability to humanly adapt to
the stressors of disease and illness is detained through vulnerability.118
Utilizing a reductionist approach, cellular or physiological adaptation is necessary for
survival of any organism. Consequently, adaptation in times of suffering is an essential
component needed for recovery. Complete human adaptation is necessary for individual survival
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and flourishing; if suffering is ignored personal identity and integrity can be lost. The medical
imperative should be in establishing a relationship with patient’s personal suffering during
illness, to promote adequate care and adaptation for the holistic care of the person. Suffering
encompasses the entire human person, not just the cellular components of organs and biological
systems. The essence of humanity cannot survive through the reductionism approach of
medicine. Human survival, care for humanity, and preservation of individual wholeness,
requires medical physicians to incorporate virtuous care in response to individual patient
suffering.119 The necessity to embrace the existence of suffering as a natural human
phenomenon, should be embraced by health care providers in order to impart knowledge of the
normalcy of suffering as an intrinsic human condition. Physicians through compassion, empathy
and wisdom should no longer allow the shadowing of suffering to remain in the recesses of
personal darkness for patients diagnosed with addiction.120
The nature of existential suffering includes the overall search for human freedom and
pursuit of meaning within one’s life and purpose.121 Current research regarding the nature of
existential suffering is frequently examined in context to end of life illnesses, such as cancer. But
the reality of the nature of existential suffering should be examined for all human experiences
throughout the lifespan. Irvin Yalom identified four intrinsic human elements that lead to the
intrinsic nature of existential suffering at end of life; he identified the elements through human
feelings of isolation, meaninglessness, loss of human freedom, and contemplation of one’s own
mortality as the essential qualities; although, it is important to note, that existential suffering
often exists during the management of care for those who are diagnosed with substance use
disorders and addiction. Often those who suffer with substance use disorders and addiction
express feelings of victimization, isolation, loss of human freedom, loss of control to create
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meaningful or authentic lives, and imminent realization that their disorder will result in death.122
Compounding feelings associate with social isolation induces personal thoughts of moral failing
or sin, which further impedes the perception of self in an intrinsically negative manner.123 The
medical patient anthropology and the societal client anthropology contribute to materializing the
four intrinsic components of Irvin Yalom’s, inner conflicts that exacerbate suffering in isolation,
meaninglessness, loss of human freedom and ultimately an increase in mortality risk that results
from an inability to ‘know’ where to find help.124
The current health care systems approach to medicine, functions in a fast forward, high
pressured functioning treatment centered disease specific paradigm that rarely attempts to assess
the potential personal, spiritual, psychological, or suffering, which often persists with illness; for
those who experience increased neurological and neurocognitive vulnerability as a result of
addiction, these essential elements of vulnerability are often mistakenly overlooked and
unseen.125 The associated consequences of the abnormal neurological and cellular immune
response for those who are diagnosed with substance use disorders and addiction, leaves many in
need, lurking in darkness. Unaddressed family distress, intrinsic physiological processes that
overpower consciousness, communication, and emotions, result in breakdowns, despair,
demoralization, loss of hope and a loss in the value and meaning in life.126 Increasing incidences
of depression and increasing risk for suicide ensue.127
The 1988 Hastings Center Report entitled, ‘A Special Challenge: Ethical Challenges of
Chronic Illness,’ identified that the medical management of addressing the chronicity of disease
and suffering are inadequately managed and it remains a relevant issue, thirty years after its first
publication; the ethical challenges, which are faced in the chronic illness management of
substance use disorders and addiction inadaquatly addresses the impact of suffering and the

228

chronicity of disease.128 The complexities of unaddressed suffering, psychological hardships,
compounding degrees of shame, isolation, betrayal, secrecy, powerlessness, impaired normalcy
and marginalization further complicate the existential suffering and confusion of life’s meaning
for those who suffer from addiction; implementing a relational approach in the management of
care, requires implementing the skill and wisdom of professionals to restore human dignity.129
Implementing a call for professional action to address the plight of human suffering and
escalating rise of mortality and comorbidities of dependency and addiction is long overdue; an
ethics of care framework is needed to re-examine the patient-physician relationship and role,
which should seek to develop a relational response of care to decrease the intrinsic suffering that
often times coincides with substance use disorders and addiction.130 The nature of existentialism,
embraces the belief that all humans suffer; yet, if one is to survive, finding the intrinsic meaning
of that suffering can motivate hope, can seek authenticity and ultimately a more meaningful
life.131
Through the tri-cooperation of developing a community approach to utilizing
professionals, the participation of family support, and incorporation of a socio-political
community outreach policy that embraces inclusion of the neurodiversity of those who suffer
with substance use disorders and addiction through empathetic and evidenced based treatment
programs that aim to decrease the suffering of individuals through supportive and empowering
programs that seek to treat the pathophysiological processes that increase the exacerbation of
addiction with known mechanisms that begin to repair cellular expression through the facilitation
of treatment paradigms that address suffering, offer implementation of pharmacological,
immunotherapies, neurocognitive enhancement and most importantly hope to restore meaning
and personhood.132
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The broad nature of suffering and its relationship with chronic illness and disease states
such as in substance use disorders and addiction surpasses physical pain, focusing on only the
physical elements of pain or the pathophysiological processes that exacerbate the biological
trajectory of disease is only one element of healthcare’s responsibility in caring for the health
needs of individuals, communities and populations; the profession of nursing has always
emphasized the intrinsic importance of considering the person as a complex spiritual, relational,
physical and psychological being; that in the care of the ‘other’ an essential and holistic
management of care is needed to treat the whole person, not just the physical self and the need
extends to caring for the ‘other where they are in space and time. For those who experience
substance use disorders and addiction, existential suffering is often witnessed, but disregarded;
however, once vulnerability and suffering are recognized within a framework of care, facilitation
of a treatment paradigm shift is actualized.133
a. Facilitating a Treatment Paradigm Shift.
The medical model of care oftentimes, focuses intently on the pathophysiological
processes, risks, etiology, and manifestations associated with disease states as a separate entity
from the overall relationship between the complex social, environmental, and personal constructs
that influence human illness; as a result, the paradigm shift, must clearly link the behavioral,
social, and complex psychological connections between physiology, brain function, and
propensity for responsive human actions in response to the physiology.134 Chronic substance use
disorders and addiction are not always acknowledged as a legitimate disease state; the ability to
see the interconnection between neurological and cellular responses transgenerationally through
cellular expression is an entirely new frontier of science. Hence, the argument ensues, that
emphatically negates the disease model paradigm and insists upon individual responsibility for
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individual’s actions that lead to chronic and disordered use of substance, as manifested in
addiction.135
However, the legitimacy of addressing individual responsibility is not negated or
minimalized by adhering to a disease paradigm or pathophysiological processes of complex
cellular dysregulation or complicated neuroimmune sequela of dysfunction for addiction, any
more that it negates the legitimacy of individual responsibility for the management of care for
other complex multifactorial genetic and epigenetic disease states.136 The complex heritability of
patients who are at increased risk for diseases such as diabetes mellitus, hypertension,
atherosclerosis, cardiovascular disease, osteoporosis, and cancer all are effected by similar, yet
uniquely different and complex interplay of environmental and social stress states, inflammatory
processes, environment influences, nutritional status, and social life circumstances that stimulate
genetic heritability and epigenetic results of cellular expression.137
The differences with the presentation of, or the comparison of the aforementioned
diseases, is that the target organs which are effected by the multifaceted etiology of disease do
not manifest the expression of that disease through the ‘essence of who one is’ intrinsically;
meaning the pro-inflammatory, neuroendocrine stress states that causes atherosclerosis,
hyperlipidemia, cardiovascular disease and hypertension progresses through manifestations of
impaired blood flow, inflammation, myocardial damage, ineffective mechanical functioning of
the heart as a result of human action, or inaction, such as deleterious food consumption and
increased sedentary life styles. Yet, the discussion that cardiac disease as an authentic disease is
never disputed through the framework of the insistence that impaired cardiac functioning results
from individual behavioral dysfunction; although the mechanisms of progression from
preliminary stages of disease to advanced progression of cardiomyopathy or failure can correlate
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to the adherence of the treatment paradigm of care, which includes strategies to educate
individuals and families regarding etiology, heritability, genetic family risks, epigenetic and
environmental influences of disease exacerbation.
Historically, not so long ago, most all disease states were associated with fluctuating
degrees of blame, shame, and stigma that was associated with moral culpability, sin and
punishment for wrongdoing; the justification, judgement paradigm, which assigns individual
fault as ‘a way to tell the story’ of a person’s intrinsic vulnerability, is not an adequate depiction
of truth; and therefore, requires the careful explication of developing a story that restores
personhood and consciousness for those who become lost in the maze of neurological cellular
expression and neuroimmune inflammatory mechanisms that block oxygenation, perfusion and
circuitry that enables and enhances human flourishing and potential.
By restoring the dignity of those who are diagnosed with substance use disorders and
addiction, health care professionals must collaboratively and convincingly embrace a model of
care that seeks to protect the intrinsic rights of individuals through an ethics of care framework.
An ethics of care framework must direct physician centered and medical models of care to
comprehensively embrace a paradigm of care shift that emphatically utilizes a holistic model of
care that incorporates relational decision making by rejecting an trajectory of dismissiveness for
those who suffer. Enhancing the care of the other while restoring and repairing human integrity,
personhood, consciousness through application of implementing treatment interventions that
seek to restore physiological functioning is paramount.138 Improving trajectories of care for those
who are diagnosed with substance use disorders and addiction are needed in order to reverse the
escalating harms.
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The exponential growth of outreach programs and education initiatives that sought to
utilize a relational and holistic approach for treatment of patient’s diagnosed with human
immunodeficiency virus (HIV) has drastically influenced the national and international
initiatives that sought to decrease stigma and marginalization for high risk populations who
suffered with HIV and AIDS; the management of care paradigm actively sought to decrease the
risk for susceptible populations through dissemination of educational information on a subject
that had previously elicited unprecedented stigma and shame. Concurrently, the development of
scientific discoveries, which innovatively impaired the viral replication of the HIV virus that
wiped out a person’s normal immune response were discovered and additional public health
prevention strategies, known as clean needle programs, met people where they were to offer
programs of assistance; the dissemination of one of the most effective public health initiatives
began a slow and methodological campaign to prevent harms from the transmission of HIV and
AIDS through the knowledge of science, through relational care of the ‘other,’ versus a stubborn
refusal to scientifically and socially perpetuate social neglect, judgement, and justification.
The paradigm shift must include changes in policy that decreases the vulnerabilities
associated with risk for substance use disorders and addiction, such as isolation, dislocation, and
marginalization, by developing authentic, professional, and safe community outreach programs;
incorporating supportive outreach programs require reintegration to work and school programs,
and a decrease in criminalization policies for those who are susceptible to sustained substance
use as a way repair consciousness, repair neuroimmune functioning and repair personal
dignity.139 The relational paradigm of care shift should assimilate the HIV initiatives and
European models of care for the most desolate substance users that were successful in breaking
through the stigma of shame, silence and fear of disease that is associated as ‘just punishment for
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the consequences of societal construct of sin and wrongdoing.140 Responding in solidarity of ‘the
other’ because of a common humanity and relatability of human frailty; rather than justify the
deleteriously neglectful refusal of care, through assigning judgement for the shame of the fall.141
It is time to decrease the suffering and despair of individuals and populations afflicted
with substance use disorders and addiction, by aggressively utilizing innovative advances in
educational initiatives, innovative redevelopment of public policy, and providing humanistic
healthcare initiatives that seek to reverse deleterious consequences of genetic and epigenetic risk
for neurological impairment. A careful consideration of the scientific contributions of
pharmacogenomics, immunotherapies, neurological manipulation and enhancement technologies
have the potential to reverse the deleterious consequences of neurological dysfunction related to
neuroimmune inflammatory states for the brain, as the development of pharmacological
cardiovascular medications, anti-hyperlipidemia medications, coronary artery bypass grafting
(CABG), coronary artery stenting, and intra-aortic balloon pumps, and ventricular assist devices
revolutionized innovative cardiovascular medicine.
b. The Contributions of Pharmacogenomics, Immunotherapies, Manipulation, and
Enhancement.
Pharmacogenomics, immunotherapies, viral manipulation, immune enhancement
interventions, social support networks, and destigmatization initiatives have all influenced the
successful management of HIV care that has contributed to drastically decreasing the rapid
proliferation of disease progression from initial onset of HIV to the rapid and destructive
spectrum of the disease’s association with AIDS; the historical progression from HIV to AIDS,
almost assuredly increased risk for early mortality. The physiological viral replication that
destroyed the body’s natural immune response, through the virus’s ability to destroy and
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replicate itself in the human- hosts CD4 cells, is often successfully halted by initiating
therapeutic pharmacological combination of medications, that halt the virus’s ability to replicate
itself at multiple replications stages. With the advances in HIV and AIDS immunology research,
the complex understanding or viral replication and transmission enabled the scientific
communities understanding of genetics, and the biological components of communicability of
disease led to pivotal educational and social outreach programs that extended support to
marginalized and vulnerable individuals and populations; the lessons learned from the joint
ventures of science, public policy, government, health care and communities resulted in a
significant decline in the horrific consequences of a deadly disease progression, improved
national health outcomes and decreased viral transmission of the HIV considerably after just four
decades of care.
Pharmacogenomics, neural manipulation, cognitive immune enhancement interventions,
public policy changes, innovative educational initiatives, and collaborative social outreach
programs potentiate the same decrease in the effects of impaired consciousness and
comorbidities of disease in the management of substance use disorders and addiction; reversing
the adverse sequela of addiction, restoring neural plasticity, and improving the social constructs
that perpetuate isolation and marginalization are needed to support the reversal of harms to
families, communities, and future generations.142
Improved understanding of environmental influences of genetic expression, methylation
and neuroimmune functioning that potentiate the neurocognitive, neuropsychiatric and
behavioral reward pathways and pathologies that increase susceptibility to substance use
disorders and addiction tendencies, will potentiate scientific advances in the activation or
deactivation of neurotransmitter responses that preclude genetic vulnerability to disease states,
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altering stress responses, repairing neural synapse dysfunction, and reversing the neuroinflammatory mediators that alter resiliency to stress, substance use, isolation and dislocation are
essential for effective treatment paradigms.143 The ethical concerns with implementing
aggressive treatment interventions on the brain have historically been cautiously approached;
altering neurological functioning has ethical considerations that the altering of ‘other’ human
organs do not precipitate.
The ethical implications of neurocognitive enhancement demand a prospective analysis
that reflects upon the significant realities of the future. Enhancing the brain compared to other
organs potentiates certain change of the concrete nature of ‘one’s’ core essence of being, this
occurs because neurocognitive enhancement interventions have the capacity to change the very
components that define individual ‘personhood.’144 The neuroethical analysis must consider the
unique relevance of such mind altering techniques that threaten to re-define the concept of one’s
human ‘identity;’ the brain is the organ that helps humans to ‘know’ and ‘understand’ the
meaning of self. It is also the organ that embodies the human mind and consciousness.145 Human
societies have evolutionarily altered and enhanced cognitive functioning throughout the
centuries, by implementing improved methods of communication, writing, mathematics, and the
sciences. The present advances in science have the ability to use invasive cognitive enhancement
modalities as treatment for dependency disorders; The current reality of advancing genetic
science potentates manipulation of neurocognitive functioning through alteration of gene
expression and reengineering of genetic design in order to eradicate medically debilitative
disease and disease processes; this new potential requires careful considerations for
establishment of applicable ethical guidelines.
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This paper has discussed the abhorrent inheritance potential of specific genes and the
transgenerational epigenetic methylation processes that can potentiate and exacerbate heritability
risk for addictive disorders. It has also examined the relationship that the overstimulation
processes that signal the hypothalamus-pituitary-adrenal-axis to continually increase the
sympathetic nervous system in response to stress, or threats. The stress response and traumatic
events can lead to disordered genetic expression that can progress to neuronal changes in
cognition, depression and substance use disorders; progressive substance use disorders to
addiction can additionally include influences that effect behavioral from environmental stimuli.
This hopeful prospect that new cognitive enhancement modalities can offer personalized
treatment for substance use disorders and addiction is exciting and revolutionary; however,
obtaining relational consent for treatment, with the advances in research, must carefully apply
personal privacy protections and avoid illusory prognostication.146 Improving the personalized
management of substance use disorders and addiction treatment must not use paternalistically
coercive measures.147
Behavior modification strategies have proven to be ethical and effective in changing
‘behavior’ risks for heart disease, hypertension, diabetes, and some cancers. Behavior
modification should similarly be considered as relevant and ethical in managing substance use
disorders and addictive. The group of alleles that influence reward, reinforcement, and cognitive
effects of alcohol and illicit drug consumption can contribute to the management of behavioral
and pharmacological interventions. Research must be encouraged to utilize and apply scientific
discovery to initiate new therapeutic processes that influence brain behavioral changes for
populations susceptible to addictive disorders; through enhanced behavioral modification
therapies such as motivational enhancement, manipulation of genetic expression, manipulation of
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metabolic responses to substance, and alteration of prolonged excitatory sympathetic nervous
system responses to stress, beneficial therapeutic treatment modalities are potentiated.148
Evidence-based treatment for substance use disorders and addiction includes
pharmacological interventions such as medications to detoxify the drug withdrawal; these
medications are used to decrease the adverse effects of the physical manifestations.149
Decreasing the effects of withdrawal supports the physiological dependency consequences of
substance use; additional pharmacological interventions potentiates the alteration of behavior,
which seeks consumption by decreasing or altering the synapsis of the reward pathway.150
Altering the reward pathway of substance use is actualized through the administration of
pharmacological medications classified as agonists, partial agonists and antagonist; agonists
activate receptors by producing the effect of an ‘already intrinsic chemical substance, partial
agonists produce a decreased response, and antagonists can block an intrinsic reward response of
substance completely.151 Blocking the intrinsic reward response of a substance, decreases the
physiologic effect of the drug.
Alcohol indirectly increases the reward pathway of dopamine, by affecting the endorphin
and gamma-aminobutyric acid GABA systems.152 Pharmacological opiate receptor agonists
prevent the responses of neurotransmitter receptors that stimulate reward pathways. Scientific
research has indicated that the antagonist Naltrexone blocks the dopaminergic release or
euphoric response related to alcohol use, especially in patients who poses specific u-opiod
receptor gene alleles.153 ’ Additional studies have indicated that the GABA agonist Valium also
decreases alcohol use in patients who were treated; however, certain medications could cause
additional misuse and abuse.154 Other pharmacological drugs that are capable of blocking the
GABA effects on reward pathways have been developed and proven effective in animal studies,
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but significant effectiveness for treatment has yet to be determined.155 Alcohol acts upon the
central nervous system through neurotransmitter and neuromodulator systems by targeting
specific genetic susceptible target alleles; as a result, the complexity of the different genes
associated with alcohol addiction, brain system dysfunction, and reward system pathways
become actively persistent over time, resulting in resistance to treatment through current
pharmacological interventions.156 Alternate behavioral modifications and anti-reward or
decreasing stress interventions may be achieved in the future with the use of corticotropin
releasing factor 1 (CRF1) receptor antagonists or altered genetic expression of the corticotrophin
releasing hormone gene.
Understanding the advances of neural development and cognition as they relate to
consciousness, beckons concerns regarding the ethical implications to potential changes in
personhood and potential consequences of the ‘unknown’ affects for those who are at risk for
increased vulnerability; fear of deleterious neurological manipulation and change cannot be
ignored.157 Careful protections must be sought to avoid an increase of harm to persons and
populations. Rigorous application of bioethical principles must govern the advances and
application of new treatment programs; collaborative cooperation of the interdisciplinary team of
healthcare providers along with transparent processes of care, and high quality of authentic
decisional programs of care that support the decline of generational harms associated with
vulnerabilities of dependency are needed to successfully improve quality of care for dependency
and addiction disorders.
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Chapter 6 Relational Consent & Quality of Care for Addiction Disorders.
The need to Improve and implement a management of care paradigm for patients
diagnosed with substance use disorders and addiction requires application of the Institute of
Medicine’s (IOM)’s quality support measures, which were included in the 2001 report entitled,
Crossing the quality Chasm: A New Health Care System for the Twenty First Century. The
support measures include, ensuring the safe delivery of health care, ensuring health care
treatment processes are effective and efficient, ensuring programs develop and implement patient
and family centered care, and ensuring timely and equitable distribution of services.1
Additionally, the Substance Abuse and Mental Health Services Administration- Health Resource
and Service Administration (SAMHSA-HRSA), and the Center for Integrated Health Solutions
(2012), further specify inclusive goals of reducing harms in the management of care for those
diagnosed with substance use disorders and addiction by promoting improved prevention
strategies, assuring provisions for patients with self-management support, improving system
design changes in order to improve delivery of care, assisting in the formation of improved
communication strategies in order to implement best practices to ensure healthy living, and
improving clinical information systems to obtain current data collection measures that seek to
improve long term health outcomes.2
Improving communication, implementing patient and family centered care paradigms,
and developing strategies that improve innovative quality of care frameworks should include the
re-interpretation of consent processes for the treatment of any neurocognitive, neuroimmune or
neuropsychological disorders that increase the risk of vulnerability or harms, due to the
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pathophysiological changes that impair neurological functioning; this includes patients who
suffer from substance use disorders and addiction. By utilizing relational decision making and
implementing revised sliding scale competency consent processes, health care would identify the
need to skillfully implement reliable assessment evaluation tools and adequately determine
methods to assist those who struggle with decisional capacity and neurocognitive functioning as
a result of substance use disorders and addiction.3 Additionally, once neurocognitive dysfunction
and decisional competency impairments are determined, a comprehensive evaluation determined
to investigate the potential for the known alterations in neuroimmune dysfunction is also
essential in order to develop a comprehensive and successful treatment plan; which is associated
with the prevention of harms for the potential chronic exacerbations of neurological sequela that
further impedes functioning and decision making.4 A management of care paradigm is necessary
in order to decrease harms and chronicity of dysfunction that increasingly result in death.
Additionally, implementing a shared decision-making paradigm of care must attempt to
integrate holistic life management skills, such as employment retention, establishment of
stability in housing, increasing strategies to support social connections, ensuring access to health
care services and improving understanding of disease and disease services; assessing the quality
of treatment for substance use disorders and addiction requires careful data collection to enhance
program development that aims to reintegrate the patients continuously with social and
interactive community participation roles. By aligning to the national outcomes measurements
(NOM) project, implementing a managememt of care paradigm which seeks to decrease
mortality and morbidity associated with the increase in consequences of substance use disorders,
and addiction is possible.5 The complexity of such treatment goal interventions require assistance
from families and communities, and acknowledgement that individuals are strengthened through
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supportive social relationships; hence, enhancing the integrity of individuals through relational
support and empowerment that decreases the deleterious consequences associated with the rise of
substance use disorders and addiction pathology.
The phenotype of substance use disorders and addiction is changing. The observable
characteristics that result from the interaction of one’s specific genetic traits with the
environment is complex and multifaceted; this environment includes cellular functioning,
cellular expression, and neuroendocrine hormone functioning, and neuroimmune cytokine
communication that is yet to be fully discovered; consequently, promising advances assuredly
indicate that improving quality of care for those who suffer from the heritability of substance use
disorders and addiction must develop in order to drastically improve the care of an increasingly
growing vulnerable populations. The need to improve quality care initiatives requires
collaboration and shared decision making paradigms that assuredly seek the deconstruction of
stigma, the development of aggressive prevention strategies, the dissemination of monumental
educational initiatives and policy development that supports the paradigm of care that supports
the comprehensive medical and social anthropology through the realization that social
responsibility can empower individual responsibility and wellness.
6.1 Management of Care for Relational Consent.
Decisional capacity determination requires assessment of the person’s ability to provide
consent or refusal of care, with the understanding that the patient has normal neurological
functioning to adequately comprehend the important health information; additionally, the patient
must be able to communicate their choice for treatment consistently over time and be able to
understand the risks and benefits of their plan of care in relationship to their expressed choices.6
However, patients who are at risk for and are diagnosed with substance use disorders and
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addiction disorders are known to exhibit impaired decisional capacity; recent diagnostic
evidence, now supported by SPECT scans and functional assessment tools clearly indicate,
physiological evidence of neurological impairments that impact attainment of treatment goals.7
Yet, even with known impaired decisional capacity, current health care decision-making
processes continue to allow individual decision making versus shared decisional processes to
prevent harm and further dysfunction; this simple adjustment must occur in the management of
care for those who are diagnosed with substance use disorders and addiction.
Implementing strategies of relational consent in the management of care for patients
diagnosed with substance use disorders and addiction requires utilization of capacity for consent
assessment tools that identify the inconsistencies of decisional capacity for patients with
confirmed impairment of neurological functioning. The implementation of diagnostic assessment
tools that confirm the neurological impairments; protective measures aim to institute the
optimum application of evidenced based practice guidelines and for those who suffer from the
neurological dysfunction as a result of substance use disorders and addiction. Implementing
protection measures through relational decision making and relational consent for those who
suffer from the increased physiological dysfunction, associated with substance use disorders in
order to improve decisional capacity functioning, decrease risk of harms and vulnerability, and
decrease risk for comorbidity complications.8
It is time to implement decisional assessment tools that standardize a threefold shared
decision making model of care, by carefully examining the implementation of sliding scale
capacity assessments, implementing professional recommendations of care through evidenced
practice models of care, consistently, while also seeking a protective third party participation in
the plan of care; shared decision making with family or surrogate decision maker, contributes to
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the implementation of patient and family centered care, which seeks to decrease risk of
professional coercion and paternalistic care paradigms; similar assessment strategies, such as the
Aid to Capacity Evaluation (ACE) and the MacArthur Competency Assessment tool (MacCAT)
are being implemented in patients who experience neurological decline during the physiological
dysfunction of Alzheimer’s disease and Parkinson’s disease, in order to provide improved
quality of care and incorporate relational, family and person centered approach to care in order to
enhance the personal dignity, requires application of the scientific evidence in ways that have not
been implemented previously.9 Implementing a new model of aggressive medical interventions,
which seeks to alter the deleterious consequences of substance use disorders and addiction,
requires medicine to assuredly disband antiquated models of assigning individual stigma and
blame, by aggressively advocating for the standardization of comprehensive assessment
strategies, that include identifying the need for relational consent after the completed risk
assessment results indicate vulnerability.
The IOM’s Crossing the Quality Chasm: A New Health System for the 21st Century,
identified the evidence that supports that the health care delivery system is significantly falling
behind in translating scientific knowledge into ‘best practices.’10 Recommendation thirteen of the
IOM’s 2001 report on Crossing the Quality Chasm: A New Health System for the 21st Century,
states, “The Agency for health care research and quality should fund research to evaluate how
the current regulatory and legal systems facilitate or inhibit the changes needed for the 21st
century health care delivery system.” The thirteenth recommendation in the IOM report,
continues to state that modifications should be implemented to help health care providers and
health care organizations to professionally accomplish the six aims of the report which were
previously identified as care which is: safe, effective, patient centered, timely, efficient and
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equitable.11 The management of substance use disorders and addiction must effectively evaluate
how the current legal and medical system facilitates the perpetuation of impaired health care
outcomes for this disparate population.
Current regulatory and legal systems are influential in the trajectory of the perpetuation
of stigma, marginalization and discrimination of those who are diagnosed with substance use
disorders and addiction; to add insult to injury, the current commodification of vulnerable
persons as it relates to the sale of addictive substances such as cigarettes, alcohol, and bad food
specifically targets the poor, the vulnerable and the less educated populations.12 The theory of
commodification asserts the justification, that the sale of such products are permissible, because
they inform populations (or the vulnerable hosts) of the risk of harms, by placing warning labels
on products; however, the full disclosure of the comprehensive risk of harms for short term and
long term health is never fully disclosed; the market distributor or agent asserts that the provision
of a warning label is sufficient information. Unfortunately, benefiting the distributer financial
gains at the cost of human lives. Therefore, it becomes necessary for health care providers to
convey the essential and complex information to consumers as it relates to the gravity of the unforeclosed damages that the marketed substance use, like alcohol, cigarettes, marijuana,
genetically modified food, and long term effects of certain pharmaceutical products, which
actually causes harms to persons, decrease health and human flourishing. It is essential to
implement mechanisms a paradigmatic and revolutionary cultural change; one that insists on
social culpability.
Implementing an ethics of care paradigm that utilizes the re-interpretation of consent in
the management of care for substance use disorders and addiction, innovatively seeks to develop
practice standards that translate scientific knowledge into clinical practice; by delivering
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innovative addiction management care that safely fosters preventative and educational initiatives
to individuals and populations, by identifying social risk and reveal commodification marketing
strategies, that disregard the value of human life. Implementing an ethics of care paradigm
embraces patient centered care. An ethics of care seeks the respectful and responsive approach
that clearly delineates the value of each person and seeks the methods which seek to restore
optimal neurological cellular and immune functioning for individuals, by not allowing the myth
of free choice to be veiled by the chameleon of commodification, big money, neglect, and
biological coercion that distorts the physiological functioning of every humans person’s
psychoneuroimmunoendocrinology system’s normal physiological response.13
Relational consent in the management of care for those who are diagnosed with substance
use disorders and addiction should attempt to achieve standardization for all patients; the
opportunity to implement a standardized response to the current deleterious harmful sequela of
addiction should be clearly illuminated across every health care institution across America.
However, typical day across hospital emergency departments and hospital admission statistics
report in excess of 4.6 million drug related emergency department visits that included harm
related consequences from drugs in 2009; and the statistical numbers suggest large increases in
harms as a result of the 2016 statistics. However, the 2009 report, places the magnitude of the
problem, which indicates the severity of the problem; the 2009 report indicates the drug related
emergency department visits showed that fifty percent of harms included prescribed
pharmaceutical medications and about forty five percent involved non-prescribed use of abused
substances.14 The unfortunate truth reveals that acute health care systems have difficulty
managing the time and resources to adequately address the 422, 896 thousand cocaine reported
visits, the 213, 118 thousand heroin visits, the 93, 562 thousand stimulant, amphetamine and
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methamphetamine visits, the 658, 263 thousand alcohol visits, and the estimated 519,650
thousand combination alcohol and drug visits that occurred in 2009.15
Our Acute care health systems are developed to care for the acute and the ‘fast’
management of disease states of care interventions; for the drug, related emergency admissions,
this means that emergent medications are administered to restore immediate oxygenation
deficiencies, poor perfusion, and adverse homeostasis functioning that results in maintenance of
vital signs, restoring consciousness, and then the patient is discharged back into the community.
Acute care systems are not structured for ‘slow medicine,’ which could seek preventative and
supportive interventions. Current health care organizations are not structured to implement care
paradigms that holistically consider the comprehensive pathology of addiction and seek the longterm amelioration of individual care.
Yet, a system that proactively and aggressively implements evidenced based practice
strategies to this large portion of the population should occur; acute care hospital systems are not
foundationally structured, in managing the resultant psychoneuroimmunoendocrinology long
term, chronic nature of substance use disorders and addiction of this magnitude. Albeit,
becoming responsive to the sequela of complications and comorbidities that substance use
disorders and addiction science reveals, must urgently seek to achieve advances in long term
quality care for patients through the reduction of risks, initiating processes of change, changing
the socio-political environment, and through the reinvention of care; the reinvention of care,
begins with immediate implementation of relational consent processes for the holistic
management in relationship for the of 4.5 million patients who are admitted to the emergency
department each year as a result of drug related hospital emergency room visits.16
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The implementation of standardized screening, standardizing diagnostic tests, and
implementing relational consent processes for incorporation of intervention paradigms, which
seek to connect patients to the resources that safely provide treatment, care and self-promotion
for a life of wellness can be proactively established. The reinvention of care for substance use
disorders and addiction, requires clear and definitive language that indisputably labels addiction
as a physiological disease state that is greatly influenced by sociocultural and epigenetic
circumstances; the reinvention of care for those with substance use disorders and addiction as a
phenotype that embraces the potential for human flourishing must begin with acute care
identification and interventions that are committed to the long term chronic disease measurement
programs.
a. The Phenotype of Addiction.
Implementing a relational consent strategy for the specific treatment of patients who are
diagnosed with substance use disorders and addiction is necessary in order to develop individual
assessment strategies that address the particularities of physiological dysfunction specific to the
neurological alterations associated with impaired functioning, that present as disordered and
fluctuating states of decisional capacity.17 The relational consent processes implement mandatory
standardization initiatives during the acute care emergency department hospitalization admission.
Admitting hospital documentation requirements include the completion of past medical history,
physical, and assessment standardization, which includes history of present condition, past
medical history, history of medication use, history of illicit drug use, history of alcohol use,
history of physical abuse, post-traumatic stress syndrome, history of past medical conditions,
history of mental health conditions and a comprehensive systems health assessment. During this
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admission process, the determination of standards related to decisional competency must be
evaluated simultaneously with determining the cause of admission.
Concurrently, determining the potential for substance use disorders and addiction should
be carefully evaluated. The incorporation of obtaining appropriate diagnostic tests that support
the evaluative diagnosis should be incorporated in the standardized plan of care. By carefully
implementing and documenting the collection of information, the health care environment
responsively and attentively begins to determine the pathology of disease and therefore
preemptively screens with inclusive diagnostic testing criteria, evaluates for the potential of
neurocognitive vulnerability and conclusively seeks to acknowledge that the phenotype of
addiction is an authentic disease, which requires careful evaluation. Completing a simplistic
neurological assessment that quickly determines if a patient is oriented to person, place and time
does not comprehensively evaluate, whether or not the patient has executive decisional
competency.
When a patient is admitted to the emergency department after a motor vehicle accident
and substance use is identified as a prospective or suspected coexisting condition in one of the
hospitalized patients, the current admission assessment strategy includes the completion of serum
alcohol and serum drug testing levels; once the admission assessment indicates actual use of
substance, or is determined to be ‘under the influence’ during the health history or the physical
exam is determined, basic neurological assessments are completed that seek the patient’s
knowledge of who they are as a person, by verbalizing their ‘name’ and stating their recognition
of their personal orientation to place and time. If the patient verbalized orientation to person,
place and time, health care providers seldom question the agency of the patient, through an
additional or more comprehensive evaluation.
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However, when completing a comprehensive cardiac assessment, health care providers,
place the patient on a heart monitor, assess a 12 lead Electrocardiogram, complete serial blood
pressure readings, monitor oxygenation levels through pulse oximetry, and obtain serum blood
work, which includes electrolyte levels that affect cardiac functioning, inflammatory markers
that determine myocardial wall damage, and lipid panels to determine possibility for
atherosclerosis. If any of the above mentioned diagnostic criteria indicates suspicion of the hearts
decreased functional capacity, additional and more invasive diagnostic procedures are
implemented, such as invasive cardiac catheterization to determine potential blockage of
coronary artery blood flow to the heart.
Yet, even when more than 4.6 million patients are admitted to hospital emergency
departments with known consequences and harms from drugs and hundreds of thousands of
patients are confirmed through admissions with complications and comorbidities of substance
use disorders and addiction from prescribed pharmaceutical medications, marijuana, cocaine,
heroin, stimulant amphetamines, methamphetamines, and alcohol additional assessment criteria
that scientifically indicate the need for additional diagnostic evaluations that could include serum
blood draws to evaluate inflammatory markers, elevated neuroendocrine hormone levels,
completion of single photon emission computed tomography scan, or neurocognitive
competency assessments are never completed to determine the extent of neurocognitive
impairment as a result from the ‘known’ substance use.
Due to the nature of heritability, the deleterious effects on future generations and entire
populations are at stake; therefore, ignoring and neglecting to identify the influences of the
complexities associated with the neurobiology and heritability of substance use disorders is
professionally irresponsible, causing great harm to millions of patients across the country yearly.
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This neglectful approach to care reflects the anthropology of addiction that reflects the social
client effectiveness anthropology of addiction, which focuses on the adherence to the
individualistic moral agency blame approach of addiction, by assuming that the ‘client knows’
the risk; but purposefully avoids self-motivation to seek intervention. The contemporary
phenotype of addiction, can no longer allow constructs of stigma to overshadow the professional
care for those in need of responsive treatment interventions for substance use disorders and
addiction; illuminating the need for aggressive diagnostic standards is essential. The validation
of the medical diagnosis that requires the implementation of a treatment plan illuminates
responsible clinical practice; the implantation of the new anthropology of addiction validates the
medical patient as partner and through the constructs of a relational social human person
anthropology standardizes, which deserves a comprehensive diagnostic evaluation that imitates
all other evidenced based diagnostic processes in current medical practices.
Therefore, seeking an anthropology of care, eliminates unnecessary suffering for future
generations.18 Developing an agreeable and consistent construct of the addiction phenotype is
difficult, diverse and conflictual; however, by adhering to the basic standards of phenotype
development, the construct should no longer illicit restrictive and cultural barricades that are not
based on scientific evidence. Such barriers, negatively influence the development of quality of
care paradigms from being actualized for those who suffer. Our current paradigm of care
neglectfully discharges hundreds of thousands of patients each day, without implementing a
long-term commitment treatment strategy that promotes human care.
The phenotype of substance use disorders and addiction, consistently demonstrate a set of
observable characteristics as stated in the American Psychiatric Association’s Diagnostic and
Statistical Manual 5th resource manual; the nuances of adjusting language, between old
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Diagnostic and Statistical Manuals have never disregarded the physiological and psychological
nature of the disease. Scientific research, extensively and continuously explicates the cellular,
genetic, and epigenetic nature of addiction, validating the complex physiological processes that
characterize the interactions of individual traits and the environment that are transmitted from
one generation to another. Additionally, the phenotype of substance use disorders and addiction
specifically calls for the implementation of relational strategies that incorporate collaborative
decision-making processes in order to combat the contributory genetic, epigenetic and
neuroimmune processes that lead to neurocognitive impairments, neuroimmune inflammatory
states and the resultant psychological comorbidities of disease that can result in inhibition of
behavioral control.19
While, examining the phenotype of substance use disorders, dependency and addiction, it
becomes evident that the physiological and progressive inability of the patient to reverse one’s
own neuroimmune inflammatory state, which impairs oxygenation, perfusion, and therefore
behavioral tendencies, will ultimately effect executive control, affective functioning, cognitive
ability and therefore autonomous decision-making.20 Additionally, the neurological dysfunction
impairs the ability to interact with external environment stimuli, communication, escalates
physiological responses to stress, impairs immune response, alters memory functioning, and
impairs executive control functioning; this neurological dysfunction necessitates the care of the
‘other’, requiring the assistance of care and the support of care, which is no less than the care of
the person with cardiac dysfunction through professional guidance.21
The formulation of shared decision-making and the implementation of re-interpretation of
consent for treatment is a necessary component to enhance functional ability and improve health
outcomes for patients who experience physiological decline of neurological functioning; the
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imperative to deconstruct stigma, decrease, vulnerabilities, dismiss antiquated treatment
programs, and improve quality of care requires the assured dissemination of an addiction
anthropology that clearly defines the phenotype of addiction and eradicates the deleterious
consequences of a culture that inflicts exponential harms on the ‘other’ through constructs of
complacency and marginalization.
The phenotype of addiction is a physiological prototype of human survival that is
influenced by the complex genetic, epigenetic, neurocircuitry, and neurobiological influences
that progress into negative physiological, psychological and societal functioning; previous
cultural norms ascribe addiction as a construct of human weakness, sin and repulsion. Yet, the
phenotype that identifies people through the constructs of weakness and sin, existed prior to the
scientific evidence that clearly illuminates that the historical construct potentiates an even larger
cultural and social consequences of harms for those who suffer from substance use disorders and
addiction. Action, which is responsive, attentive, aggressively based on evidence, applies
professional and scientific knowledge through the implementation of responsible and
accountable treatment paradigm shifts. Richard Brodie, correlates the communication of ideas,
such as stigma, paternalism, authoritative justification and judgment paradigms as viruses of the
mind.22 Viruses of the mind can occur through language, culture and performative actions that
have the potential for irreversible consequences if not evaluated reflectively.23 An ethics of care
does not ascribe to ethics as a practice of rules ascribed from an authoritative judgement. An
ethics of care focuses on the ordinary and intrinsic human accomplishments that results from
thought, speech, and actions toward the other; dissemination of educational initiatives that
promote relational support, provision of educational initiatives, in order to reduce harms for
those who are diagnosed with substance use disorders and addiction, promotes prevention
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strategies, improve delivery of care, implement best practices that ensure healthy living and
ensure long term health outcomes.24 An Ethics of care approach to the management of care for
substance use disorders and addiction, embraces the intrinsic actions of responsive and
responsible health care delivery versus the radical neglect of ‘the other’.25
b. Disseminating a Relational Education Paradigm.
Educational initiatives must clarify the etiological causes of substance use disorders and
addiction in order to eradicate antiquated constructs of shame, blame, and stigma by properly
providing shared responsibility of care for individuals, families, and communities through social
systems that embrace an ethics of care framework that work toward improving quality of life for
those who are presently disempowered and marginalized.26 Cultivating a culture of relational
care versus stigmatization and blame for those susceptible to substance use disorders and
addiction will require a radical cultural shift from seemingly ingrained cultural and social
constructs of social deviance; constructs of social deviances at the turn of the century included
interracial marriages, artificial contraception use, and homosexual activity.27 Yet, as social policy
and regulation of laws have emerged to encompass more compassionate constructs that portray
the true dignity of each human person, social constructs that previously criminalized prescribed
cultural actions as deviances, are no longer permissible by law.28 It is the role of health care
providers and systems to holistically care for the ‘other’ and not to determine that care based
upon constructs of bias and stigma.
Disseminating a relational educational model that emulates the initiatives of the HIV/
AID’s epidemic of the 1980s as an educational paradigm of care, that influenced a pendulum
shift in the cultural climate related to the associated stigma and marginalization of male
homosexuals and intravenous (IV) drug users was successful in decreasing the harms associated
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with an aggressive virus; disseminating educational paradigms of care to decrease disease
transmission, successful dissemination of disease prevention strategies and empowerment of the
vulnerable immerged through the slow development of social policies and care paradigms that
sought to increase public policy awareness and quality of care initiatives through educational and
social reform.29
National health care quality initiatives for the prevention and care of HIV and AIDS
actively disseminated complex care programs in order to provide equitable dissemination of
prevention, safety, improved quality of services, access to timely services, and realigned
constructs of blame toward individuals to refocus on national prevention strategies that included
efficient and effective care processes that sought patient and family centered care approaches
that helped to decrease stigma and marginalization.30
National health care initiatives are needed to focus on the prevention of addiction
education and dependency dysfunction by utilizing similar care strategies that tackle the
complexities of social constructs through the de-stigmatization of individuals and seek to
eliminate fear, isolation and individual marginalization strategies, the successful dissemination of
improved prevention strategies are needed. By offering quality service education initiatives that
seek to implement individual and family support programs, which focus on incremental severity
of disease and through the adaptation of early school aged education through adolescent
education initiatives that address the nature of the disease and various stages of use and risk for
those most susceptible.31
Instituting public health policy change requires initiating grassroot efforts that
transparently reveal statistics of heritability, likely hood of ‘at risk populations’ and the
distribution of those statistics publically in order to share essential health research education with
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communities. Grassroots initiatives can provide distinct examples of how public health initiatives
can reduce the development and progression of disease. This public health phenomenon was
witnessed by the benefits of syringe distribution centers and medical outreach care, which was
offered to patients within community street services for those who were at risk for HIV and
AIDS. French policy significantly changed from a curative policy of ‘drug abuse treatment to a
preventative policy of drug use’ in the 1990’s, when awareness of initiatives was implemented to
decrease the transmission of HIV and AIDS; prompting government policy to begin looking at
public health initiatives to support community wellbeing.32 With the help of the media and
dissemination of information related to the distribution of ‘clean’ needles and its known effect to
stop the transmission of HIV and AIDS circulated; the public’s response began to support the
population health incentives that supported transformative management of drug use.33
Additional interventions such as the development of methadone clinics also revealed the
decline in HIV transmission.34 Such discoveries and information transmission certainly can shift
the restrictive power of governmental authority. Additional use of the media is needed to
accurately disseminate health research information and to reframe substance use disorders and
addiction from an individual weakness toward a more conclusive social responsibility and
expansion of health promotion.35 Education and research must redirect the harms of addictive
substance use from incarceration to treatment.
Education and research regarding substance use disorders, addiction, and management of
care requires implementation of interventions that decrease susceptibility to genetic inheritance,
behavior modification therapies, and pharmacological intervention to prevent deleterious
consequences of use. Genetic inheritance of disease is evident by changes proven to occur with
alterations of gene expression after drug use and sustained periods of stress. Central nervous
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system responsiveness to the changes in perceived stress and wellbeing after drug consumption
can be permanently altered.36 Understanding the genetic predisposition of substance use
disorders and addiction becomes relevant knowledge that requires improved dissemination to
individuals, families and communities within the nature of progressive continuum and
management of disease, versus personal failure, shame and blame. The strong genetic and
epigenetic alteration of gene expression along with the advances in neuroimmunity provides the
public health discourse support for seeking programs that voluntarily enhance motivational
change techniques as a viable methodology of treatment.37
Ethically justifying relational methods of treatment should be available for those who
suffer from substance use disorders and addiction over incarceration. Personalized options to
participate in treatment programs have been studied to improve outcomes of some offenders. By
being treated with dignity and respect, individualized and relational plans of care can be
implemented. Due to the nature of addiction, implementing an ‘all in one’ treatment intervention
cannot be realistic or effective. Given the nature of influences that affect substance use disorders
and addiction, particular treatment modalities must address the specific implications of the
commodification of the human host by addressing the specific agent and environmental
influences that negatively impact the contributory societal constructs of coercion to
influences market consumption.38
Lastly, education initiatives must inform populations and communities how enhanced
participation in medicalized prevention and controlled pharmacological recovery initiatives,
assist the physiological processes of healing the neurological alterations that occur with sustained
substance use and addiction. Increasing the knowledge and implementation of
pharmacogenomics in substance use disorders and addiction treatment is an essential
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management option and is increasingly noted as an essential element of recovery.39 It is essential
that relational education paradigms clearly provide the transparent scientific evidence to improve
paradigms of management of care. Community populations are leery of medicalization and
pharmacological interventions that seek to decrease the isolative and physical responses to
addiction. However, due to the increased knowledge of neurotransmission, neuroimmune, and
stress responses that influence substance use disorders and addiction, pharmacological,
pharmacogenomics, and evidenced based psychosocial treatments such as motivational
interviewing, and social skills training dramatically improve patient outcomes.40
Current pharmacological treatment management for alcohol use disorders include:
naltrexone, disulfiram, and acamprosate and pharmacological treatment management for opioid
use disorders include: the opioid agonist methadone, medicalized heroin, buprenorphine and
naloxone.41 These treatment options are controversial because medicalizing heroin inflicts fear of
legalization, and methadone clinics potentiate increased consumption as a result of treatment
intervention use along with street drug use; additionally, naltrexone and Valium use could also
potentiate further misuse for the one who suffers from substance use disorders and addiction.42
Historically, educational information was delivered via passive education strategies,
today active family involvement and community participation in education initiatives must be
implemented for prevention strategies to achieve the desired effects.43 Education initiatives
should seek the skills of medical providers coinciding with family and supportive community
participation; implementing a relational and a holistic approach to the management of care,
which includes education is necessary. The annual 2013 National Prevention, Health Promotion,
and Public Health Council implemented a prevention of substance use and excessive alcohol use
recommendation by presenting fourteen actions to promote the prevention of substance use
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disorders. They included: screening, intervention, referral to medical treatment programs, along
with resources for parents, resources for schools, recognition enhancement, prevention
intervention, and decision-making education, such ‘as just think twice.’44
Yet, this standard of care has yet to be implemented in 2018 as a standardization process
or initiative across American emergency departments. Screening interventions are not
incorporated, referral to medical treatment programs are not consistently achieved, stigma free
resources are not offered, nor are decision making education optional consistently provided for
family members during an acute substance use or addiction crisis. An ethics of care paradigm,
which seeks to implement relational consent and shared decision making actualizes professional
responsibility and accountability in revolutionizing the expansion of community participation of
family and relational involvement, which necessitates community response during this national
health crisis. Improving quality standards in order to seek decreasing vulnerabilities in patient
care is imperative.
6.2 Improving Quality and Decreasing Vulnerabilities in Patient Care.
Improving quality and decreasing vulnerabilities in patient care requires cultural
redevelopment of national prevention strategies, improvement of diagnostic testing,
implementation of national educational initiatives, and implementation of constructs of care that
aim to increase community support and decrease marginalization and criminalization for those
who are susceptible for substance use disorders and addiction; measures include providing
reliable and safe standards that improve quality of care, improve interventions that address
vulnerability as noted in determinants of health across populations, and provide equitably
delivery of care for disparate populations at risk for substance use disorders and addiction.45
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Decreasing vulnerability, disseminating and initiating cultural change in order to improve
quality of care delivery requires prompt and nonjudgmental access to care versus treating
individuals at the severe end of the addiction spectrum disorder as outcasts and products of
extreme social deviance through criminalization; through implementation of empathetic and
positive professional support strategies, non-punitive crisis intervention, and empowerment of
communities, families, and health care systems posit influences of relational empowerment
toward wellness, recovery and human flourishing.46
Improving quality of care for those who suffer from substance use disorders and
addiction require a comprehensive public health investigation that holistically attempts to seek an
epidemiological perspective that helps to determine effectiveness of current intervention policies.
The epidemiological research on substance use consumption indicates an overall decline in drug
use since the 1990’s; however, the research also indicates that heavy drug consumption
consistently occurs in increased magnitude across urban and metropolitan sections of
disadvantaged populations. Records evaluated in hospital emergency departments determine this
evidence.47 The prohibition of drugs in the U.S. is undoubtedly failing; proponents of the
decriminalization of drugs began in the 1980’s when Baltimore Maryland’s Mayor Kurt L.
Schmoke proposed a national debate, which supported the decriminalize illicit drugs.48
Mayor Schmoke was a visionary politician and a Harvard Law graduate who starkly
agreed that ‘the nation should have a war on drugs, but that the war should be primarily a public
health war and not a criminal justice war.’49 Similarly, substances such as tobacco and alcohol
are addictive substances that can predict patterns of future substance use behaviors and disorders.
Both tobacco and alcohol consumption have been widely researched over the past few decades
and the research reveals the implications of the long-term healthcare consequence; this research
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is statistically significant. Tobacco and alcohol use combined account for more than five hundred
thousand deaths per year.50 Tobacco and alcohol use is legal in the US; however, in an attempt to
restrict consumption and in an attempt to increase prevention, age restrictions for purchasing
were initiated and are sustained through policy restrictions. Mayor Schmoke’s visionary
expression and idea to decriminalize drugs did not attempt to de-emphasize law; rather he
recognized and wanted to learn from similar trends and progression of organized crime and
violence from the prohibition of alcohol in the 1920’s.
Mayor Schmoke recognized the correlation between prohibition of drug use in the 1980’s
with the prohibition of alcohol in the 1920’s. Both prohibitions brought about increased crime
and harms, which ravaged the American people; however during the prohibition of alcohol, the
American people recognized that the harms of prohibition outweighed the benefits from
restrictions.51 As a consequence, the U.S. government lifted the ban on alcohol and legalized its
consumption. Since that time regulatory laws have become part of U.S. legal structures and the
management of health consequences from alcohol consumption has become part of the public
health management of care. Regulation of alcohol and tobacco currently includes restrictions of
use through high taxation, restriction in purchasing, and restriction of availability of sales.52
If the scientific community recognizes the escalating pattern of evidence that supports the
medical model of substance use and addiction, and science has identified the relationship
between the pathophysiological and neurological mechanisms that physically influence
substance use disorders development and addiction, then how can criminalization of disease
progression adequately deter substance use.53 The medical model also clearly indicates that
addiction is a chronic and recurring disorder by the very nature and complexity of the disease;
attempting to solved advancing drug use through criminalization becomes a very ineffective way
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to attempt to solve the national problem. Consequently, the premise that drug users ‘are’ criminal
and need managed through incarceration only greatly underscores scientific evidence and the
medical model of substance use and addiction science. The prohibition of drugs and the
criminalization of drug users is confusing, narrow, and misguided.54 Hence, the unsatisfactory
results of the current ‘War on drugs.’ Instead, criminalization of drugs has enabled
marginalization of populations, increased market costs of illegal substances, increased risk for
death and disease progression, and increased crime through black market trafficking.55
Those in favor of continued prohibition of all illegal substances argue that the current
‘War on Drugs’ and criminalization protects children, decreases crime, prevents immorality, and
prevents further addictive substance disorders.56 The criminalization debate focuses the need for
laws against select substance users and addicts because of the moral debate that indicates the
debasement of humanity with the use of substances such as heroin and cocaine.57 This moral
claim suggests that tobacco shortens an addict’s life, but that it does not alter the ‘human soul’ as
does the effects of cocaine and heroin; therefore ‘criminalizing certain ‘drugs’ as morally
justified according prohibition proponents. However, the debate does not satisfactorily discuss
the same ‘soul’ altering consequences as a result of harmful use of alcohol; despite the fact that
the consequences of other illicit drugs result in similar harms to individuals.58 Morally
correlating the use of ‘substances users’ as criminal only supports ‘social discrimination’ and
social isolation. Hence, encouraging community education and support through proper
management of care is the necessary intervention in order to improve quality and decrease the
perpetuation of vulnerability. Scientific evidence correctly identifies substance use disorders and
addiction through physiological and neurological impairment of functioning; therefore,
improving quality requires actualizing the phenotype of addiction through scientific constructs,
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not historical culturally and social constructs that were not based on evidence. Criminalization,
unjustly increases human vulnerability; as a result, only focusing on the host’s susceptibility to
substance use disorders and addiction through criminalization. This outlook, substantially
increases vulnerability for future generations and humanity as a whole, without improving the
comprehensive nature of substance use disorders and addiction through health care quality
improvement initiatives, which failed to recognize or acknowledge the public health model of
care, by highlighting the need to focus management through all three points of care, including
the individual host, the distributor agent and the environment. 59
a. Improving Quality
Application of similar initiatives to improve health quality and decrease unnecessary
deaths as a result of complex systems failure in hospital organizations should be systematically
applied to the development of complex systems approach to improving quality and health
outcomes for the management of substance use disorders and addiction; the care paradigm shift
for the treatment of dependency disorders and addiction must incorporate sustainable public
health goals. An estimated sixty-seven billion dollars a year are spent on the management of care
for illicit drug use and misuse; yet, over sixty-four thousand United States citizens died in 2016
from over dose deaths alone and over eighty-five thousand persons per year die from alcohol
misuse.60
Implementing systems changes that seeks to improve the quality of healthcare delivery
for those diagnosed with substance use disorders and addiction must recognize the importance of
constructing care models that avoid the implementation of punitive and devaluing responses to
individual error and misjudgment in health care decision-making.61 Application of improving
quality of care for those who suffer from substance use disorders a and addiction require the
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same application of dignity and respect in order to eradicate social stigma and eliminate
perpetuation of perceptions of social deviance.62 Seeking quality methods to improve the care of
addiction includes accurately assessing the National Outcomes Measurements (NOM)s criteria,
which include improving recovery treatment centers, increasing trained employment retention,
decreasing criminal justice involvement, increasing stability in housing, increasing social support
systems, increasing access to services, increasing affordability of medical costs, continuing the
use of evidenced based treatment programs, improving patient perception of care, and improving
rates of abstinence when indicated.63
Improving quality of treatment for this disparate population is certainly compounded by
the complex nature of neurological dysfunction and its effect on decisional capacity of
individualized care; quality improvement initiatives that utilize an ethics of care framework,
which provide a unique opportunity to ensure the relationality of supportive care environments
by embracing collaboration, implementing shared decision-making processes, seeking to
disseminate evidenced based treatment standards, deconstructing stigma, while also instituting
rigorous strategies that hold patients accountable for responsible and responsive behavior
initiatives that seeks to increase cooperation in the treatment plan through partnership. Increasing
partnerships provide the relational hope that encourages the enhancement of a lifelong supportive
commitment to physiological, and psychological recovery that holistically values the personal
wellbeing of the ‘other.64
Improving patient outcomes and quality requires an examination of the essential
components of healthcare quality. A focus on quality acknowledges that the patient is the
primary focus of all healthcare services. This focus for those with substance use disorders and
addiction, should adhere to the evidence that supports patient safety above all other aspects of the
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healthcare delivery system; patient centered care acknowledges that the purpose of healthcare
functioning should adhere to global norms, application of evidenced based practice, and require
professional excellence standards nationally that support the management of care from acute care
transitions of care, through acute care hospital discharge, and into long term coordination of care
treatment access across the lifespan.65 As previously mentioned, In 2001, the IOM’s report,
Crossing the Quality Chasm identified six goals, which are necessary in order to improve the
overall quality of healthcare delivery. The goals were to, ensure safe healthcare, ensure effective
healthcare, to ensure patient-centered healthcare, to ensure timely healthcare, to ensure efficient
healthcare and to ensure equitable healthcare.66
Quality of care for healthcare has been specifically defined by the IOM. The IOM’s
definition of quality emphasizes on patient outcomes to the ‘degree to which health services for
individuals and populations increase the likelihood of desired health outcomes and are consistent
with current professional knowledge.’67 However, quality entails a broader perspective of
measurements rather than just the analysis of patient outcomes. Additionally, outcome
measurements should include a broad criterion, one that views abstract and subjective concepts
like patient satisfaction with life, patient feelings of well-being, patient perception of optimal
social functioning, physical functioning, functional and social outcomes and mortality.68
Unfortunately, healthcare often focuses on more measurable outcomes, unrelated to patient
perceptions of functional limitations. Healthcare services and healthcare interventions can inflict
an array of unintended side effects that change a patient’s quality of life. In order for healthcare
to truly examine the full range of organizational quality issues, healthcare quality should include
a complex analysis and examination that includes healthcare processes, structures, and outcomes
for this desperate population.69
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Healthcare quality should evaluate all three types of quality improvement measurements
in the management of care for substance use disorders and addiction as specified by the
Donabedian Triad; recognizing the importance and connection between processes, structures,
and outcomes.70 Quality processes involve the examination of the entire patient experience.
Process examination includes efficiency, timeliness, and effectiveness of the entire healthcare
experience for the patient. The examination of healthcare quality structures requires an
examination related to the adequacy of equipment, professional training, and environmental
influences. Then, in conjunction with process and structure evaluations, the evaluation of patient
outcomes can more holistically be obtained. This examination of patient outcomes critically
requires inclusion of all three components of Avedis Donabedian’s taxonomy.71 Evidenced based
practice (EBP) assists in providing quality healthcare, by utilizing research to scientifically
determine patient outcomes in relation to best clinical practices. EBP was formulated upon
clinical research trials that seek improvement initiatives by gathering information about medical
processes and outcomes; hence, allowing research to translate into best practice protocols.72
Evidenced based practices in the management of care for substance use disorders and addiction
should promote public systems or organizational, transparency and accountability.
Developing organizational systems of care that value quality requires moral
responsibility. Organizational moral responsibility and values of organizational transparency and
accountability are leading components within the organizations operationalized functioning
processes. This operational process includes the implementation of an organizational ethics
paradigm that should recognize that the patient as the valued center of all healthcare services.
The operational process should also recognize that healthcare systems are complex systems that
work at the edge of their operational capacity.73 When systems work on the edge of their
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operational capacity, the system experiences hazardous and stressful situations that require the
pulling together of multifaceted relationships between participants.74 High reliable
Organizations(HRO)’s attempt to anticipate problems and develop systems to avoid accidental
injury or hazards in the work environment. High reliable organizations in healthcare are
organizations that are committed to a culture of quality and safety for patients consistently over
time.75 Yet, the commitment to culturally high quality and safety management of those who are
diagnosed with substance use disorder and addiction, experience poor and inconsistent quality of
national standards; this development requires, significant leadership change that is able to
foresee the need for transformational care change. The Transformational leadership required for
the management of substance use disorders and addiction requires implementing the social
principle of ‘shared-decision making.’76 This commitment to excellence in health care delivery
for substance use disorders and addiction care, requires the implementation of standardized
evidenced based practice guidelines, and clinical pathways to ensure consistency in best practice
implementation.77
The American Society of Addiction Medicine, developed comprehensive practice
guidelines entitled: National Practice Guideline for the Use of Medications in the Treatment of
Addiction Involving Opioid Use, addressing the opioid epidemic, June 1, 2015 in the U.S.78 Their
recommendations included: assessment and diagnosis of opioid use disorders, treatment options,
treating opioid withdrawal, treatment recommendations for the use of methadone, naltrexone,
buprenorphine, psychosocial treatment in conjunction with medication interventions for opioid
use disorder, and special considerations for specific vulnerable populations.79 Yet, the
standardized implementation in application on organizational levels have yet to be formally
established. Additionally, the guidelines do not suggest how to initialize standard processes of
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care at ‘ground’ zero in our nations emergency departments. Other diseases that present in
emergency departments across the country, have standardized emergent practice guidelines
initiated to prevent heart, liver, or kidney organ failure; yet, the implementation of addiction
management with the aim to prevent acute and chronic ‘brain failure’ or neurological health
consequences have not been prioritized in health care institutions beyond the acute management
of care for the physiological prevention of death for acute overdoses. The implementation of
medical or health care follow up beyond the acute overdose state is simply perceived as an
individual person’s choice; standardized guidelines at this point are not materialized, under the
false guise of individual autonomy.
To make matters worse, health care organizational systems have yet to implement the
American Society of Addiction Medicine’s practice guidelines universally; presupposing, that
the long-term ability to adequately address the chronicity of addiction is not likely to be achieved
under the current instantaneous, quick and easy fix ‘fast’ medicine paradigm; the current medical
paradigm of acute medicine should not justify the disconnection of care.80 The department of
Veterans Affairs (VA) instituted national initiatives to implement practice care guidelines across
all levels of care for veterans who are at risk for substance use disorders, consistently since
before 2005; The updated practice guidelines were published in 2015 as a result of carefully
evaluated research, which shows standardized practice guidelines that reach out across the care
continuum as a necessary process and provide effective management benefits for veterans who
suffer with substance use disorders and addiction.81 These practice guidelines hope to achieve the
following outcomes: First to assess the patient’s individual condition and implement
collaborative patient involvement for the implementation of the best treatment methodology.
Second, the VA hopes to optimize each patient’s recovery by eliminating or decreasing
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substance consumption. Third, the VA hopes to improve the patient’s health outcomes and
comprehensive wellness, by assisting the veteran to live a self-directed life style and to reach
actualization of one’s own health goals. Additionally, the VA hopes to decrease associated
comorbidities of disease through the implementation of patient-centered care.82 Achieving
optimal patient outcomes requires implementation of patient, physician, organizational
collaboration and shared decision-making strategies,
b. Collaboration and Shared Decision-making.
An ethics of care incorporates the essence of nurturing and nurturance as a fundamental
principle necessary in personal interactions with another, through collaboration, improving
quality of care and share decision-making. This aim is often difficult to achieve in the
institutionalism of healthcare. However, dissemination of educational initiatives to reconnect
families and communities within a world that isolates one another because of a sense of the
necessity for individual autonomy without considering the developmental necessity of social
constructs of connectedness, and relationship, families and communities often find themselves
without the supportive tools to increase relational strength. Relational strength is a fundamental
method to decrease human vulnerability, for those who are at risk for harms by the coercion of
substance and market systems; implementing an organizational systems approach to achieve an
authentic collaborative management of care framework necessitates shared responsibility of
patient and societal outcomes.83
Including the patient and the patient’s social support systems as valuable, collaborative
and relational members of the health care team becomes a relatively new concept in the
application of health care decision-making; a cultural shift that still requires the careful
deliberation in identifying the preferences, values, and engagement of individual stakeholder’s
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health needs, while also ensuring partnerships of trust and open communication.84 Partnership
development requires the establishment of shared treatment goals, shared plan of care strategies,
clear identification of team member roles, development of clear communication networks, and
establishment of patient health outcome goals.85
The IOM’s report in 1999, To Err is Human: Building a Safer Health System determined
that errors in healthcare occurred through faulty system failures, not because of the recklessness
of an individuals or individual groups.86 This realization was the result of a collaborative
research initiative that sought to find answers to the ever-growing problem of adverse events in
healthcare. The current system of managing the care of those who are vulnerable to substance
use disorders and addiction is perhaps the most silenced error of neglect of all times, as a result
of ethical blind spots and viruses of the mind, which unknowingly extinguishes the breath of
those most vulnerable through the loss of life from substance use disorders and addiction.87
The IOM’s recommendations include creating national leadership, improving research
and education, implementing reporting systems, increasing performance standards, and
implementing organizational wide safety systems, in order to prevent system errors.88 Additional
reflection on scientific evidence, the admission that erred cultural understanding related to
disease pathology and the courage to communicate the facts are necessary. The IOM report
strongly supported system enhancements strategies to improve communication and deliberation
processes within healthcare organizations. Communication and deliberation process serve to
heighten ethical decision-making capabilities of the organization. Ethical decision-making
capabilities that improve patient safety recognize the importance of shared decision-making
processes amongst all stakeholders in order to improve the functioning of the entire system.89
Why should processes to improve the outcomes of substance use disorders and addiction, adhere
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so stringently to individual autonomous methodology that require individuals with known
neurological dysfunction, to navigate the terrain of illness and dysfunction alone.
Since the publication of To Err is Human, healthcare continues to talk about iatrogenic
harm and error in a drastically different way; yet, its application to the exponential harms
associated with substance use disorders and addiction are rarely if ever included in the ultimate
cost of healthcare error.90 The organizational discussion switched from recording individual
incident of errors to the development of processes that decrease iatrogenic harms, or processes
that aim to prevent iatrogenic harms from even occurring, through relational guidelines and
policies of checks and balances. This system wide deliberation process seeks to develop quality
leadership that promotes accountability and responsibility in building a culture of accountability
and safety versus a culture of individual patient blame.91
An open organizational system that encourages inter-collaboration, relational deliberation
and patient and family centered decision-making requires transformational leadership that
recognizes the importance of innovative change, which is necessary for the management of
substance use disorders and addiction.92A transformational leader in addressing the issues of
substance use disorders and addiction quality initiatives openly respects the collaboration of
individuals to efficiently pursue individual, community, and organizational desired goals.93
Transformational leadership in healthcare requires implementing the social principle of ‘shareddecision making in the management of care to decrease the deleterious consequences of current
substance use disorder and addiction management.’94
Additionally, deliberation and decision-making processes have been implemented to
improve system wide efficiency and accountability by introducing accreditation and government
regulations. Joint Commission on the Accreditation of Health Organizations (JCAHO) now
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requires accountability of safe practices in order to remain an accredited healthcare
organization.95 JCAHO’s safe practice initiatives include mandatory documentation by hospitals
systems to complete the following: improve the accuracy of patient identification, improve the
effectiveness of communication, improve safe medication administration and usage, and
decrease iatrogenic harms in healthcare organizations.96 The National Quality Forum (NQF) was
influential in establishing national standards that required mandatory reporting of hospital or
iatrogenic harms to patients.97 Yet, the harms from that result from the neglect to institute a
comprehensively adhered to practice guidelines that adheres to quality guidelines across the
continuum for the management of substance use disorders and addiction continues to not be
addressed.
The NQF functions to improve the quality of American healthcare, through
implementation of improved patient safety recommendations.98 Mandatory reporting involves,
reporting all serious events in hospitals, that include: pressure ulcers, catheter associated urinary
tract infections, failure to check for blood incompatibility, wrong site operations, and objects left
in patients after surgery.99 Event reporting is encouraged to determine a systems approach for the
error. The incident or error is evaluated and analyzed to determine the cause, to decrease likely
hood of repeating the error, and to monitor improvement efforts over time.100 The same stringent
processes to evaluate the effectiveness of implementing best practices across the continuum of
care for those patients who are admitted to acute care emergency departments with substance use
disorders should be implemented. Mandatory reporting should occur, every time that a patient is
admitted to the emergency department without the completion of recommended practice
guideline screening assessments, without proper guideline adherence of standardized
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interventions including pharmaceutical and psychosocial interventions, referral for follow up or
transfer to appropriate treatment settings.101
According to research, patient harms and decreased access to healthcare occur
approximately thirty percent more frequently for vulnerable populations102 The National
Healthcare Quality Report (NHQR) reveals staggering discrepancies and shortfalls between
quality of care between patient populations as well. The NHQR indicates that prevention of
disease through routine diagnostic testing occurs half as frequently for women of low education
and economic status in the United States (US). Women with less than a high school education
and women who live below the poverty line are less likely to obtain a Papanicolaou smear or Pap
test, for cervical cancer screening. African Americans and Hispanics require an increase in acute
care hospitalizations due to complications from diabetes, compared to white patient
populations.103 The Agency for Healthcare Research and Quality (AHRQ), helps support
investigative research that examines disparate healthcare treatment and interventions for
vulnerable population.104 Research has also revealed that there are increases in medication
administration errors in elderly populations and there are increases in handoff errors during
hospital discharges for the elderly and poor; because of the above mentioned barriers of care;
statistics indicate that the ‘invisible epidemic’ of substance use disorders and addiction occurs
increasingly in older adult population and most often in desperate or vulnerable populations.105
The underlying premise, to include patients and family members in the participation of
their personal healthcare plan of care appears at first glance to be an advantageous method to
decrease errors and to increase quality of patient care; especially as it relates to quality and safety
in the delivery of quality substance use and addiction policy development. The simple
acknowledgement that focuses on patients as a vulnerable population helps to redirect the
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responsibility of primary advocacy for the patient back to healthcare professionals and healthcare
organizations. Healthcare organizations, healthcare professionals, and healthcare insurance
providers must understand the fundamental issues that deter patient participation at an optimal
functioning capacity. Issues such as healthcare literacy, language proficiency, communication
skills, conflict management skills, and basic physical and cognitive functioning disorders, such
as substance use impairs full capacity of patient participation in all aspects of their own
healthcare management; therefore, requiring relational decision making and consent processes is
difficult.106
Combinations of low health literacy, low language proficiency, and poor communication
skills are often sources of increased medical harms that directly affect patient outcomes.
Attempted resolution to decrease patient errors requires the same complex methodology as
resolution methods for entire systems. An integrated participatory framework of collaboration,
teamwork, improved communication, and improved healthcare system strategies must be
established across all levels of healthcare. Increased attention must be made to decrease errors
and outcomes in patient populations; this goal should be accomplished by facilitating improved
outreach and education for especially vulnerable populations.107
Promoting collective responsibility and accountability is an appropriate way for
healthcare systems to examine safety and excellence from a systems approach is necessary.
Collaboration and collective responsibility promotes unity amongst the individual members of an
organization and an incentive to continually move towards the mission of healing and promoting
health within the communities that healthcare systems serve. Collective responsibility must be
mutually valued as an organizational moral imperative by patients and by each member of the
health care team. This moral imperative collectively values the importance of the public
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reporting of errors, honesty in disclosure of harms, and the importance to adhere to the
regulatory and accreditation standards.108 The collective acknowledgement that each and every
member of the team shares the responsibility is not sufficient alone in meeting the requirements.
Collective responsibility acknowledges collaboration as an essential element necessary to
incorporate amongst members of the healthcare team, which include patients, families, and
communities.
Collaboration is perhaps one of the most essential components necessary to successfully
navigate through the complexities of today’s healthcare environment. Collaboration is an
essential element necessary to rebuild communication, decrease patient harms, enhance working
environments, and improve overall care to vulnerable patients within healthcare. Gaps in trust,
gaps in patient centered care, and gaps in communication must be narrowed in order to improve
the functioning of comprehensive healthcare systems to represent patient and family centered
systems that provide the best practice standards consistently to the most vulnerable.109 Trust
cannot be established for those diagnosed with substance use disorders and addiction if fear of
incarceration ensues; rather the commitment to the implementation of best practice guidelines. In
order for healthcare providers and patients to successfully adhere to clinical practice guidelines,
universal excellence, and improved paradigms of care that increase the evidenced based practice
interventions that support patient wellbeing, healthcare teams must collaborate collectively with
patients and families to support best practices. Collaboration, must transition from acute care
settings to outpatient support services and away from prisons, in order to enhance a culture of
practice excellence, which truly seeks the dignity through an ethics of care paradigm change in
the management of substance use disorders and addiction.110
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Establishing and continuing collaborative relationships in healthcare is an essential
component for rebuilding public and patient trust. Establishing relationships with patients,
professionals, and members of the organization as collegial partners in the management of care
paradigms should help eliminate a ‘shame and blame’ culture when failure to implement best
practices do occur.111 Through collective collaboration, institutions, patients, professionals
recognize the integrated responsibility of all members within the complex methods of treatment,
intervention, and overall management of patient care.112
Patricia Benner has long noted the benefits of patient education and patient management
of disease processes not in isolation to, but rather in conjunction with, healthcare practitioners
through collaborative partnership.113 Benner also recognizes the importance and need of
healthcare professionals to incorporate the processes of co-acting with one another and co-acting
with patients though collaborative sharing of wisdom. Collaboration and leadership supports
transforming knowledge through experiential knowledge and collaboration to decrease injury
and harms in healthcare. Ultimately translating transformational collaboration and collective
responsibility into improved quality outcomes for patients, which seek to facilitate professional
and societal prevention of harm strategies for those who suffer from substance use disorders and
addiction.114
6.3 Professional and Societal Prevention Strategies.
Current prevention strategies that seek to decrease the use of substances that cause
substance use disorders and addiction in communities continue to incorporate educational
strategies that place responsibility of actions for person’s as they relate to ‘free choices’ despite
the physiological disease risk model and sequela of use that predispose adolescence and
vulnerable populations to substance use, dependency and addiction; on a social and community
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level, adolescence receive substance use education from public school systems, with very little
collaboration with health care professionals. However collaboration with health care
professionals who have specialized professional experiences in substance use disorder and
addiction management is necessary in order to disseminate current evidenced based risk
education and outreach systems of support for at risk populations at the community level.115 The
stigmatization and fear of criminal consequences of substance use persists at early ages within
school systems, fear cannot suffice for sufficient educational restraint from substance use; rather,
encouraging adolescence and young adults to relationally seek support for prevention is
necessary. Implementation of educational paradigms that seek to support children who live in
high risk environments, must also occur within community and school programs, by developing
increased strategies that seek to develop life coping strategies and social resistance skills.116
Prevention strategies should seek to develop open ‘safe’ communication environments and lifeskills that are free from stigma and fear, while seeking the development of positive health
promotion education initiatives.117
Individuals who are diagnosed with or suffer with substance use disorders or addiction
are harmful to self and to others; the most often affected societal harms occur to the children of
parents or caregivers who raise children in a homes where the primary care providers display
manifestations of substance use disorders, concomitant mental health disorders and addiction.118
When a nurse or an airline pilot presents with the manifestations of substance use disorders or
addiction, professional programs seek the protection of the community through program
prevention strategies that implement alternatives to discipline programs through the promotion of
early detection, early intervention and early treatment for the professional that exhibits
manifestations of substance use disorders and addiction; program development sought to protect
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the professional from the loss of permanent professional licensure; yet, despite the success of
such developed plans for professionals to achieve sobriety and recovery from substance use,
society continues to impede the development of such strategy development for general
populations and parents.119
Professional and societal prevention strategies must first seek to deconstruct stigma
associated with substance use disorders and addiction and to adjust the development of
prevention and professional strategies to help manage positive outcomes of disease sequela for
those who are affected. The growing need to develop responsible policies for managing
substance use disorder prevention strategies and to develop responsible policies that
acknowledge the vulnerability of populations; this requires including the individual, hereditary,
and social constructs that increase susceptibility. Professional and societal prevention strategies
need to clearly disseminate the factors that influence personal and societal responsibility. Factors
that increase personal responsibility include, awareness of the substance use addiction problem
and identifying one’s risk, or understanding one’s own genetic predisposition, developing a
supportive social support system, obtaining psychiatric and medical care when needed, and
understanding the addiction process.120
Successful professional strategies that assist the nurse or the pilot in obtaining sobriety
and recovery, requires the development of contractual and relational accountability; this
contractual and relational accountability is achieved through what is named, the alternate-todiscipline program for nursing and the recovering alcoholic airmen and medical certification
standards for sobriety.121 Additionally, both the pilot and the nurse are monitored through
licensure renewal or certification to practice their profession through integrated legal systems
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that monitor driving records, which then identify individuals of professional risk through
mandatory reporting of violations associated with substance use history.122
The strategy developed to enhance accountability for nurses, which also increase quality
and safety for patient related care, adheres to the philosophy of an ethic of care and relational
consent for treatment. This process promotes accountability for not only the individual wellbeing of the nurse who is identified as having a substance use disorder, but synchronizes the
promotion of safety of the patients that nurses care for through programs that seek to
reintegration the nurse into the work environment.123 The formal process is not entitled
‘relational consent’; rather the structural developed program is identified as a ‘monitoring
program, which requires the commitment of a legal contract that requires the nurses signature of
a formal monitoring agreement. If the nurse does not agree to the legal contractual participation
of the moral monitoring program, then the nurse risks loss of licensure to practice her profession
and criminal discipline.124 The consequences are professionally debilitating, potentiating
financial destruction and many may say the relational and contractual consent for ‘non
disciplinary’ action through commitment to participate in the alternate-to-discipline program is
coercive and paternalistic; yet, the success to sobriety, recovery, and reintegration to professional
practice, and ultimately to potentiating human homeostasis and flourishing is achieved through
the long-term commitment of substance use treatment availability, professional mentoring, and
relational support of care.
Utilizing an ethics of care, includes supportive recovery centers, relational consent
processes, development of an action plan, development of a culture of transparency, so that help
can be obtained and the development of relational boundaries of responsibility across all care
continuums, which include public health and educational institutions occur; public health policy
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support is needed to proliferate the massive educational and cultural dissemination of prevention
and health promotion strategies in order revolutionize community and national outcomes results
to susceptibility.125 In order to accelerated the actualization of national prevention strategies and
improvement goals for substance use disorders, addiction and to end the substance use associated
death epidemic, increasing accurate and essential educational initiatives that seek to decrease
stigma are necessary.126
a. Deconstructing Stigma.
Intrinsic loss of respect and dignity occurs for those who are stigmatized against.
According to sociologist Erving Goffman, stigma occurs when societal norms as they relate to
human appearance, behavior, or actions break from societal expectations and result in
degradation of personal character; hence, stigma results in negative and inferior judgment of
individuals from ‘others’ in accordance to particularly shaming or cultural, environmental, and
social constructs of unacceptable human qualities.127 Additionally, stigma allows the
marginalization of others to somehow justify the action of ‘separation’ of the ‘other’ as a moral
act.128
President Nixon’s attempt to decrease the harmful effects of the use of illicit drugs in the
1970’s, sustained the shame and blame mentality, propagated public fear and continued the
defamation of personal character of the ‘other’ with the initiation of the ‘war on drugs.’129 The
social consequences of placing stigma, marginalization, and criminalization for those with
addiction dysfunction increased the isolation of those with substance use disorders and addiction;
decreasing the likelihood of those who suffer the perpetual decline in wellbeing from chronic
substance use disorders and addiction to invoke a plea for help.
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An ethics of care seeks to deconstruct stigma by implementing processes that disseminate
educational initiatives that embrace community centered care and relational support; the
development of processes that supportively seek the wellbeing of individuals will exponentially
decrease further isolation and vulnerability, while repairing dignity, repairing health, and reigniting purpose and meaning.130 An ethics of care, uncovers the correlation between the social
determinants of health, uncovers the results of genetic heritability research, utilizes of
physiological and psychological evidence that reveals the inter-relatedness of the complexities of
biological, personal, familial, and social constructs that predispose individuals to mal-adaptive
coping strategies to the stressors of life that potentiate advanced cognitive dysregulation.131
An ethics of care recognizes that individuals are strengthened in relationships and that by
discriminating against individuals who are in need of support only increases vulnerability,
increases physiological stress, perpetuates separation and increase the comorbidities of
disease.132 Holistic management of care paradigms and professional standards of ethical delivery
of care require the development of prevention, implementation, and evaluation strategies that
strive to reduce population harms and improves health outcomes of populations through
development of cooperative programs between host, agent, and environment.133 The
implementation of the NCSBN’s development and striving to provide nurses with substance use
disorders, aims to restore the dignity of nurses who suffer the trajectory of harms, while also
seeking the optimal protection of the patients that nurses care for, without betraying public trust.
National initiatives to protect our nation’s youth, while supporting parental dignity is necessary
in order to deconstruct stigma across national communities and homes.
By implementing contractual programs and relational consent processes for the
development of treatment programs, increasing transparency, promoting alternate-to-discipline
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programs for parents and children, promoting parental accountability through the implementation
of professional and relational monitoring programs for those who require long term relational
support could occur; therefore, this process for nurses who suffer from substance use disorders
and addiction is often associated with long term recovery and sobriety. Deconstructing stigma,
requires the implementation of paradigm of action that supports paradigmatic change that seeks
to decrease harms and empower programs of relational support in response to the vulnerability of
persons.
Deconstructing stigma requires implementation of clinical pathways, support of insurance
coverage for acute care management, transitions of care management from early identification
programs, which promote long term recovery programs and chronic management programs that
implement evidenced based treatment changes throughout the spectrum of the disorder.134
Schaefer, et al, describes the professional challenges that professional treatment programs have
as it relates to developing extended program participation as it related to long term continuation
of care for those who suffer from substance use disorders and addiction.135 Yet, professional
nursing’s alternate-to-discipline programs obtain participant commitment through relational
contracts and relational mentorship that function as a checks and balance system, in order to
ensure participant’s long term relational commitment to recovery.
The profession of nursing turned away from the antiquated theory’s that support strict
punitive measures of punishment by the commitment of a long term relational commitment that
begins with a contractual and relational agreement of consent for the implementation of a care
paradigm that embraces human potential in response to the stressors of environmental and
professional practice, the human physiological aspects of vulnerability, and a community and
social response and attention of solidarity to the ‘other,’ while still seeking the protection from
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harms for individuals and communities. The development of a policy imperative of prevention,
seeks to address the prevention form substance use disorders and it seeks to implement the policy
of harms prevention that persist because of the lack of acknowledging the role of social response
and solidarity. The alternative-to-punishment program provides hope for the development of
harms reduction strategies that can coincide with public health initiatives to decrease societal
harms related to substance use disorders and addiction for future generations; additional
initiatives to limit market influences that increase profits for agents or distributors are also
imperative in order to prevent the harms to individual or family hosts.
b. Policy Imperative of Prevention
Public health policy must refocus its view on health promotion and disease prevention
strategies; in 2010, the Global Commission on Drug Policy released the reports, The War on
Drugs and Taking Control: Pathways to Drug Policies that Work. The publications revealed the
research and global statistics that support the associated harms that occurred with the previous
public policy on the way on drugs, while assigning responsibility to a global drug framework that
perpetuated the marginalization and stigmatization of vulnerable patients through legal systems
that criminalized drug possession and usage.136 The 2011 and 2014 policy recommendations
included the need to place health and communities first, ensuring equitable access to medication
and treatment interventions for individuals by eliminating criminalization of individual users and
in order to reduce the power of underground criminal organizations through medical distribution
and support; pathways of care recommends that health policy reform seek to improve the
humane treatment of those who are marginalized by the physiological sequela of disease and a
systems corruption that is unable to proactively empower individuals through the previous
policy.137
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Therefore, harms reduction strategies must innovatively support national initiatives that
incorporate professional standards of shared decision-making in order to disseminate educational
material to populations, while implementing collaborative quality improvement measures, and
that remove individuals and communities from harms.138 To achieve this goal, health care
systems must embrace organizational functioning goals, which seek to overcome intrinsic
disservices to individuals and populations at greatest risk for substance use disorders and
addiction. In order to accomplish such goals, organizations should emulate the moral
accountability of the organizations, such as the policy’s implemented by the National Council for
State Board of Nursing, which provides just delivery of substance use disorder and addiction
services to those who are vulnerable and susceptible to disease by implementing deliberative
processes that set limits to market influences, redefines professional values and recommits
integrity to individuals by providing equal access and compassionate care to a population who is
in need.
Organizational healthcare systems, public health policy, implementation programs, and
healthcare professionals have the moral responsibility to function as an integral and participatory
component of society; all aspects of the health care systems should function comprehensively
through a paradigm of care that ensures the intrinsic qualities of a morally functioning agent. As
a morally functioning agent, one’s character is shaped by one’s moral actions.139 Similarly,
individual persons and organizations are justified in developing morality as a guide toward
fruitful and prosperous living; healthcare organizations, public health policy and the
implementation of comprehensive health care programs should seek the care of those with
substance use disorders and addiction by incorporating plans, which include right action,
directional discernment, and directional navigation that recognizes the supportive evidence in
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developing new treatment interventions for those vulnerable to substance use disorders and
addiction.140
Health care organizations and health care professionals are called to function within the
world in service of those who are suffering and those who are ill. Organizational health care
markets have the potential to be saturated with the same greed and power as other financial
market systems that function on philosophies of power and wealth.141 Social responsibility and
the awareness of the commodification of substances to vulnerable populations has societal
consequences that require the development of aggressive prevention and treatment strategies.142
However, to avoid societal complicity, health care systems, public health systems and
professionals are called to function morally within a capitalistic market, to pursue economic
survival, to ensure fair access of care to the poor and the vulnerable, and to seek the elements of
care for those entrusted to health care services.143 By utilizing the principle of moral cooperation
and by incorporating methods of operational transparency, individuals within organizations are
provided with the guidance and tools to function within a framework of an ethics of care during
difficult situations; hence, limiting decreased patient participation and patient neglect for
vulnerable populations, such as those with substance use disorders and addiction.144
It is the role of health care systems, public health policy, professionals, individuals,
communities, government, and humanitarian aid policy to prepare, promote and formulate
initiatives that identify the values in the preparation and planning for natural disasters; it should
also be the role of society to prepare, promote and formulate initiatives that identify the value of
preparation and planning for the national solution to the opioid and substance use epidemic. Part
of the planning requirements for natural disasters closely evaluate the equitable distribution of
public services and rights of citizens to identify public health risks of pandemic outbreaks,
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accidental catastrophes such mass casualty explosions, accidents, and natural disasters; they
should also consider the massive loss of life, which substance use disorders and addiction have
caused.145 Human dignity is an intrinsic human moral value that necessitates the fair allocation
of resources; therefore implementation of public health, government, and humanitarian aid
mandates the fair distribution of material and management programs that seek preservation of
life for the most vulnerable; this same outlook should invoke solidarity of quality initiatives and
best practices.
Moral intuition in the United States often permeates the compassionate participatory
responses of individuals, communities and organizations when there is an infringement of the
principles that represent human dignity.146 There was an acknowledged delayed response of the
disaster relief response planning after hurricane Katrina in New Orleans and as a result of
hurricane Maria in Puerto Rico. Yet, the outcry of society seems silenced in response to the
devastating loss of life that has resulted from the delayed implementation of treatment programs
in the management of care for substance use disorders and addiction. This violation of human
dignity, must initiate a compensatory movement of solidarity in order to seek the enhancement of
individual commitment to participation in preparation and planning for improved evidenced
based treatment paradigms for patients who suffer from substance use disorders and addition.147
Policies must consider methodologies that support educational initiatives for all
constructs of care, which include socio-political, governmental, comprehensive levels of
education and academia education for health care providers in order to decrease sequela of harms
as a result of the current substance use epidemic; additionally, policy must support substance use
and addiction crisis recovery center development, improved community distribution of
emergency antagonist medications that decrease harms from overdose, development of patient
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centered medical homes, implementation of relational consent processes to support long term
and chronic treatment programs, and the development of partnership program pathways that
facilitate optimal care coordination, transitions of care and humane support that actualizes
optimal treatment goals and outcomes through community and relational partnerships.148
Until universal actions of solidarity, transparency, responsibility, and accountability
occur for individuals, families, communities, health care organizations and market systems,
harms will continue to exponentially affect those who are the most vulnerable to the sequela of
substance use disorders and addiction, through the antiquated paradigm of individual blame and
labeling. Implementing the deconstruction of stigma and developing a robust paradigm of care,
through shared decision making, interactive and participatory community prevention strategies,
and the development of a long-term commitment to an ethics of care in order to meet the moral
obligation which ‘goes’ beyond the limited constructs of absolute autonomy must occur.
Developing a framework of care that recognizes the benefits of relational consent in order to
promote human flourishing for those who suffer from the coercive effects of substance, biology,
and societal influences is one that intrinsically recognizes the intrinsic dignity of the other
through the actions of care for the most vulnerable.
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Chapter 7 Conclusion
This dissertation purposefully, examines the essential elements that investigate the
cellular and pathophysiological processes that incorporate an extensive examination of the
neurobiological, genetic and epigenetic analysis of substance use disorders and addiction. It
purposefully focuses on the role of professionals and health care systems, which include public
health prevention and transitions of care management improvement processes for those who
suffer from substance use disorders and addiction. It carefully examines the criteria for
decisional capacity and the nuances of obtaining consent for the management of care framework,
for those who are vulnerable to the known neurological, neurocognitive, and neuroimmune
dysfunction of the brain.1 This dissertation asserts that by utilizing an ethics of care framework, a
paradigmatic change in the management of care for those with substance use disorders and
addiction should occur.
This assertion affirms that an ethics of care framework can decrease harms associated
with societal constructs of blame, stigma and marginalization for patients by implementing
educational initiatives that recognizes that the empowerment of human wellness occurs through
relational structures of care that acknowledges impaired decisional capacity for those with
addiction.2 Health care organizations and professionals that seek to provide educational resources
and implement community initiatives of care, by promoting non-judgmental support for those
who are diagnosed with substance use disorders will create healthcare environments that extend
beyond the walls of institutions and become embedded within a cultural shift that is focused on
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the development of care initiatives that implement clinical pathways which seek to transform
lives through relational partnerships that encourage individual human flourishing.3
This dissertation purposefully discusses the criteria of moral agency, by illustrating the
differences between the autonomous actions of individuals who have full decisional capacity and
those who have impaired neurological functioning that results in deleterious executive decisional
functioning ability for those diagnosed with substance use disorders and addiction.4 The
examination carefully evaluates the criteria of decisional capacity for those who are diagnosed
substance use disorders and addiction. It is the ethical responsibility of the care provider to
ensure that patients meet the criteria for decisional capacity; when patient’s do not meet the
criteria, it is the responsibility of the health care provider to recognize incapacity and to
implement systematic processes that include proper assessment, monitoring of diagnostic tests,
and implementation of evidenced based practice interventions that seeks relational approaches of
care through the re-interpretation of consent.5 The re-interpretation of informed consent
actualities an ethics of care framework, by seeking to decrease the harms for those who are most
vulnerable through the implementation of a strategies that promote a collective commitment to
individual, professional and global accountability.6
This dissertation spends very little time discussing the responsible accountability of
individuals who are diagnosed with substance use disorders and addiction, not because the one
who is diagnosed with substance use disorders and addiction are exempt from responsibility and
accountability; but rather, because the focus of the writing was to acknowledge the imperative of
health care providers and health care organizations with their associated professional role in
recognizing the potential gaps in care and ethical blind spots that impede best practices.7
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Improving best practice goals aim to increase quality of care initiates, increase patient safety and
ultimately decrease patient harms, through professional intervention strategy development.8
An ethics of care explicitly examines the necessity of reciprocal elements of care, which
are essential components between the provider of care and the ‘one’ who receives the care. An
Ethics of care framework, which seeks the re-interpretation of consent for those who are
diagnosed with substance use disorders and addiction, does not assert that those who suffer from
substance use disorders and addiction are exempt from the essential elements of responsibility
and accountability for the development of substance use disorders, addiction or sequela of
dysfunction. Rather, individual accountability and individual responsibility are essential
components within the patient provider relationship.9 Patients who are diagnosed with substance
use disorders and addiction are responsible for their own physiological inherited genetic and
epigenetic susceptibility to disease progression; the management of care paradigm must also
include incorporation of methods that promote and instruct individual accountability and
responsibility for the one who suffers from substance use disorders and addiction.10 Methods that
promote and instruct accountability and responsibility can be compared to a parent’s
perseverance in teaching a child health coping strategies and resiliency despite human
imperfection and vulnerability.11
An ethics of care truly seeks the actualization of individuals by recognizing that the
intrinsic dignity of each person is often times felt through actions of human encouragement and
values of belief. Healthcare providers that recognize the inherent dignity of those with substance
use disorders and addiction seek to encourage, authentically support, and holistically educate
patients related to the etiology of disease, increased risk for disease, expected trajectory of
disease, and educate patients on the importance of managing their disease through the best
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practice standards.12 However, implementing those actions without authenticating care values,
becomes meaningless without authenticity; the beneficial characteristics of care lose implicit
value without authenticity and respectful presence. Implementing care values seeks to provide
the tireless characteristics of encouragement to the other in order to promote human
flourishing.13 Relationships of care reflect mutual responsibility and accountability within the
relationship. Initiatives should seek relational structures that incrementally increase individual
responsibility, without negating the patient’s self-worth through degradation.14
Implementing constructs of care, which reflect power dominance of physicians over
patients, potentiates the implementation of authoritative coercion that can potentiate further
harms for those who are labeled as impaired or vulnerable from addiction; however,
implementing relational consent and contracts of care with patients, families, communities, and
health care providers, seeks to improve patient accountability through relational decisionmaking, the development of frequent substance screening, promotes open and honest
communication that develops a treatment plan through accountability and participating in an
attempt to improve individual patient outcomes.15 However, restoring optimal neurological
functioning and restoring individual capacity is the goal of treatment; it is recognized that the
intrinsic essence of individual personhood is associated with the repair of consciousness through
the slow neurological repair, which aims to restore an optimal state of neurological
homeostasis.16
As a result, seeking to repair neurological functioning includes the necessity to decrease
the effects of neuroimmune, neurocircuitry and neurobiological alterations that alter brain
functioning; this fluctuating in brain functioning is an expected result of the substance use
disorder and addiction trajectory of waxing and waning repair and harms; however, teaching
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patients methods to enhance individual agency promotes self-worth and aims to restore intrinsic
dignity of the patient.17 Utilizing the language of neurodiversity as a means to express personal
and fluctuating differences in one’s own understanding of neurological functioning is a means to
describe various levels of neurological processes and enhance the ability to improve one’s own
responsibility for agency.18 The ability to understand the complex mechanisms of addiction,
seeks to restore decision-making ability, and seeks to improve the development one’s actions in
relationship to others.
The neurodiversity dialogue embraces the acknowledgement that neurological alterations
occur because of the disease trajectory of substance use disorders and addiction; yet, the ability
to improve neurological functioning due to the implementation of processes through neural
plasticity enables the brain’s dysfunction from substance use and addiction to begin the process
of healing itself, through purposeful participation in evidenced based plans of care.19 The
combined partnership of patient and health care providers, synergistically complements one
another. The care provider needs the authentic participation and commitment of the patient, the
patient needs the collaborative benefit of a skilled provider of care to make accurate diagnoses,
implement timely response to exacerbations of dysfunction and implement consistent long term
treatment plans, despite complications and persistence in relapse.20 Additionally, and perhaps
most importantly, the patient and the care provider benefit from the commitment of family and
community, which support recognition of patient fluctuations during times of high risk and
relapse, through relational support plans, hope and forgiveness.21
The language of the neurodiversity framework potentiates a renewed respect and
appreciation for those who ‘think’ differently than others; therefore, validating self-worth of the
one with altered brain functioning in a beneficial way versus through negative constructs that
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potentiate further harm.22 All chronic disease states present as spectrum disorders; meaning that
along a continuum of care, all chronic disease states have periods of acute acerbations and
periods of remission.23 Patient’s diagnosed with heart disease and diabetic have the same
potential for the development of fluctuating trajectory of disease states. Alterations in blood
pressures and fluctuating blood glucose levels indicate fluctuating periods of stability and
periods of acute exacerbations for patients diagnosed with heart disease and diabetes; the waxing
and waning levels of physiological dysfunction, fluctuates between optimal levels of control and
extreme levels of loss of control during circumstances that precipitate exacerbations.24
Consequently, patients are encouraged to maintain close communications with providers of care
during an acute exacerbation without discouragement of reaching out to healthcare providers in
fear of asking for relational assistance in the complex management of acute physiological
changes in disease states.
During periods of remission from heart disease, diabetes, substance use disorders and
addiction, patients and family members often times feel a sense of achievement over the selfmanagement of disease trajectory. Yet, during times of acute exacerbation in substance use
disorders and addiction, overarching feelings of shame, personal failure, and loss of hope can
occur, which can negatively affect prompt healthcare assistance through the acute relapse or
exacerbation phase.25 However, if patients and families were consistently encouraged to continue
persevering through treatment plans despite initial signs of relapse and sought to understand the
importance of seeking help immediately, for the assistance of medical interventions because of
increased negative stress response states, increased craving stages, and impaired neurological
preoccupation states then an increased individual responsibility and accountability could be
achieved through shared decisional standards of care.26 Implementing shared decisional
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paradigms of care that seek medical assistance and responsive care paradigms that support the
relapse or acute exacerbations of the sequela of disease state harms initiates supportive plans of
care. Unfortunately, for those diagnosed with substance use disorders and addiction, reciprocal
action is not always responsive to the care required for the achievement of relational support
because inconsistent management of care processes and marginalization.
Utilizing an ethics of care to re-conceptualizes autonomy through empowerment of
relational autonomy and relational decision-making requires a careful analysis of the sequela of
chronic neurological and cognitive impairments associated with addiction disorders and how
support through vulnerability can promote neurological repair and improve support. Vigilant
implementation of a relational re-interpretation of consent must be attentively formulated for this
vulnerable and marginalized population; implementing the institute of Medicines and the
National Behavioral Health Quality Framework (NBHQF) care coordination improvement
initiatives must occur between transition of care programs in order to improve care between
acute care systems, public health outreach programs, and assist in transitions of care
environments, by educating patients, families, and communities.27
This complex endeavor requires implementation of improved systems of care
coordination by facilitating clear and concise health care initiatives that aim to place the health of
individuals and the safety of communities first; policy development must adhere to standards of
least restrictive means, while also embracing strong multilevel prevention education strategies
that simultaneously seek to decrease stigma and social isolation in order to embrace the
responsibility of extended human dignity for the vulnerable by avoiding social constructs of
shame, blame, discrimination, stigmatization, and isolation in order to empower others through
relationship, connectedness, responsiveness, communication, education, discussion, solidarity,
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community and professional support that seeks to deconstruct the deleterious isolation of those
most susceptible to the perpetuation of generational dysfunction and harm
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